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TOTAL SYNTHESIS OF ULOCLADOL A AND ANALOGUES, ALTERNARIOL 9-METHYL 
ETHER AND ALTERNARIOL 
by Lauren Jayne Sudlow 
Ulocladol  A  is  a  natural  product  which  has  been  shown  to  exhibit  tyrosine  kinase 
inhibitory  activity  against  the  enzyme  Lck.  It  was  isolated  from  the  marine  sponge 
Callyspongia vaginalis in 1999. Prior to the commencement of this project there had been 
three reported syntheses of ulocladol A, all of which started from intermediates prepared 
in the synthesis of graphislactones C and D. The routes were relatively long and did not 
provide much scope for analogous compounds. 
We proposed it would be possible to prepare ulocladol A via a route which would allow for 
the synthesis of analogues. Any analogues prepared would be tested against five tyrosine 
kinases to determine whether any SAR could be elucidated. 
This report details the use of Suzuki coupling methodology to prepare ulocladol A and 
eighteen analogues. Several different catalyst systems are reported due to the steric and 
electronic effects of the substrates used in the Suzuki reaction; also included in the report 
are  the results  of  the  biological  testing.  Two  of  the  analogues,  2.47  and  2.60,  exhibit 
greater  inhibitory  activity  than  ulocladol  A  and  show  good  activity  against  four  other 
tyrosine kinases. 
In  addition  to  the  synthesis  of  ulocladol  A  and  analogues,  the  report  also  details  the 
synthesis of alternariol 9-methyl ether and alternariol in the shortest convergent synthesis 
to date. iii 
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1. Introduction 
1.1  Natural Products 
A compound which is derived from a source such as a plant, animal or microorganism is 
defined as a natural product.1 Although a large number of natural products are biologically 
inactive or have no known biological activity, there are some which exhibit interesting 
activity. Many of these biologically active natural products have been used medicinally for 
thousands  of  years.  The  first  written  record,  dating  back  to  2600  BC,  contained 
approximately 1000 substances from plant sources which  were used to treat illnesses 
from simple colds to parasitic infections.2 Other early records include the Egyptian Ebers 
Papyrus dating from 1500  BC and the Chinese Materia Medica dating from 1100  BC. The 
records also included formulae of how to administer the crude natural products, such as 
gargles, poultices and infusions. However, it wasn’t until the start of the 19th century that 
Friedrich Sertürner isolated morphine, the first pharmacologically active, pure compound 
from a plant.3 This isolation led to huge interest in the extraction and purification of drugs 
from plants, as well as the vast screening of microorganisms following the discovery of 
penicillin by Alexander Fleming in 1928. Towards the end of the 20th century natural 
products or natural product inspired compounds accounted for approximately 80% of 
drugs, including morphine, lovastatin and paclitaxel (Figure 1).3 
 
Figure 1 – Natural products 
The three natural products were isolated from different natural sources: morphine, an 
analgesic, was isolated from the opium poppy plant; lovastatin, used to lower cholesterol, 
was isolated from the fungus Aspergillus terreus and paclitaxel, an anti-cancer agent, was 
isolated from the Pacific yew tree. They all have very different structures which are highly 
oxygenated with three or more rings and multiple stereogenic centres. 2 
Despite the quantity of drugs derived from natural products and the huge variation in 
structure, the arrival of high throughput screening and combinatorial chemistry towards 
the  end  of  the  20th  century  caused  the  interest  in  natural  products  to  decline. 
Pharmaceutical companies placed great emphasis on the ability to prepare and screen 
large  libraries  of  synthetic  compounds  quickly  and  consequently  vastly  reduced  or 
terminated their research in the more time consuming area of natural products.4 They 
began  screening  large  libraries  of  compounds,  assuming  that  if  they  screened  enough 
compounds  a  lead  would  be  found.  The  early  libraries  often  contained  peptides  and 
nucleotides which were easy to synthesise through combinatorial chemistry and could 
undergo functional group interconversions to prepare large numbers of compounds for 
screening. However, the compounds were often limited in the variety of functional groups, 
chiral  centres  and  ring  systems  usually  observed  in  natural  products  and  small  drug 
molecules,  resulting in  disappointment in  the  pharmaceutical industry  when  the  large 
quantities of new drugs anticipated failed to arise. 
Although the process of combinatorial chemistry and screening of synthetic libraries has 
been  refined  and  emphasis  is  now  placed  on  quality,  not  quantity  of  compounds,  a 
revitalisation in the area of natural products has taken place. There are several reasons for 
this, one of which is the competition created by the refinement of synthesis and screening 
of  synthetic  compounds.  This  refinement  has  meant  that  the  process  of  extraction, 
isolation and testing of natural products has had to evolve in order to remain viable, and 
automation is increasingly being used in the extraction and isolation stages. 
A second reason is the chemical diversity seen within natural products. Natural products 
occupy  a  more  diverse  area  of  chemical  space  when  compared  to  that  of  synthetic 
compounds,  with  less  aromaticity  and  nitrogen  atoms  but  a  greater  number  of  chiral 
centres,  ring  systems  and  oxygen  atoms.  A  comparison  between  the  chemical  space 
occupied  by  natural  products,  drugs  and  a  selection  of  combinatorial  compounds 
demonstrates this diversity (Figure 2).4 3 
 
 
Figure 2 – Occupation of chemical space 
The graphs show that combinatorial compounds a) occupy a relatively localised area of 
chemical space. Natural products b) and drugs c) cover a much more diverse area as well 
as the same area as combinatorial compounds. This diversity has been demonstrated in 
the period between 2005 and 2007, with approval being given for the introduction of 13 
natural product based drugs, of which, five were members of new classes (Figure 3).5 
 
Figure 3 – Approved natural product based drugs 
Ziconotide is derived from a toxin produced by the cone snail Conus magus. It is a member 
of the conotoxin class of drugs and is used in the treatment of chronic pain.6 Exenatide, 
derived from a hormone found in the saliva of the Gila monster, is an incretin mimetic used 
to  improve  control  of  blood  sugar  levels  in  type  II  diabetics  by  enhancing  glucose-
dependent insulin secretion, slowing gastric emptying and suppressing elevated glucagon 
secretion.7  Retapamulin  is  a  topical  antibiotic  derived  from  the  natural  product 4 
pleuromutilin which is produced by the mushroom Pleurotus mutilus. It is the first of a new 
class of drugs, named the pleuromutilin antibiotics, which have been shown to be effective 
against some Gram-positive bacteria, including MRSA.8 Trabectidin, isolated from the sea 
squirt Ecteinascidia turbinate, and ixabepilone, an epothilone secreted by the bacterium 
Sorangium cellulosum, are both members of new classes of drugs aimed at the treatment of 
cancer. Trabectidin is a tetrahydroisoquinoline alkaloid which has been approved for the 
treatment of advanced soft tissue sarcoma, given orphan drug status in the treatment of 
relapsed ovarian cancer and is currently undergoing clinical trials for the treatment of 
breast and prostate cancer. Trabectidin is thought to bind to the minor groove of DNA and 
cause inhibition of cell proliferation by interrupting the cell cycle. Ixabepilone acts against 
tumour cells in a different way, by binding to microtubule β-subunits and stabilising them. 
This blocks the cells in the mitotic phase causing apoptosis; the same mechanism of action 
employed by Taxol. An advantage of Ixabepilone is its ability to remain active against 
cancers which are resistant to Taxol. 
In addition to Trabectidin and Ixabepilone, nearly 40% of more than 200 natural product 
inspired  compounds,  undergoing  preclinical  and  clinical  trials  in  2008, were  aimed  at 
cancer targets.9 As the overall age-standardised incidence rate for cancer has increased by 
25% in the period between 1977 and 2006, cancer therapies are becoming increasingly 
important.10  Recent  breakthroughs  in  the  understanding  of  cell  communication  have 
encouraged  research  into  specific  targets,  with  focus  on  what  causes  cancer  cells  to 
replicate allowing tumours to grow. One of the areas being focused on is protein kinases. 
1.2  Protein Kinases 
Protein kinases are enzymes which catalyse the modification of protein substrates through 
phosphorylation of specific amino acid residues. This phosphorylation takes place in the 
enzyme active site and leads to a conformational change in the protein substrate. The 
conformational change results from several factors: the addition of the phosphate group to 
the  amino  acid  residue  disrupts  hydrogen  bonding  on  the  phosphorylated  functional 
group;  and  the  introduction  of  the  two  negative  charges,  from  the  phosphate  group, 
enables  the  formation  of  ionic  bonds  with cationic  species  leading  to  a change  in  the 
tertiary structure of the protein substrate. This conformational change is the means by 
which  many  cellular  processes  are  regulated;  these  include  metabolism,  transcription, 
differentiation, apoptosis, ion transport and hormone responses.11 5 
Prior to catalysing the phosphorylation of a protein substrate, the protein kinase must 
itself  be  activated.  Protein  kinases  have  two  conformations:  one  active,  where 
phosphorylation  of  the  protein  substrate  can  take  place,  and  one  inactive,  where  no 
phosphorylation occurs. 
The  protein  kinase  domain  consists  of  two  lobes,  the  N-lobe  and  the  C-lobe,  which 
sandwich the enzyme active site. The N-lobe is the smaller of the two and consists of a five-
stranded  β-sheet  and  one  α-helix;  the  C-lobe is  larger,  predominantly  consisting  of  α-
helices (Figure 4). 
 
Figure 4 - The active and inactive forms of two protein kinase domains12 
Figure  4  shows  the  active  conformation  of  the  protein  kinase  Lck,  and  the  inactive 
conformation of the protein kinase Src. When in the inactive conformation an activation 
loop, a chain of 20-30 amino acids, is folded into the enzyme active site preventing access 
through steric hindrance. In the active conformation the activation loop has been extended 
away from the entrance to the active site which allows access. Activation of the protein 
kinase  occurs  through  phosphorylation  of  the  activation  loop,  which  stabilises  the 
resulting active conformation. In addition to activating the protein kinase, the activation 
loop also functions as a binding platform for the protein substrate. Once in the active 
conformation  the  protein  kinase  plays  a  role  in  three  aspects  of  the  phosphorylation 
process:- 6 
  Firstly, it must bind a phosphate donor, known as the cofactor or coenzyme. 
  Secondly, it must bind a protein substrate. 
  Thirdly, it must enable the transfer of a phosphate group between the cofactor and 
the protein substrate. 
The protein kinase active site has two binding sites: one for the cofactor and one for the 
protein  substrate.  In  order  for  phosphorylation  of  the  protein  substrate  to  occur,  the 
enzyme  must  firstly  bind  a cofactor;  without  this cofactor  phosphorylation  would  not 
occur. In the case of protein kinases the cofactor is usually adenosine triphosphate (ATP). 
The way in which ATP binds to the enzyme active site of the epidermal growth factor 
receptor is illustrative of the way that ATP binds to all other kinase active sites (Figure 5). 
 
Figure 5 - Binding of ATP to the kinase active site of the epidermal growth factor receptor11 
The figure demonstrates how the enzyme active site binds ATP in several ways. Towards 
the back of the active site there are two hydrogen bonds between the amino acid residues 
of the protein backbone and the adenine functionality of ATP, whilst the ribose sugar rests 
in a pocket at the base of the active site. The phosphate chain extends out towards the 
entrance of the enzyme active site, along the cleft,  forming a complex with a divalent 
cation, usually Mg2+ or Mn2+, and several hydrogen bonds with amino acid residues. The 
divalent cation  reduces  the  likelihood  of  dissociation  of  the  cofactor  from  the enzyme 
active site. 7 
Figure 5 also shows a hydrophobic pocket towards the top of the active site opposite the 
ribose pocket. This pocket is guarded by an amino acid residue known as the “gatekeeper 
residue.”13 The size of the gatekeeper residue varies between different protein kinases 
allowing  selectivity  between different  protein  substrates.  In  addition  to  the  selectivity 
inferred by the gatekeeper, the hydrophobic pocket itself is lined with amino acid residues. 
These  amino  acids  differ  depending  on  the  protein  kinase,  allowing  specific  protein 
substrates to be recognised and bound within the hydrophobic pocket. 
The  third  role  the  protein  kinase  has  is  enabling  the  transfer  of  a  phosphate  group 
between  the  cofactor  and  the  protein  substrate.  The  active  site  of  the  protein  kinase 
facilitates the transfer by bringing the phosphate chain of the cofactor and the amino acid 
residue of the protein substrate into close proximity with each other. 
There are two main categories of protein kinases which are grouped according to the 
amino acid side chain, on the protein substrate, that is phosphorylated:- 
  The serine-threonine kinases 
  The tyrosine kinases 
1.2.1  The Serine-Threonine Kinases 
The  serine-threonine  kinases  are  a  class  of  protein  kinase  which  catalyse  the 
phosphorylation  of  the  hydroxyl  group  of  serine  and  threonine  amino  acid  residues 
(Figure 6). 8 
 
Figure 6 - Phosphorylation of serine and threonine residues 
Following the reaction the phosphorylated amino acid residue is now a charged species 
and has increased in size due to the phosphate group. This leads to a conformational 
change in the protein substrate which then goes on to regulate a cellular process. In the 
process of phosphorylating the protein substrate, the cofactor, ATP, loses a phosphate 
group becoming adenosine diphosphate, ADP. ATP can be regenerated through metabolic 
processes and also by an enzyme called phosphatase. Phosphatase has the opposite effect 
to a protein kinase as it removes phosphate groups from amino acid residues, acting as an 
“off switch” to the protein kinases “on switch.” 
1.2.2  The Tyrosine Kinases 
The tyrosine kinases phosphorylate tyrosine amino acid residues on protein substrates 
(Figure 7). 9 
 
Figure 7 - Phosphorylation of tyrosine residue 
This phosphorylation causes an effect on cellular processes within the body. Mutation or 
deregulation of a protein kinase can have serious consequences within the body, leading to 
diseases such as: endocrine disorders, cardiovascular diseases, immunodeficiencies and 
cancer.  For  this  reason  there  is  great  interest  in  the  area  of  protein  kinases  for  the 
treatment of disease. 
One of the areas of interest for research is cancer and there are currently several drugs on 
the market which act on protein kinases. The first drug developed to specifically inhibit 
one enzyme was Imatinib, marketed as Glivec (UK) and Gleevec (USA), which is a tyrosine 
kinase inhibitor (Figure 8). 
 
Figure 8 - Imatinib 
Imatinib was developed through rational drug design by Nicholas Lydon, Brian Druker and 
Charles Sawyers at the end of the 20th century. It is used in the treatment of chronic 
myelogenous leukaemia, a relatively rare cancer affecting approximately 600 people per 
year  in  the  UK.  Chronic  myelogenous  leukaemia  is  caused  by  the  Philadelphia 10 
chromosome, an abnormal gene formed by the translocation of chromosomes 9 and 22. 
This translocation fuses the Bcr (breakpoint cluster region) and Abl (Abelson leukaemia 
virus) genes, creating the fusion protein Bcr-Abl which produces an abnormal tyrosine 
kinase.  The  tyrosine  kinase  is  permanently  active  causing  excessive  production  of 
abnormal  white  blood  cells  through  increased  mitosis  and  prevention  of  apoptosis. 
Imatinib acts as an ATP mimic, competitively binding to the ATP binding site on the Bcr-
Abl protein thereby inhibiting enzyme activity and preventing the transduction of energy 
signals necessary for cell growth and death (Figure 9). 
 
Figure 9 - Binding of Gleevec14 
Treatment  of  early  stage  chronic  myeloid  leukaemia  with  Imatinib  has  resulted  in 
remission for nearly 100% of cases. 
Although  none  of  the  approved  drugs  targeting  protein  kinases  are  natural  product 
derived  compounds,  there  are  currently  several  in  clinical  trials.  These  include  the 
isoflavone genistein, alvocidib and enzastaurin (Figure 10). 11 
 
Figure 10 – Kinase targeted drugs developed from natural products 
Genistein is a tyrosine kinase inhibitor which is currently undergoing clinical trials for 
breast, prostrate, brain and cervical cancer. Alvovidib is derived from the natural product 
rohitukine, an alkaloid isolated from the stem bark of Dysoxylum binectarifum. It is a cyclin-
dependent kinase inhibitor which is currently in clinical trials for the treatment of chronic 
lymphocytic  leukaemia.  Enzastaurin  was  developed  from  the  natural  product 
staurosporine, an alkaloid isolated from the bacteria Streptomyces staurosporeus. It is a 
serine-threonine kinase inhibitor and is currently undergoing phase II and III clinical trials 
for the treatment of cancer. 
Three other natural products which have shown anticancer activity are ulocladol A (1.1), 
alternariol  9-methyl  ether  (1.2)  and  alternariol  (1.3).  Ulocladol  A has  shown  tyrosine 
kinase inhibitory activity and alternariol and alternariol 9-methyl ether have both shown 
activity against KB and KBv200 cell lines (Figure 11). 
 
Figure 11 – Structures of ulocladol A, alternariol 9-methyl ether and alternariol 
 
   12 
1.3  Ulocladol A 
1.3.1  Isolation and Biological Activity 
In 1999 an ethyl acetate extract of the fungal culture of Ulocladium botrytis, isolated from 
the marine sponge Callyspongia vaginalis, showed tyrosine kinase inhibitory activity and 
antimicrobial activity.15 Bio-assay guided work up by VLC and HPLC led to the isolation of 
ulocladol A and the anti-fungal metabolite 1.4 (Figure 12). 
 
Figure 12 – 1-Hydroxy-6-methyl-8-(hydroxymethyl)xanthone 
The anti-fungal metabolite 1.4 was identified as 1-hydroxy-6-methyl-8-(hydroxymethyl) 
xanthone, a compound previously isolated by Ayer and Taylor in 1976 and Hein et al. in 
1998.16, 17 Ulocladol A was found to exhibit tyrosine kinase inhibitory activity against p56lck 
with a reduction in enzyme activity to 7% at 0.02 µg/µL. 
Ulocladol A also adheres to Lipinski’s ‘Rule of Five,’ which states that poor oral absorption 
or permeation is more likely when:- 
  There are more than 5 H-bond donors 
  The molecular weight is over 500 
  The Log P is over 5 
  There are more than 10 H-bond acceptors 
Ulocladol A was found to have a biaryl core linked by a seven membered lactone ring, as 
shown in Figure 11. It has three hydrogen bond donor groups and seven hydrogen bond 
acceptor groups; a molecular weight of 318 Daltons and a Log P which is predicted to be 
1.81. This suggests that ulocladol A would be a good lead for further investigation. 
It is likely that ulocladol A is subject to axial chirality, due to the restricted rotation about 
the aryl-aryl bond, resulting in the formation of atropisomers. Atropisomerism is typically 
found in ortho substituted biaryl systems where steric congestion restricts free rotation 
about the carbon-carbon biaryl bond.18 Extensive studies of atropisomers have found that 
it is possible to resolve the different isomers if the biaryls are tetra-ortho- substituted, 13 
although this is less likely if two of the substituents are small. Tri-ortho- substituted biaryls 
can  be  interconverted,  although  not  usually  at  room  temperature  and  finally,  di-ortho 
substituted biaryls can usually only be resolved if the substituents are large. In the case of 
ulocladol A the ortho substituents are not particularly large, but they are linked through 
the  lactone  ring  and  it  is  unknown  how  this  will  affect  the  stereochemistry  of  the 
compound. 
The exact conformation of the natural product has not been determined and it is uncertain 
whether it is racemic or one specific atropisomer. In a laboratory synthesis of compounds 
of this nature, it is possible to control stereochemistry depending on the reagents and 
route involved. If a palladium-mediated coupling reaction was applied, axial chirality can 
be controlled through the use of chiral catalysts and ligands. However, due to the unknown 
stereochemistry  of  ulocladol  A,  we  will  not  initially  focus  on  preparing  a  specific 
atropisomer and instead will use a racemic route. 
1.3.2  Predicted Interaction of Ulocladol A with Enzyme Active Site 
The industrial sponsor of the project provided a model of ulocladol A docked into the 
active site of the enzyme Lck.19 This model shows some interesting interactions (Figure 
13). 
 
Figure 13 – Predicted interaction of ulocladol A with Lck binding site 
Figure 13a shows the spatial orientation of ulocladol A in the binding pocket of the Lck 
active site. The right hand ring of ulocladol A with the dihydroxymethoxy phenyl moiety 
points into the back of the pocket, presumably due to interactions with hydrogen bond 14 
acceptor sites. The carbonyl of the lactone ring forms a hydrogen bond with the “hinge” of 
the active site whilst the left hand ring is towards the periphery of the binding pocket. 
Figure  13b  shows a cartoon representation of the Lck enzyme. The active site can be 
observed towards the top of the model, located in the space between the hinged β-sheet 
and the  main body of the enzyme made up of α-helices. It is also possible to see the 
carbonyl  of  the  lactone  ring  pointing  towards  the  inside  hinge  of  the  enzyme.  The 
predicted interactions can be seen more clearly in an expanded view of the active site 
(Figure 14).19 
 
Figure 14 – The front view (a) and top view (b) of the predicted interactions of ulocladol A within the 
active site of Lck 
Figure 14 shows the expected hydrogen bonding interaction between the lactone carbonyl 
and the hydrogen atom on the nitrogen of the tyrosine amino acid residue. It also shows 
three  additional  predicted  hydrogen  bonding  interactions,  between  the  phenolic  and 
methoxy moieties on the left hand ring and the enzyme active site, further stabilising the 
binding of ulocladol A. With this is mind, it was proposed that the substitution of the right 
hand ring would provide further scope for improving the activity of any analogues of 
ulocladol A, whilst substitution of the left hand ring would be of less significance due to the 
predicted interactions already in place. 
A paper by Martin et al. details the synthesis of a novel series of furanopyrimidines which 
were also found to be inhibitors of Lck.20 One of the best compounds was 2,3-diphenyl-N-
(2-(piperazin-1-yl)ethyl)furo[2,3-b]pyridin-4-amine (1.5) (Figure 15). 15 
 
Figure 15 – Structure of 2,3-diphenyl-N-(2-(piperazin-1-yl)ethyl)furo[2,3-b]pyridin-4-amine 
Inhibitor  1.5  was  found  to  be  a  potent  inhibitor  of  Lck  with  an  IC50  of  0.21  μM.  A 
comparison of an X-ray crystal structure of 1.5 bound to the active site of Lck with the X-
ray structure of ulocladol A bound to the active site of Lck, shows that the two molecules 
appear to sit in the same pocket (Figure 16).21 
 
Figure 16 – Predicted X-ray structure of 1.5 bound to Lck binding site 
The compound sits in the hinge of the active site in the same orientation as ulocladol A. 
The nitrogen in the pyridine ring points into the left hand side of the pocket and appears to 
interact with the same site as the ester in the lactone ring of ulocladol A. In addition, the 
piperizine  ring  points  to  the  front  right  of  the  pocket  in  the  same  direction  that  the 
phenolic groups on the right hand ring of ulocladol A point. 
1.3.3  Synthetic Approaches to Ulocladol A 
There have been four total syntheses of ulocladol A, three of which were reported by Abe 
et al.  in  a  paper  published in  2006.22  Abe  described  three  routes  to  ulocladol  A:  one 
involved the demethylation of a hydroxyl group on another, previously synthesised natural 
product; one required a  benzyl  deprotection and the third a ring opening and closing 16 
procedure. The three syntheses required the use of intermediates reported in an earlier 
synthesis of a group of natural products called graphislactones. 
1.3.3.1  Synthesis of Graphislactone D Followed by Selective Demethylation 
In 2005 Abe et al. reported the 12 step synthesis of graphislactone D (1.19) (Scheme 1).23 
 
Scheme 1 17 
Commercially  available  methyl  3,4-dihydroxy-5-methoxybenzoate  (1.6)  was  selectively 
benzyl  protected  and  then  reduced  to  prepare  benzyl  alcohol  1.8,  which  was  then 
protected with a silyl protecting group to afford 1.9. 
Aromatic substitution of 3,5-dimethoxyaniline (1.10) followed by the introduction of an 
aldehyde using the Vilsmeier reaction afforded 1.12. Oxidation using hydrogen peroxide 
yielded  1.13  which  then  underwent  esterification  with  1.9  to  furnish  ester  1.14. 
Palladium-mediated,  intramolecular,  biaryl  coupling  of  1.14  yielded  the  six-membered 
lactone 1.15. Silyl deprotection of 1.15 followed by treatment with methanolic potassium 
carbonate resulted in the ring reconstruction of 1.16, via a ring opened intermediate 1.17, 
to  yield  the  seven-membered  lactone  1.18.  Benzyl  deprotection  of  1.18  afforded 
graphislactone D (1.19) in 4% overall yield. 
The following year Abe reported the selective demethylation of graphislactone D (1.19) 
with boron tribromide to afford ulocladol A in 21-73% yield. Despite best efforts, Abe was 
unable to reproduce the high yields in repeat reactions. 
1.3.3.2  Synthesis by Selective Demethylation and Deprotection of Intermediate 1.18 
Due to the difficulties observed following the demethylation of 1.19 to afford ulocladol A, 
Abe reversed the order of demethylation and debenzylation (Scheme 2). 
 
Scheme 2 
Using the Lewis acid aluminium chloride, Abe selectively demethylated 1.18 in 83% yield 
to  afford  benzyl protected  1.20.  Standard  hydrogenolysis  protocol  yielded  ulocladol  A 
(1.1) in 60% yield. 
1.3.3.3  Synthesis From 2-Iodo-4,6-dimethoxybenzalydehyde 
The third method reported by Abe et al. involved intermediate 1.26, which was prepared 
by the group in a previously reported synthesis of graphislactone C (Scheme 3).23 18 
 
Scheme 3 
Aldehyde  1.12,  prepared  as  an  intermediate  in  the  synthesis  of  graphislactone  D, 
underwent selective cleavage of one of the methoxy groups ortho to the aldehyde, with 
AlCl3 in 60% yield, to liberate a hydroxyl group which was then protected with a benzyl 
protecting group, 1.22, in 87% yield. The aldehyde was then oxidised to the carboxylic 
acid 1.23 in 98% yield. Condensation of carboxylic acid 1.23 and phenol 1.9 led to the 
formation of ester 1.24 in 65% yield. Palladium mediated biaryl coupling gave  1.25 in 
90% yield. Although not reported in either of the papers associated with the synthesis of 
graphislactone  C  or  ulocladol  A  published by  Abe  et al., intermediate  1.25  underwent 
deprotection  of  the  silyl  protecting  group  to  yield  1.26.  Intermediate  1.26  required  a 
reconstruction of the six-membered lactone ring (Scheme 4). 19 
 
Scheme 4 
Reconstruction  of  the  six-membered  lactone  ring  1.26,  using  potassium  carbonate  in 
methanol,  resulted  in  the  formation  of  a  seven-membered  lactone  ring  1.28  via  the 
intermediate 1.27 in 82% yield. Standard hydrogenolysis of the benzyl protecting groups 
furnished ulocladol A in 63% yield. 
1.3.3.4  Synthesis From 2,5-Dihydroxy-2,2-dimethyl-benzo[1,3]dioxin-4-one 
In the final six months of this project, Podlech et al. reported a total synthesis of ulocladol 
A.24  The  reported  synthesis  detailed  much  of  the  work  that  was  currently  being 
undertaken and the effect of this will be discussed in greater detail in subsequent chapters. 
However, the reported work only details the synthesis of ulocladol A, with no reference to 
the potential for synthesis of analogues (Scheme 5). 20 
 
Scheme 5 
Due to the reported work being published at a time when very similar work was underway 
in our laboratory, the published route will be discussed in context with the work carried 
out in this project. 
1.4  Alternariol and Alternariol 9-Methyl Ether 
1.4.1  Isolation and Biological Activity 
Alternariol  (1.3) and alternariol 9-methyl ether (1.2) are secondary metabolites of the 
Alternaria fungi,  first  isolated  by  Raistrick  et al.  in  1953.25  Raistrick  et al.  successfully 
determined the structure of alternariol, but were unable to conclusively determine the 
position of the methyl ether in alternariol 9-methyl ether. It wasn’t until 1961 that the 
structure  of  alternariol  9-methyl  ether  was  deduced  by  Thomas  through  a  series  of 
analytical and exploratory experiments.26 21 
The two natural products have caused significant problems agriculturally through crop 
fouling.  In  addition,  both  alternariol  and  alternariol  9-methyl  ether  have  shown  anti-
cancer potential, inhibiting KB and KBv200 cell lines (Table 1). 
  KB (IC50, µg/mL)  KBv200 (IC50, µg/mL) 
Alternariol 9-methyl ether  4.82  4.94 
Alternariol  3.17  3.12 
Table 1 – Biological activity of alternariol 9-methyl ether and alternariol 
1.4.2  Synthetic Approaches 
Since their isolation in 1953 there have been several total syntheses of alternariol and 
alternariol  9-methyl  ether.  In  total,  alternariol  has  been  prepared  four  times  and 
alternariol 9-methyl ether has been prepared twice.27-30 
1.4.2.1  Synthesis From Methyl Orsellinate 
The first synthesis of alternariol was reported in 1977 by Harris et al. and involved the use 
of a biomimetic route.27 A biomimetic route is a synthetic route to a molecule which aims 
to imitate a reaction pathway found in nature. Harris et al. utilise a synthetic route based 
on the acetate pathway used in nature to synthesise polyketides and fatty acids; these are 
essential precursors in the formation of many compounds, including prostaglandins and 
anthraquinones.31 In nature, the first step of the acetate pathway is the conversion of 




The reaction is catalysed by the enzyme acetyl-CoA carboxylase and requires the presence 
of ATP, CO2, in the form of HCO3, and biotin, the coenzyme. Malonyl-CoA is a more reactive 
nucleophile  than  acetyl-CoA  due  to  the  increased  acidity  of  the  α-methylene  protons, 
enabling the acetate pathway to occur (Scheme 7). 22 
 
Scheme 7 
Following the synthesis of malonyl-CoA, the second step is a Claisen type condensation 
reaction  with  acetyl-CoA,  furnishing  acetoacetyl-CoA.  Whilst  this  reaction  is 
thermodynamically  unfavourable,  it  is  pushed  to  completion  by  the  release  of  CO2. 
Repetition  of  this  condensation  reaction results  in  the  formation  of  poly-β-ketoesters, 
which can undergo further reaction leading to fatty acids and polycyclic compounds such 
as emodin anthrone.32 
Harris et al. were able to successfully apply a biomimetic route, inspired by the acetate 
pathway, to the synthesis of alternariol, isolating the product in six steps (Scheme 8).27 23 
 
Scheme 8 
Starting from methyl orsellinate (1.38), Harris et al. used dilithioacetylacetone to extend 
the ester to a carbonyl chain with six carbon atoms. This chain was extended again and 
oxidised  to  form  carboxylic  acid  1.40.  Esterification  followed  by  hydrogenation  of  a 
methoxy group led to 1.42 in 86% yield. Reaction of 1.42 with a 1 M methanolic sodium 
acetate solution yielded the precursor to alternariol 1.43 in 64% yield. Demethylation of 
1.43 with HI furnished the desired product alternariol (1.3) in 90% yield. 
1.4.2.2  Synthesis From 2,4-Dinitroaniline 
A second synthesis published in 1977 by Sόti et al. reported the use of the Hurtley reaction 
to couple the left and right hand rings (Scheme 9).28 24 
 
Scheme 9 
From  2,4-dinitroaniline (1.44),  Sόti  et al.  used  the  Sandmeyer  reaction  to  prepare  the 
brominated  benzonitrile  compound  1.45.  Sodium  methoxide  was  used  to  furnish  the 
desired dimethoxy product 1.46 which was then hydrolysed to the amide 1.47 using a 
solution of KOH in 1:1 water: ethanol. The precursor to alternariol 9-methyl ether (1.2) 
and alternariol (1.3), 1.48, was prepared by the Hurtley reaction, coupling the amide 1.47 
with  orcinol,  although  in  poor  yield.  Complete  demethylation  using  HI  furnished 
alternariol  (1.3)  in  81%  yield,  whilst  incomplete  demethylation  using  HBr  furnished 
alternariol 9-methyl ether in 73%. This linear route led to the isolation of alternariol 9-
methyl ether and alternariol, each in five steps and approximately 2% overall yield. 
1.4.2.3  Synthesis From 2,4-Dimethyoxy-6-methylbenzaldehyde 
The third synthesis of alternariol (1.3) was reported by Rao et al. in 1990 (Scheme 10).29 25 
 
Scheme 10 
Rao  et  al.  began  the  synthesis  with  the  commercially  available  2,4-dimethyoxy-6-
methylbenzaldehyde  (1.49),  converting  to  the  cinnamic  acid  1.50  by  refluxing  with 
malonic acid and pyridine. Esterification of the acid, followed by dibromination of the 
alkene afforded 1.52 in 64% over the two steps. Subsequent dehydrobromination using 
aqueous KOH furnished the alkyne 1.53 in 80% yield. Esterification of the free acid 1.53 
followed by a cycloaddition reaction with 1,4-dimethoxycyclohexa-1,5-diene afforded the 
precursor to alternariol,  1.55. Demethylation using BBr3 afforded the desired product, 
alternariol, in seven steps and 5% overall. 
1.4.2.4  Synthesis From Orcinol 
The most recent synthesis of alternariol 9-methyl ether and alternariol was a seven step 
convergent synthesis reported by Podlech et al. in 2005 (Scheme 11).30 26 
 
Scheme 11 
Commercially available orcinol (1.56) was first methylated and then brominated to yield 
1.57 in 98% over two steps. Lithiation using  n-butyllithium followed by trapping with 
triisopropyl borate resulted in the formation of boronic acid 1.58. The boronic acid 1.58 
was then immediately reacted with aldehyde 1.60 using Suzuki methodology to yield the 
biaryl  system  1.61,  which  was  subsequently  oxidised  to  the  carboxylic  acid  1.62. 
Demethylation using the Lewis acid boron tribromide resulted in a mixture of alternariol 
and alternariol 9-methyl ether in 73% and 20% yield respectively. 
1.5  Project Aims 
1.5.1  Ulocladol A and Analogues 
We intend to design a synthetic route to ulocladol A which will allow the synthesis of 
analogues. Any analogues prepared will be tested for biological activity and the results 
compared with those of the natural product. We intend to determine the SAR of ulocladol A 
so that this knowledge can be used to prepare a more active, drug-like compound. 
   27 
1.5.2  Alternariol and Alternariol 9-Methyl Ether 
Due  to  the  similarities in  structure  between  ulocladol  A,  alternariol  and  alternariol  9-
methyl ether we hope to adapt the synthetic route used to prepare ulocladol A in order to 
prepare alternariol  and  alternariol  9-methyl  ether. Due  to  the  extensive work  already 
undertaken in the preparation of these compounds, we do not intend to prepare analogues 
of these compounds. 29 
2  Synthesis of Ulocladol A and Analogues 
2.1  C-H Activated Coupling of Esters 
The three reported syntheses of ulocladol A by Abe et al. all involved rearrangement of the 
lactone ring.22 In each case the first step was the formation of an ester bond, which was 
then followed by palladium mediated coupling of the biaryl rings resulting in the formation 
of  a  six  membered  lactone  ring.  This  six  membered  lactone  ring  then  underwent 
rearrangement to form the desired seven membered ring. We proposed that it would be 
possible to prepare the protected benzyl benzoate ester 2.3, from a substituted benzoyl 
chloride 2.1 and a substituted benzyl alcohol 2.2, which would then undergo palladium 
mediated biaryl coupling. This would yield the desired seven membered lactone ring 2.4 
without need for further rearrangement (Scheme 12). 
 
Scheme 12 
Formation of other functionalised esters would also allow for the synthesis of analogues of 
ulocladol, with potential for substitution on both left and right hand rings. 
In 2006 Gaunt et al. published their work on C-H activated Heck coupling (Scheme 13).33 
 
Scheme 13 
They selectively coupled a pyrrole ring 2.5 and an alkene 2.6, using Pd(OAc)2 as a catalyst 
and t-BuOOBz as an oxidant, forming the carbon-carbon bond of 2.7 in good yield. We 
decided to apply these reaction conditions to simple benzyl benzoate esters in order to 
prepare a biaryl compound with a central seven membered lactone ring. 30 
We  decided  to  use  a  simple  ester  with  limited  functionalisation  to  test  the  reaction 
conditions. We prepared the ester 3,4,5-trimethoxybenzyl benzoate (2.10) from benzoyl 
chloride  (2.8)  and  3,4,5-trimethoxybenzyl  alcohol  (2.9),  using  standard  esterification 
methodology, in excellent yield (Scheme 14). 
 
Scheme 14 
We then attempted to intramolecularly couple the two aromatic rings of 2.10 using the 
conditions  reported  by  Gaunt  et al.  However,  we  were  unsuccessful  and  the  desired 
product 2.11 was not prepared. 1H NMR and mass spectrometry suggested that the ester 
bond had broken and the only compounds isolated at the end of the reaction were starting 
material,  benzoic  acid  and  3,4,5-trimethoxybenzyl  alcohol.  We  repeated  the  reaction, 
increasing the temperature to 70 °C and extending the time to 120 h, but were again 
unsuccessful. 
Further background reading into C-H activated, intramolecular coupling led us to a paper 
by Harayama et al.34 Harayama reported his research into aryl-aryl coupling of two rings 
linked by an amide with a halide functional group on one of the rings (Scheme 15). 
 
Scheme 15 
2-Bromo-N-methyl-N-phenylbenzamide (2.12) was successfully cyclised using Pd(OAc)2, 
DPPP and n-Bu3P to prepare 5-methylphenanthridin-6(5H)-one (2.13). 31 
We therefore decided to prepare an ester with a halide present on one of the rings. We 
successfully  mono-brominated  3,4,5-trimethoxybenzyl  alcohol  (2.9),  using  N-
bromosuccinimide  to  prepare  2-bromo-3,4,5-trimethoxybenzyl  alcohol  (2.14)  in  good 
yield (Scheme 16). 
 
Scheme 16 
The  ester  2-bromo-3,4,5-trimethoxybenzyl  benzoate  (2.15)  was  prepared  by  reacting 
benzoyl chloride (2.8) and 2.14, in the presence of triethylamine, in good yield. We then 
attempted to prepare the cyclised product 2.11, by intramolecularly coupling ester 2.15 in 




An  earlier  paper  by  Ames  and  Opalko,  published  in  1984,  reported  their  findings  on 
palladium-mediated  cyclisation  of  bromo  substituted  phenyl  benzoates.35  They 
determined that the location of the bromine functional group was important in the C-H 
activated coupling reaction (Scheme 18). 32 
 
Scheme 18 
When  bromine  was  situated  on  the  left  hand  ring,  2.16,  the  cyclisation  occurred  as 
expected, proceeding via a seven membered intermediate  2.17. The intermediate then 
underwent elimination of palladium to yield benzocoumarin (2.18), the desired cyclised 
product. If bromine was situated on the right hand ring 2.19, the desired reaction did not 
take place and instead, 2.19 underwent hydrolysis of the ester and no cyclised product or 
starting material was isolated. 
As we had undertaken the reaction with the bromine on the right hand ring, we decided to 
repeat  the  reaction  using  an  ester  with  bromine  situated  on  the  right  hand  ring.  We 
prepared the ester 3,4,5-trimethoxybenzyl-2-bromobenzoate (2.21) through reaction of 2-
bromobenzoyl  chloride  (2.20)  and  3,4,5-trimethoxybenzyl  alcohol  (2.9)  in  reasonable 
yield (Scheme 19). 
 
Scheme 19 
We then attempted to intramolecularly couple 3,4,5-trimethoxybenzyl-2-bromobenzoate 
in the presence of Pd(OAc)2, n-Bu3P, DPPP, DMF and K2CO3. However, the reaction was 
again unsuccessful and we were only able to isolate starting material and decomposed 
starting material from the crude reaction mixture. We repeated the reaction with different 
catalysts, ligands and bases but were still unsuccessful. 33 
Further research implied that in some cases bromine was not reactive enough for a C-H 
activated reaction to take place, and a more reactive halide was required. A paper by 
Harayama et al. reported his use of C-H activation to intramolecularly couple iodinated 
esters in the synthesis of the natural product arnottin I.36 
Harayama et al. used phenyl o-iodobenzoate as a test substrate for optimisation of the 
reaction conditions (Scheme 20). 
 
Scheme 20 
They  successfully  prepared  benzocoumarin  (2.18)  from  phenyl  o-iodobenzoate  (2.22) 
using a range of conditions (Table 2). 
Run  Catalyst  Ligand  Base  Time (h)  Temp 
Yield (%) of 
2.18 
1  Pd(OAc)2  None  NaOAc  1  Reflux  84 
2  Pd(OAc)2  DPPP  NaOAc  2  Reflux  75 
3  Pd(OAc)2  PPh3  NaOAc  2  130 °C  73 
4  Pd(acac)2  PPh3  NaOAc  2.5  130 °C  57 
5  Pd(OAc)2  PPh3  Ag2CO3  24  Reflux  38 
Table 2-Reported Conditions and Yields in the Synthesis of Benzocoumarin  
They determined that the best results were obtained using Pd(OAc)2 as a catalyst, sodium 
acetate as a base and DMF as the solvent. They reported varying results regarding the use 
of a ligand, with the best result being obtained when no ligand was present in the reaction, 
as shown in entry 1. Changing the base from sodium acetate to silver carbonate had a 
detrimental effect on the yield, reducing it by 35%, as shown in entry 5. 
Harayama et al. also reported their efforts to couple the regioisomer of 2.22, where the 
iodo group was on the right hand ring 2.23 (Scheme 21). 34 
 
Scheme 21 
They  successfully  prepared  benzocoumarin  (2.18)  from  o-iodophenyl  benzoate  (2.23) 
using Pd(OAc)2, PPh3 and NaOAc. However, at 6%, the yield was very low, suggesting that 
despite the more reactive halogen the location is still very important. 
We decided to try the reagents reported by Harayama et al. for the C-H activated coupling 
of an iodo-substituted ester. Prior to this we had to iodinate the required ester and we 
proposed to do this through halogen exchange of 2.21. We tried to exchange the bromine 
atom  for  an  iodine  atom  using  catalytic  copper  iodide,  sodium  iodide  and  N,N’-
dimethylethylene diamine (Scheme 22). 
 
Scheme 22 
The reaction mixture was heated at 110 °C for 23 h,  after which TLC showed starting 
material remained. We added additional amounts of CuI, NaI and N,N’-dimethylethylene 
diamine and then heated for an additional 48 h at 110 °C. After a total reaction time of 71 h 
we  stopped  the  reaction.  Crude  1H NMR  suggested  that  we  had a  mixture  of  starting 
material  2.21  and  product  2.24.  We  tried  to  separate  the  mixture  using  column 
chromatography but were unsuccessful as the product and starting material ran at the 
same Rf. The presence of iodinated product 2.24 was confirmed by mass spectrometry 
with the presence of a peak at 451 m/z corresponding to a [M+Na]+ molecular ion. 1H NMR 
suggested that there was a 2:1 ratio of starting material:desired product. Despite this, we 
decided  to  proceed  with  the  coupling  reaction  using  the  mixture  of  brominated  and 
iodinated esters (Scheme 23). 35 
 
Scheme 23 
We initially tried the reaction in the absence of the ligand. After 4 h there was no change in 
TLC from starting material, so 2 equivalents of the ligand was added and the reaction 
stirred at 130 °C for a further 20 h. After a total of 24 h, TLC indicated a change with the 
appearance of a second spot on the TLC plate. 1H NMR and mass spectrometry of the crude 
product  suggested  that  the  reaction  had  not  been  successful.  Instead  of  the  expected 
product, the palladium had inserted into the C-I bond and then eliminated to form a C-H 
bond rather than cyclising to form the desired seven-membered ring (Scheme 24). 
 
Scheme 24 
This resulted in the formation of 2.10, which was confirmed by mass spectrometry and 
comparison  of  the  1H  NMR  spectrum  with  the  spectrum  of  the  previously  prepared 
unhalogenated ester. A mixture of the brominated and iodinated starting material was also 
isolated. 
Despite functionalising the ester with a more reactive halogen as suggested by Harayama 
et al.  the  aryl-aryl  bond  forming  reaction  was  still  unsuccessful.  When comparing  the 
prepared ester 2.24 with the esters reported by Harayama there are several differences. 
The methoxy groups present on the right hand ring of ester 2.24 may have more than one 
detrimental effect on the reaction; not only are they sterically bulky groups, but they are 
electron donating groups which could have an electronic effect on the reaction. In addition 
to the effects of the methoxy groups, we are trying to form a seven membered lactone ring. 36 
In  order  to  form  the  seven  membered  ring  the  intermediate  palladacycle  is  an  eight 
membered ring. This ring size is much more difficult to form than the seven membered 
palladacycle  intermediate  prepared  by  Harayama.  It  is  possible  that  these  differences 
caused the C-H activation reaction to be unsuccessful. Therefore, we decided to move away 
from this route to ulocladol A. 
2.2  Ullmann Coupling 
A paper published by Tsuboi et al. in 2007 reported their work on the total synthesis of 
3,3’,4’-tri-o-methylellagic acid.37 They successfully used intramolecular Ullmann coupling 




The  system was cyclised  using  one  equivalent  of  copper in  59% yield.  This  ester  had 
several bulky electron donating  and withdrawing groups, which suggested that, in this 
system, the electronic and steric nature of nearby groups did not affect the reaction. We 
decided to try this method on our test model which would still cyclise to yield a seven-
membered lactone ring. We successfully reacted 2-bromobenzoyl chloride (2.20) and 2-
bromo-3,4,5-trimethoxybenzyl alcohol (2.14), in the presence of triethylamine, to prepare 
the  dihalogenated  2-bromo-3,4,5-trimethoxybenzyl  2-bromobenzoate  (2.27)  in 
quantitative yield (Scheme 26). 37 
 
Scheme 26 
Having successfully prepared the ester, the next step was to couple the two aryl rings 
under the conditions reported by Tsuboi et al. (Scheme 27). 
 
Scheme 27 
Unfortunately  we  were  not  successful,  with  both  1H  NMR  and  mass  spectrometry 
suggesting that copper insertion into one of the C-Br bonds had occurred but cyclisation 
had not taken place. Instead, when the copper eliminated, a C-H bond formed, which was 
confirmed by 1H NMR with the addition of an extra proton signal in the aromatic region 
and  the  presence  of  an  isotope  pattern  in  the  mass  spectrum  indicative  of  only  one 
bromine atom in the molecule. We repeated the reaction, extending the reaction time to 48 
h and increasing the quantity of copper to two equivalents, but were still unsuccessful. 
Another  paper  by  Kanth  et al.  reported  their  research  on  the  homo-coupling  of  aryl 
magnesium bromides catalysed by zinc bromide.38 They successfully coupled a range of 
aryl magnesium bromides at room temperature in good yield. Although Kanth et al. only 
reported work on homo-coupling we were hopeful that the conditions would be applicable 
to our system, as the two rings would be held in close proximity due to the linking ester 




The first step was the formation of a Grignard reagent which was then added to a mixture 
of zinc bromide in ether and then stirred for 6 h at rt. After 6 h no change was observed in 
the TLC. We extended the reaction time by 24 h and warmed to 35 °C but the reaction 
failed and no insertion into either of the C-Br bonds was observed. 
 A third procedure by Yuan et al. reported their research on the homo-coupling of various 
aryl  halide  compounds  catalysed  by manganese  (II) chloride.39 We  decided  to  use  the 
conditions reported by Yuan et al. to try and couple the ester 2.27 (Scheme 29). 
 
Scheme 29 
After  24  h  no  change  was  observed  in  TLC.  Crude  1H  NMR  and  mass  spectrometry 
suggested that there was no insertion into either C-Br bond. Literature searches revealed 
that it was possible to form a biaryl carbon-carbon bond with a linking seven-membered 
ring and this was demonstrated in a paper by Fagnou et al (Scheme 30).40 39 
 
Scheme 30 
Fagnou et al. reported the successful formation of a carbon-carbon bond, with a linking 
seven-membered ring, through C-H activation. The paper reported the use of both chloride 
and  bromide  with  good  yields  observed  in  each.  From  this  paper  we  were  able  to 
determine that the methoxy groups did not impose steric and electronic effects on the 
reaction to a degree that would prevent the coupling from occurring. This implied that the 
problems we observed in our reactions could be caused by a different part of the molecule. 
The major difference between the compounds we prepared and those reported by Fagnou 
et al.  is  the  presence  of  an  ester  linking  bond.  We  proposed  that  the  lack  of  success 
observed in both the C-H activated coupling and Ullmann coupling could be due to the 
inability of the two reactive sites to come into close enough proximity for the reaction to 
occur. The ester bond is relatively rigid and less likely to rotate round into a conformation 
which would allow the two desired sites to react. In addition to this, the CH2 would allow 
for rotation of the right hand ring away from the left hand ring in order to reduce steric 
hindrance, reducing the possibility of interaction of the two rings. This would explain why, 
in some cases, we observed palladium insertion into a C-X bond, but no carbon-carbon 
bond formation. 
This implies that, in the case of our system, the ester bond is an obstacle in the coupling 
reaction. Therefore, we proposed that if we were to replace the ester with an ether we 
would be able to successfully couple the two aryl rings and then reintroduce the carbonyl 
at a later stage. The next step was to prepare an ether system which we could use to test 
the arylation coupling conditions. Fagnou et al. reported success coupling ethers which 
were mono-brominated on the left hand ring. Unfortunately, despite attempting to prepare 
ethers which were mono-brominated on either the left hand or right hand ring, we were 
only able to prepare the dibrominated ether 2.33 (Scheme 31). 40 
 
Scheme 31 
Ether  2.33  was  prepared  by  reacting  2-bromobenzaldehyde  with  2-bromo-3,4,5-
trimethoxybenzyl  alcohol  in  24%  yield.  We  then  tried  to  form  a  carbon-carbon  bond 
between the aryl rings of ether 2.33 following the conditions reported by Fagnou et al., 
although with SPhos in place of DavePhos (Scheme 32). 
 
Scheme 32 
However,  1H  NMR  and  mass  spectrometry  suggested  that  the  reaction  had  been 
unsuccessful with no product observed. 
Due to the lack of success in C-H activated coupling and Ullmann coupling, we decided to 
change  the  proposed  route  to  ulocladol  and concentrate  on  cross  coupling.  Instead  of 
forming the carbon-carbon bond through intramolecular coupling once the ester bond was 
in place, we proposed to firstly form the carbon-carbon bond and then cyclise to prepare 
the seven-membered lactone. 
2.3  Suzuki Coupling  
There are several different methods of forming a carbon-carbon bond between two aryl 
rings. Some of the better known methods include Stille, Negishi and Suzuki coupling.41-46 
All three of these reactions require an organometallic reagent and a catalyst. The reactions 
are usually mediated by palladium and involve the coupling of an aryl halide or triflate 41 
with  an  organostannane  in  the  Stille  reaction,  an  organozinc  in  the  Negishi  or  an 
organoboron in the Suzuki reaction. We proposed that it would be possible to prepare 
ulocladol A through the Suzuki reaction using an aryl triflate and an aryl boronate (Figure 
17). 
 
Figure 17 – Suzuki coupling reaction 
The first step involves oxidative addition of the aryl triflate to a zerovalent palladium 
source  yielding  a  palladium  (II)  complex.  Transmetallation  between  the  palladium 
complex and  the  organoboron compound  followed  by reductive  elimination  yields  the 
desired cross coupled product with regeneration of the palladium zerovalent catalyst.  
Retrosynthesis  of  ulocladol  A  using  Suzuki  coupling  as  the  key  step  in  this  synthesis 
provided us with two fragments (Scheme 33). 42 
 
Scheme 33 
Splitting ulocladol A across the carbon-carbon bond and the ester group gave fragments 
2.35 and 2.36, both of which would need to carry a group in the X and Y positions that 
would be suitable for cross coupling. Fragment 2.35 is similar to a known compound 2.37 
which  was  used  in  Suzuki  couplings  by  Takahashi  et  al.  in  the  total  synthesis  of 
dehydroaltenusin (Scheme 34).47 
 
Scheme 34 
We  proposed  ulocladol  A  could  be  prepared  by  coupling  the  triflate  2.40  with  the 
corresponding boronic acid. 
The first step was to protect the carboxylic acid as an acetonide. Takahashi et al. reported 
their  use  of  thionyl  chloride,  acetone  and  catalytic  DMAP  to  prepare  acetonide  2.38. 
However, this method proved unsuccessful and we were unable to obtain the desired 
product. Further investigation yielded an alternative method reported by Danishefsky et 
al.,  to  protect  the  carboxylic  acid as  an  acetonide.48  The  commercially  available  2,4,6-43 
trihydroxybenzoic acid monohydrate (2.37) was successfully protected using TFA, TFAA 
and acetone in 61% yield (Scheme 35). 
 
Scheme 35 
Compared to the literature yields this was an increase of 5% and 27% for the thionyl 
chloride and TFA methods respectively. 
The phenol para to the protected carboxylic acid was then selectively alkylated using a 
standard Mitsunobu protocol to prepare 2.38 as a white solid in 87% yield. We proposed 
that the selectivity observed in this reaction could be due to several factors. Following the 
first protecting step, the two phenols have different signals in the 1H NMR spectrum. The 
phenol ortho to the carbonyl corresponds to a sharp singlet at 10.45 ppm, whereas the 
phenol para to the carbonyl is a broad singlet at 9.66 ppm. This suggests the presence of a 
hydrogen bond between the hydrogen of the ortho phenol and the carbonyl oxygen atom. 
This hydrogen bond lowers the acidity of the proton therefore reducing the likelihood of 
this phenol reacting in the Mitsunobu reaction. In addition to this, not only is the proton on 
the phenol para to the carbonyl likely to be more acidic, and therefore more reactive, than 
the phenol ortho to the carbonyl, it is also not sterically hindered by neighbouring groups. 
The next step in the synthesis was to convert the remaining phenol into a triflate group 
which could then be used in a Suzuki coupling reaction. The procedure reported by both 
Takahashi  et al.,  and  Danishefsky  et al.  described  the  use  of  trifluoromethanesulfonic 
anhydride in the presence of pyridine to prepare the triflate 2.40 (Scheme 36). 44 
 
Scheme 36 
However, the reaction was unsuccessful under these conditions and only starting material 
was isolated. Following an alternative procedure reported by Frantz et al., we successfully 
prepared  2.40  in  81%,  by  adding  trifluoromethanesulfonic  anhydride  to  a  biphasic 
solution of aqueous LiOH and toluene.49 The product was confirmed by 1H NMR with the 
loss of the phenolic OH signal at 10.43 ppm and mass spectrometry with a molecular ion 
peak at 357 m/z. 
Having  successfully  prepared  the  left  hand  side  of  ulocladol  A  we  decided  to  test  the 
stability of the triflate to Suzuki coupling conditions with a commercially available boronic 
acid 2.44 (Figure 18). 
 
Figure 18 – 2-(Hydroxymethyl)benzeneboronic acid hemiester 
We chose 2.44 as the test boronic acid for two reasons. Firstly, there were no additional 
substituents  on  the  benzene  ring  which  could  adversely  affect  the  Suzuki  reaction. 
Secondly, the boronic acid was trapped in a five-membered ring with the benzyl alcohol 
required for the formation of the lactone ring. This meant that it was not necessary to 
protect the alcohol during the Suzuki reaction and then add an additional deprotection 
step once the reaction was complete. 
A  1990  paper  by  Suzuki  et  al.  reported  their  research  on  palladium-mediated  cross 
coupling.50  Suzuki  et al.  successfully  coupled  a  range  of  aryl  and  vinyl  triflates  with 45 
organoboron compounds using 2.5 mol% of PdCl2(dppf) and excess K3PO4 in THF. We 
applied these conditions to the triflate 2.40 and the boronic acid 2.44 (Scheme 37). 
 
Scheme 37 
The reaction was successful, and we obtained the cyclised product  2.45 in 34% yield 
following purification. We were surprised to discover that the lactone ring had cyclised in 
situ and proposed that this was due to the basic nature of the benzyl alcohol anion which 
can intramolecularly attack the carbonyl causing loss of the acetonide protecting group. 
This resulted in the preparation of an analogue of ulocladol A in four steps. 
The structure of the product was confirmed by  1H NMR and mass spectrometry. Several 
key signals were observed in the 1H NMR spectrum. There was a sharp peak at 10.64 ppm, 
indicating the presence of a hydrogen bonded phenol; two doublets at 6.61 and 6.63 ppm 
indicating the two aromatic protons on the left hand ring; two broad singlets at 5.00 and 
5.17 ppm assigned to the two protons on the CH2 of the lactone ring; and a singlet at 3.89 
indicating the presence of the methoxy group on the left hand ring. A multiplet at 7.35 – 
7.69 ppm, which integrated at four protons, indicated the presence of the four aromatic 
protons on the right hand ring. The presence of a peak at 255 m/z confirmed the presence 
of a product with a [M-H]ˉ molecular ion. The analogue  2.45  was tested for biological 
activity  against  a  variety  of  tyrosine  kinase inhibitors  and  was  found  to  have  limited 
activity. This implied that the substituents on the right hand ring were important in the 
activity of ulocladol A against tyrosine kinase. 
It was proposed that the Structure-Activity Relationships (SAR) of ulocladol A could be 
investigated,  by  coupling  the  prepared  triflate  2.40  with  substituted  organoboron 
compounds. The activity of these analogues could then be compared to the activity of 2.45, 
allowing us to establish the effect of right hand ring substituents on biological activity. 46 
It was possible to purchase one cyclised benzene boronic acid with a substituent. This was 
2-hydroxymethyl-5-nitrophenylboronic acid, (2.46) (Scheme 38). 
 
Scheme 38 
2.46 was cross coupled with triflate 2.40 to prepare 2.47 in 32% yield. The product was 
confirmed by mass  spectrometry  with  a  peak  at m/z  300  for  the  [M-H]ˉ mass ion.  In 
addition,  all  the  major  signals  in  the  positive  electrospray  mass  spectrum  could  be 
attributed to ions relating to the product mass ion. However, the  1H NMR suggested the 
presence of 2 compounds, with double the expected number of signals in the spectrum 
apart from the hydrogen bonded phenol. The signal for the phenol at 10.61 ppm is the only 
peak that is not duplicated and does not integrate to two protons (Figure 19). 47 
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Figure 19 – 1H NMR spectrum of 2.47 
TLC and mass spectrometry are both consistent with only one compound being present, 
whereas NMR suggests two, very similar compounds. Closer inspection of the aromatic 
region shows that each peak appears to be doubled, although the distance between each 
set of corresponding peaks is variable (Figure 20). 48 
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Figure 20 – Aromatic region of 1H NMR spectrum of 2.47 
The  protons  closest  to  the  aryl-aryl  bond  appear  to  experience  the  greatest  distance 
between corresponding peaks, whilst those furthest away are only slightly shifted. This 
can be observed with the signals on the right hand ring. Proton 11, the proton ortho to the 
aryl-aryl bond, appears to correspond to the two signals at 8.44 ppm and 8.55 ppm. The 
difference between the two shifts is 0.1 ppm. The signals corresponding to proton 9, the 
proton para to the aryl-aryl bond on the right hand ring, at 8.30 ppm and 8.35 ppm are 
only separated by 0.05 ppm, half the distance of the protons closest to the carbon-carbon 
bond. The peaks at 7.64 ppm and 7.71 ppm, corresponding to proton 8, which is the only 
proton meta to the aryl-aryl bond, are separated by 0.07 ppm. This appears to suggest that 
the further the distance from the aryl-aryl bond the proton is the smaller the difference in 
the shifts between corresponding peaks. 
This  is  not  observed  in  the  same  way  for  the  protons  on  the  right  hand  ring.  Closer 
inspection of the signals at 7.05 ppm, 7.15 ppm, 6.70 ppm and 6.69 ppm suggests that the 
two protons at 7.05 ppm and 7.15 ppm couple to each other, as do the two protons at 6.70 
ppm and 6.69 ppm. In the case of these four protons, not only are the distances between 
the coupled signals different, but the shifts of the peaks are also quite different. We are 49 
unsure why this occurs and also why  1H NMR suggests that there are two compounds 
present. 
The  presence  of  two  compounds  could  also  be  observed with  the  13C  NMR  spectrum 
Instead of the expected 15 signals, 24 were observed. 13 of the peaks could be attributed 
to the aromatic C-H, CH2 and OCH3 carbons with 2 signals for each of the CH2 and OCH3 
groups and 9 for the 5 aromatic C-H carbons. The remaining 11 signals correspond to the 
remaining 8 quaternary carbons. 
Due to the similarities in shifts of the corresponding peaks and the presence of only one 
mass ion  peak  we  believe  that  the  two  compounds  must  be  very  closely related.  One 
possibility  is  the  presence  of  regioisomers.  Whilst  we  can  be  certain  from  NMR 
experiments that the triflate starting material was one compound, we are unsure about the 
commercially bought 2-hydroxymethyl-5-nitrophenylboronic acid (2.46). Unfortunately, 
all of the starting material was consumed in the reaction so we were unable to determine 
whether more than one compound was present. If we were able to prepare regioisomers of 
analogue 2.47 we would be able to compare the 1H NMR spectra. This would allow us to 
determine whether the explanation for the doubling of the peaks was due to the presence 
of more than one regioisomer. 
As  no  additional  cyclised  benzene  boronic  acids  were  commercially  available,  it  was 
decided to prepare them synthetically. Zhdankin and co-workers published a route to the 




Zhdankin suggested that the reaction went through a dianion intermediate 2.49 which was 
trapped with triisopropyl borate and then hydrolysed to form the desired boronic acid. We 50 
proposed to use this method to prepare substituted benzene boronic acids which could 
then be coupled with the triflate. 
As the unsubstituted analogue of ulocladol A had already been successfully prepared it was 
decided to synthesise a benzene boronic acid with one substituent which would not affect 
the lithiation and trapping reaction. With this in mind we decided to prepare 2-bromo-4-
methylbenzyl alcohol (Scheme 40). 
 
Scheme 40 
We  successfully  reduced  carboxylic  acid  2.50  to  benzyl  alcohol  2.51,  using  sodium 
borohydride and zirconium chloride, in 90% yield.52 The next step was to prepare the 
cyclised boronic acid. Following the procedure reported by Zhdankin and co-workers, we 
attempted to prepare the dianion species 2.52 and then trap with triisopropyl borate to 
yield the desired product  2.53. However, the reaction failed. We changed the reaction 
conditions experimenting with time, temperature and equivalents of n-BuLi and B(Oi-Pr)3. 
In addition the borate was also changed and fresh triisopropyl borate, trimethyl borate 
and triethyl borate were all tried but to no avail and we were only able to isolate 4-
methylbenzyl alcohol from the crude reaction. This led us to the conclusion that it was the 
trapping  step  which  was  causing  the  problem.  Treatment  of  2-bromo-4-methylbenzyl 
alcohol with butyllithium leads to the formation of a dianion species 2.52 which should 
then trap a borate molecule. If a borate has not been successfully trapped, addition of 
hydrochloric acid will cause protonation of the dianion species forming 4-methylbenzyl 
alcohol as a side product of the reaction. 
As we were unable to prepare substituted benzene boronic acids in this way we decided to 
consider another route to ulocladol A and its analogues. A common solution to problems 
with Suzuki cross coupling is to exchange the location of the functional groups involved in 51 
the reaction. In this case, if we were to exchange the triflate group on the left hand ring for 
a boronic acid, we would have a lot more options for groups on the right hand ring. As well 
as coupling the boronic acid with a triflate group, it would also be possible to use halides. 
As these are much more readily available it would allow a more in depth investigation into 
the SAR of the right hand ring. 
Following a procedure reported by Altemöller et al. we were able to substitute the triflate 
group with a boronic ester (Scheme 41).53 
 
Scheme 41 
However, it was necessary to adapt the conditions reported by Altemöller  et al. as we 

















0.50  16.84a  0.05  3  Dioxane  4  54 
1  0.25  16.84a  0.05  3  Dioxane  4.75  0 
2  0.84  16.84a  0.06  3  THF  12  26 
3  1.40  15b  0.06  3  THF  4  49 
4  1.25  10b  0.06  3  THF  4  59 
5  1.00  5b  0.06  3  THF  4  83 
6  4.00  5b  0.06  3  THF  4  92 
7  0.84  2.5b  0.06  3  THF  6  36 
a:  1-2% Triethylamine stabilised solution     b:  1M solution in THF 
Table 3-Optimisation of Conditions for the Formation of the Boronic Ester 
Altemöller et al. reported a yield of 54% of the desired product 2.55 and 22% yield of the 
side  product  2.56.  When  we  repeated  the  reaction  using  the  conditions  reported  by 
Altemöller et al. we were unable to isolate any product, and the only identifiable products 52 
of the reaction were starting material, the side product  2.56 and an alkyl residue. We 
found that if dioxane was replaced with THF, catalyst loading increased to 6 mol% and the 
reaction  time  extended  to  12  h  the yield  increased  to  26%.  However  this  was  not  an 
acceptable yield for an intermediate in the synthesis. In addition to the poor yield we also 
observed  an  impurity  in  the  product  which  could  not  be  removed  by  column 
chromatography, recrystallisation or acid and base washes. We were unable to determine 
the identity of the impurity with absolute certainty but proposed that it was related to the 
structure of pinacol borane. We hoped that if we were able to reduce the quantity of 
pinacol borane required in the reaction, without adversely affecting the yield, we would be 
able to reduce the quantity of impurity in the product. 
We  had  observed  that  the  yield  was  adversely  affected  if  triethylamine  and 
tetrahydrofuran were not freshly distilled for the reaction. As Altemöller et al. had used a 
1-2% triethylamine stabilised solution as their source of pinacol borane, we considered 
the possibility that this was adversely affecting the reaction. If the triethylamine used to 
stabilise the pinacol borane was wet or impure it could cause problems in the reaction. 
Therefore it was decided to try using a 1 M solution of pinacol borane in THF. We found 
that 15 equivalents of a 1 M solution increased the yield of the reaction by 23%. The 
reaction time was also affected, reducing it back down to 4 h. However, a large quantity of 
impurity was still observed in the product. In an attempt to reduce the quantity of the 
impurity, we reduced the equivalents of pinacol borane to 10 (entry 4). We were surprised 
to discover that this did not have a detrimental effect on the yield, and actually caused an 
increase  to  59% whilst  retaining  the  shorter  reaction  time.  We  repeated the  reaction 
reducing the equivalents of pinacol borane to 5 and were able to increase the yield to 83%. 
We found that this also caused a decrease in the quantity of impurity observed in the 
product, as well as being a reproducible reaction on a larger scale. Further reduction of 
pinacol borane to 2 equivalents caused a decrease in yield to 36%. 
Having successfully prepared the boronic ester intermediate the next step was to couple 
the  boronic  ester  with  a  bromobenzyl  alcohol.  Due  to  the  previously  attempted  C-H 
activation route we had a stock of 2-bromo-4-methylbenzyl alcohol (2.51) and 2-bromo-
3,4,5-trimethoxybenzyl alcohol (2.14) readily available. We proposed to test stability of 
the  boronic  ester  to  the  Suzuki  reaction  conditions  by  coupling  with  the  methoxy 
substituted bromobenzyl alcohol. We decided not to protect the benzyl alcohol because, if 53 
the reaction was successful, this would negate the need to add an additional two steps to 
the synthesis. Using the Suzuki conditions applied to the synthesis of analogues 2.45 and 




The reaction proceeded in moderate yield and the uncyclised, protected product 2.57 was 
isolated following column chromatography. The uncyclised product was confirmed by  1H 
NMR through the absence of a signal at approximately 10.5 ppm for the hydrogen bonded 
phenol on the left hand ring, and the addition of two singlets at 1.78 ppm and 1.74 ppm 
indicating the presence of the additional methyl groups on the acetonide protecting group. 
There were five signals in the aromatic region as expected, as well as a singlet at 3.85 ppm 
for  the  methyl  group  on  the  right  hand  ring  and  a  multiplet  between  4.34-4.42  ppm 
indicating the benzyl CH2. We then proceeded to cyclise the lactone ring through addition 
of base. We hoped the base would deprotonate the benzyl alcohol which would then attack 
the acetonide carbonyl as proposed in the Suzuki coupling reactions to prepare 2.45 and 
2.58 (Scheme 43). 
 
Scheme 43 
The uncyclised compound 2.57 was stirred in a suspension of NaH in THF for 5 h, after 
which aqueous workup and column chromatography yielded 50% of the desired product 54 
2.58 as an off white solid. Only one compound was observed in the 1H NMR spectrum, with 
only 5 signals for the 5 aromatic protons. 
One of the aims of the project was to try to gather information about the SAR of ulocladol 
A. Having established that both the boronic ester starting material and the unprotected 
bromobenzyl alcohol were stable and reactive under Suzuki coupling conditions, we began 
to target analogues based on commercially available starting materials, ease of synthesis of 
starting  materials  and  location  and  functionality  of  substituents.  From  the  earlier 
attempted synthesis of the bromo substituted esters we had a supply of 2-bromo-3,4,5-
trimethoxybenzyl  alcohol,  which  could  be  coupled  with  the  boronic  ester  to  yield  an 
analogue with substituents in the same location as ulocladol A. The boronic ester was 




Coupling  of  2.55  with  2.14  produced  a  mixture  of  uncyclised  product  2.59,  cyclised 
product 2.60, the impurity observed in the boronic ester starting material and unreacted 
2.14. As the mixture could not be separated by column chromatography it was further 
reacted  with  NaH  in  the  hope  that  this  would  yield  only  cyclised  product  2.60.  The 
reaction successfully transformed the uncyclised product 2.59 to cyclised product 2.60 in 
22%  yield  over  two  steps  and  removed  the  impurity  from  the  boronic  ester  starting 
material. However, the unreacted starting material was not removed. The impurity could 55 
not be removed with acid and base washes or through recrystallisation. The product was 
confirmed by mass spectrometry with a signal at 369 m/z for the [M+Na]+ mass ion. 
Having  successfully  prepared  the  trimethoxy  analogue,  we  proposed  that  it  would  be 
possible to prepare ulocladol A by selectively removing methoxy groups from the right 
hand ring. A literature procedure by Reeder et al. reported the use of boron tribromide to 
demethylate a methoxy group on a hexasubstituted benzene ring (Scheme 45).54 
 
Scheme 45 
Following this procedure we attempted to selectively demethylate two of the methoxy 
groups of the trimethoxy analogue 2.60, in the 4 and 5 positions of the right hand ring 
using boron tribromide (Scheme 46). 
 
Scheme 46 
However the reaction was unsuccessful and no product was isolated. We repeated the 
reaction, extending the reaction time and increasing the temperature of the reaction, but 
no demethylation of any of the methoxy groups was observed and only starting material 
was isolated. 
As the demethylation reaction had been unsuccessful, we decided to concentrate on the 
SAR of ulocladol A by continuing to prepare analogues with comparable functional groups. 56 
We were able to purchase 2-bromo-5-methoxybenzoic acid (2.63) which we successfully 
reduced to the benzyl alcohol 2.64 in 87% yield (Scheme 47). 
 
Scheme 47 
We chose this benzyl alcohol because, when coupled with the boronic ester, it would yield 
an analogue with a methoxy group in the same position on the right hand ring as the 
natural product. When comparing the biological activity of this analogue with ulocladol A 
we will be able to determine whether the absent phenols on the right hand ring play a part 
in the biological activity of the natural product.  The next step in the synthesis was to 




The  uncyclised  compound  2.65  was  isolated  in  21%  yield,  although  with  impurities 
observed in the 1H NMR. We decided to cyclise the lactone ring and purify the product at a 
later  stage.  The  lactone  was  formed  using  sodium  hydride  to  deprotect  and  cyclise 
furnishing the desired product 2.66 in 62% yield. The product was confirmed by mass 57 
spectrometry, with a peak at 287 m/z for the [M+H]+ mass ion, and 1H NMR, with 5 signals 
in the aromatic region, a phenol at 10.59 ppm, 2 methoxy signals and 2 broad singlets at 
5.13 ppm and 4.78 ppm for the CH2. 
With  five  analogues  of  ulocladol  A  prepared,  it  was  necessary  to  prepare  the  natural 
product itself in order to have a fair comparison of biological activity. Literature searches 
revealed a route to a compound which could be used to prepare the natural product. The 
four-step synthesis yielded the desired product 2.71 in 17% overall yield (Scheme 49).55-57 
 
Scheme 49 
The commercially available starting material, 5-bromovanillin (2.67), was hydrolytically 
dehalogenated using catalytic copper powder and aqueous sodium hydroxide to furnish 
the  aldehyde  2.68.  The  product  was  recrystallised  from  toluene  and  the  structure 
confirmed by mass spectrometry and 1H NMR. Selective aromatic bromination followed by 
acetyl protection of the phenolic groups led to the isolation of the protected aldehyde 2.70. 
We  then  successfully  reduced  the  aldehyde  to  the  benzyl  alcohol  using  sodium 
borohydride in excellent yield. The next step was to couple the bromobenzyl alcohol 2.71 
with  the  boronic  ester  intermediate  using  the  Suzuki  conditions  already  established 
(Scheme 50). 58 
 
Scheme 50 
The reaction was unsuccessful and no product, cyclised or uncyclised, was isolated from 
the reaction. The only compounds isolated from the reaction were boronic ester starting 
material and the phenol 2.39 as a by-product of the reaction. We proposed that the failure 
of  the  reaction  could  have  several  explanations.  Firstly,  it  is  possible  that  the  acetyl 
protecting groups are not stable to the basic conditions of the Suzuki reaction. If this were 
the  case  and  the  acetyl  groups were  removed  prior  to  the  reaction,  the  free  phenolic 
groups could interfere with the reaction. Secondly, the bulkiness of substituent groups can 
have an effect on the reaction and. whilst we have previously coupled a penta-substituted 
bromobenzyl alcohol, 2.14, under these Suzuki conditions, the yield was very low. In this 
case, the acetyl groups are bulky groups and this could have had an adverse steric effect on 
the reaction. Finally, the electronic nature of the acetyl groups may have an effect on the 
reaction. Unlike the trimethoxy substituted bromobenzyl alcohol, the acetyl groups are 
electron withdrawing groups resulting in an electron deficient ring. This electronic effect 
may have adversely affected the reaction. 
In  order  to  determine  whether  the  reaction  failed  because  of  the  sensitivity  of  the 
protecting groups to the basic reaction conditions or because of steric hindrance around 
the ring, we decided to repeat the reaction using different catalyst systems which were 
more accepting of steric bulk. If the reactions still failed, it would imply that the acetyl 
protecting groups were not stable under Suzuki coupling conditions. In addition to this we 
would also be able to test a different catalyst system which could lead to higher yields of 
the desired product. 59 
A paper by Buchwald et al. reported their research on Suzuki coupling reactions between a 
boronic acid and a sterically hindered bromide(Scheme 51).58 
 
Scheme 51 
SPhos is often used as a ligand in Suzuki coupling reactions containing bulky, sterically 
hindered reagents. As shown in Scheme 51, Buchwald et al. successfully cross-coupled a 
boronic acid 2.74 with a hindered aryl bromide 2.75, furnishing the desired biaryl product 
2.76 in 93%. The aryl bromide 2.75 bears some resemblance to 2.71, the aryl bromide 
required to prepare ulocladol A, with both bromides being penta-substituted with four out 
of the five functional groups containing oxygen atoms. The location of functional groups, 
with respect to the bromide, is also the same in both compounds. Due to these similarities 
we decided to apply the Suzuki conditions to our substrates (Scheme 52). 
 
Scheme 52 
We  attempted  to couple  the boronic  ester  2.55  with  the  aryl  bromide  2.71  but  were 
unsuccessful. Mass spectrometry of the crude reaction mixture showed no mass ion peaks 
for  either  the  cyclised  or  uncyclised  products  and  the  only  recognisable  peak  in  the 
spectrum was that of the boronic ester starting material. Crude  1H NMR confirmed this 60 
with no peaks between 4 and 6 ppm which is the region where the protons from the CH2, 
either cyclised into the lactone ring or as the benzyl alcohol, are usually observed. In 
addition to the lack of desired product, there was also no indication of the presence of the 
bromobenzyl alcohol starting material 2.71 in the crude reaction mixture. This implied 
that the acetyl protecting groups were problematic in the Suzuki coupling reaction and it 
would be necessary to determine which protecting groups could be used successfully.  
Due to the similarities between our substrates and those used by Buchwald  et al., we 
decided to test the reported reaction conditions on other bromobenzyl alcohols in the 
hope that the reaction yields could be improved. Commercially available 2-bromo-4,5-
dimethoxybenzyl  alcohol  (2.77)  was  coupled  with  the  boronic  ester  2.55  using  the 
reported conditions (Scheme 53). 
 
Scheme 53 
Analysis of the crude material, with the presence of characteristic signals in the  1H NMR 
spectrum  for  the  phenol  and  benzylic  CH2  at  10.69  ppm  and  5.02  ppm  respectively, 
suggested  that  the  lactone  ring  had  cyclised  in  situ.  Purification  by  column 
chromatography yielded the desired product 2.78 with an impurity which ran at the same 
Rf. We were unable to separate this impurity by column chromatography, and instead used 
acid and base washes. The impurity was determined to be unreacted bromobenzyl alcohol. 
The clean product was confirmed by mass spectrometry with a mass ion peak at m/z 339 
[M+Na]+.  1H  NMR  of  the  pure compound  showed  four  signals  in  the  aromatic region, 
integrating as four protons, and three singlets between 3.90 – 3.97 ppm for the three 
methoxy groups, in addition to the signals at 10.69 and 5.02 ppm. 
Although  the  yield  of  this  reaction was  still  low,  the  cyclisation  step  occurred  in situ, 
negating the need for an additional step in the reaction. For this reason we decided to 
continue with the Buchwald conditions for other bromobenzyl alcohols. 61 
We were able to purchase a precursor for a regioisomer of the bromobenzyl alcohol 2.77. 
The  ester,  methyl-3,5-dimethoxybenzoate  (2.79),  was  transformed  into  the  desired 
bromobenzyl alcohol in two steps (Scheme 54).59 
 
Scheme 54 
Methyl-3,5-dimethoxybenzoate  (2.79)  was  selectively  brominated  using  N-
bromosuccinimide to yield methyl-2-bromo-3,5-dimethoxybenzoate (2.80) in 80%. The 
ester  was  then  reduced  using  DIBAL  to  furnish  2-bromo-3,5-dimethoxybenzyl  alcohol 
(2.81)  in  70%  yield.  The  structures  of  both  products  were  confirmed  by  mass 
spectrometry and NMR spectroscopy. We then went on to couple the bromobenzyl alcohol 
2.81 with the boronic ester 2.55 (Scheme 55). 
 
Scheme 55 
The desired, cyclised product 2.82 was isolated in 8% yield after purification by column 
chromatography and acid and base washes to remove additional impurities. The molecular 
weight was confirmed by mass spectrometry with a peak at m/z 339 for the [M+Na]+ 
molecular ion. In addition, NMR spectrometry confirmed the structure with characteristic 
peaks of: a singlet at 10.18 ppm for the phenolic OH group on the left hand ring; four 
doublets between 6.54 – 6.82 ppm for the four aromatic protons; two broad doublets at 
5.11 ppm and 4.82 ppm for the CH2 and three singlets between 3.80 – 3.88 ppm for the 
three methoxy groups. 62 
As well as determining the SAR of ulocladol A, one of the aims of the project was to prepare 
an analogue which was not only more biologically active but also more bioavailable. With 
this  in  mind,  we  looked  into  purchasing  bromobenzyl  alcohols  which  could  increase 
biological activity, change the Log P or give us further insight into SAR. We were able to 
purchase four bromobenzyl alcohols which could be coupled with the boronic ester using 
the Suzuki coupling conditions reported by Buchwald et al. The first coupling was between 
the boronic ester and a para, nitrile substituted bromobenzyl alcohol. The nitrile group 
occupies the same position as one of the phenol groups on the right hand ring of ulocladol 
A. Whilst it is not a hydrogen bond donor it could accept hydrogen bonds and will give an 




The reaction was successful and the desired cyclised product  2.84 was isolated in 6% 
yield. The molecular weight of the product was confirmed by mass spectrometry with a 
mass ion signal corresponding to a [M+Na]+ molecular ion of m/z 304. The structure was 
confirmed by  1H NMR with the presence of characteristic signals at: 10.56 ppm for the 
phenolic  OH;  four  doublets  and  one  doublet  of  doublets  in  the  aromatic  region 
corresponding to the five aromatic protons and two broad signals at 5.16 ppm and 5.02 
ppm for the CH2 protons. 
The second and third bromobenzyl alcohols to be coupled with the boronic ester were 
both fluorine derivatives: one with a trifluoromethyl substituent 2.85b and the other with 
a fluoro substituent 2.85a (Scheme 57). 63 
 
Scheme 57 
The two analogues were successfully prepared using the conditions reported by Buchwald 
et al. The correct structures were confirmed by mass spectrometry and 1H NMR with the 
expected characteristic peaks in the 1H NMR spectra and the corresponding molecular ion 
signals in the mass spectra. 13C NMR spectrometry for both compounds showed splitting 
due to fluorine half spin. The greatest effect was seen in the  13C NMR spectrum for the 
fluoro substituted analogue 2.86, with splitting all around the right hand ring. The ipso 
carbon was split into a doublet with a coupling constant of 250.5 Hz; the ortho carbons 
were split into doublets with coupling constants of 21.4 Hz and 22.1 Hz; the meta carbons 
were split into doublets with coupling constants of 8.3 Hz and 7.8 Hz and the para carbon 
was split into a doublet with a coupling constant of 3.4 Hz. 
The effect of the fluorine half spin was less apparent in the  13C NMR spectrum of the 
trifluoromethyl substituted analogue 2.87 with the splitting only apparent on the ipso and 
ortho carbons. The signals were split into quartets with a coupling constant of 33.0 Hz for 
the ipso carbon and coupling constants of 3.6 Hz and 3.7 Hz for the  ortho carbons. No 
signal was observed for the carbon of the trifluoromethyl group itself. 
The fourth bromobenzyl alcohol purchased was (6-bromo-1,3-benzodioxol-5-yl)methanol 
(2.88) which was successfully coupled with the boronic ester (Scheme 58). 64 
 
Scheme 58 
The product was confirmed by mass spectrometry, with a peak at m/z 323 corresponding 
to the [M+Na]+ molecular ion, and  1H NMR, with characteristic peaks at: 10.59 for the 
phenolic OH; two doublets and two singlets for the four aromatic protons; a singlet at 6.06 
ppm for the oxazole CH2; two doublets at 5.10 ppm and 4.83 ppm, with coupling constants 
of 11.7 Hz and 11.5 Hz respectively, for the CH2 and a singlet at 3.89 ppm for the methoxy 
group on the left hand ring. 
Having established that it was possible to use the conditions reported by Buchwald et al. to 
couple the pinacol ester with bromobenzyl alcohols, we decided to further investigate a 
coupling which would furnish ulocladol A. We have proposed that the acetyl protected 
fragment 2.71 was not stable to the basic conditions of the Suzuki reaction so a base stable 
protecting group would be required. However, prior to investigating protecting groups, we 
decided to try and couple the pinacol ester with the unprotected bromobenzyl alcohol. We 
attempted to reduce the aldehyde to the benzyl alcohol 2.90 using sodium borohydride in 
methanol (Scheme 59). 
 
Scheme 59 
Unfortunately  the  reaction  was  unsuccessful  and  no  product  could  be  seen  by  mass 
spectrometry or NMR spectroscopy. As TLC suggested that the crude product did not move 
from the baseline in a 20% methanol in DCM solvent system, the reaction was abandoned. 65 




However the reaction was unsuccessful and neither product 2.91 nor starting material 
were isolated. Having established that we were unable to either couple the unprotected 
aldehyde with the pinacol ester or reduce the aldehyde to the unprotected benzyl alcohol, 
we  decided  to  protect  the  catechol  with  a  protecting  group  which  would  neither  be 
sterically hindering nor base labile. With these considerations in mind, we decided to try 
and protect the catechol with a linked protecting group which would reduce steric bulk 
and  allow  the  Suzuki  coupling  to  take  place.  A  group  which  fits  these  criteria  is  the 
acetonide group. We hoped to use dimethoxypropane to form the protected catechol 2.92. 
Several different sets of reaction conditions were attempted and these are shown below 
(Table 4). 
 
Entry  Reagents  Solvent  Conditions  Method  Result 






Toluene  Reflux, 86 h  Dean-Stark 
No 
product 66 






Toluene  Reflux, 16 h  Soxhlet extractor 
No 
product 






Benzene  Reflux, 16 h  Soxhlet extractor 
No 
product 
7  Acetone, p-TsOH.H2O64  Benzene  Reflux, 24 h  Dean-Stark 
No 
product 
Table 4 – Acetonide protecting group conditions 
Unfortunately, all of the reaction conditions attempted using toluene as a solvent were 
unsuccessful, entry 1-5. Several of the reported methods for protecting catechols with 
acetonides use benzene as a solvent instead of toluene. This is because benzene is a better 
azeotrope for water than toluene so when Dean-Stark or Soxhlet extractor apparatus are 
used,  water is  removed  more  effectively  from  the  reaction vessel.  For  this  reason  we 
decided  to  retry  two  sets  of  conditions,  entries  6  and  7,  using  benzene  as  a  solvent. 
However, the reactions were still unsuccessful resulting in the investigation into different 
protecting groups. 
A paper by Mayor et al. reported investigations into a variety of different protecting groups 
for catechols.65 Following the literature procedures we attempted to protect the catechol 
with two different protecting groups (Scheme 61). 
 
Scheme 61 
Despite  literature  precedence,  the  reactions  were  again  unsuccessful,  and  neither  the 
protected catechol 2.93 nor 2.94 were isolated. 67 
A  literature  procedure  reported  the  use  of  a  silyl  group  to  protect  a  catechol 
functionality.66 Following the reported reaction conditions we attempted to protect the 
catechol 2.69 using a diisopropylsilyl protecting group 2.95 (Scheme 62). 
 
Scheme 62 
We tried the reaction with both triethylamine and imidazole as the base, as well as with 
and without the additive HOBt.66, 67 Unfortunately, we were unable to isolate any product 
so investigation into a silyl protecting group was discontinued. Instead we focused on 




However both methods were unsuccessful and we were unable to protect the catechol 
with either the boronate 2.96 or benzylidene 2.97 protecting group. 
Due to the disappointing lack of success in protecting the catechol with a linked protecting 
group, we decided to revise our attempts to protect the catechol with individual protecting 
groups. 
The Boc protecting group is a well-known protecting group and is widely used in the 
protection of both amines and alcohols. As the Boc group is base stable, due to it being a 
carbonate and sterically hindered, it should not be susceptible to the basic conditions of 68 
the Suzuki reaction. Using a standard Boc protection procedure we successfully protected 
the catechol in 95% (Scheme 64).69 
 
Scheme 64 
The  benzaldehyde  2.98  was  then  reduced  to  the  benzyl  alcohol  2.99  using  sodium 
borohydride at -50 °C. The low temperature was required to prevent deprotection of the 
catechol which was observed at higher temperatures. With the benzyl alcohol in hand we 
then went on to react with the boronic ester (Scheme 65). 
 
Scheme 65 
However, no product or precursor of the product was isolated from the reaction mixture. 
Mass spectrometry also suggested that neither of the starting materials were present. We 
proposed that the Boc protecting groups were not stable to the Suzuki coupling conditions 
resulting in no product forming. 
It was decided to investigate a more stable protecting group for the catechol. A literature 
procedure reported the use of iodoacetonitrile to alkylate a hydroxyl group. We proposed 
that  we  could  protect  the  catechol  with  nitrile  groups  which  could  then  be  removed 
following the Suzuki coupling reaction. Following the literature procedure by Broka et al. 
we successfully alkylated the catechol to yield the desired product 2.101 (Scheme 66).70 69 
 
Scheme 66 
Although  the  alkylation  step  was  low  yielding  we  continued  with  the  reduction  step 
preparing  the  desired  bromobenzyl  alcohol  2.102  in  92%.  We  repeated  the  Suzuki 
reaction under the same conditions as attempted with the Boc protected bromobenzyl 
alcohol, unfortunately this reaction was also unsuccessful. 
We were unsure whether the lack of success with the Suzuki coupling reaction was due to 
the protecting group, the steric hindrance or the Suzuki conditions. Therefore, we decided 
to try the coupling reaction with a less sterically hindered bromobenzyl alcohol. We were 
able to purchase 4-formyl-2-methoxyphenyl acetate (2.103) which could be brominated 
and  protected  to  furnish  a  similar  bromobenzyl  alcohol  to  that  required  to  prepare 
ulocladol A, although without the phenol ortho to the bromine (Scheme 67). 70 
 
Scheme 67 
We  selectively  brominated  2.103  para  to  the methoxy  group  to yield  the  brominated 
benzaldehyde  2.104  in  94%.  The  benzaldehyde  was  then  reduced  with  sodium 
borohydride to yield the acetyl protected phenol  2.105 in 82%. We also prepared the 
cyanomethyl protected phenol 2.108 in 20% over four steps. 
The next step was to couple the two bromides with the pinacol ester 2.55, using the Suzuki 
coupling conditions reported by Buchwald (Scheme 68). 
 
Scheme 68 
Unfortunately the Suzuki coupling reactions were both unsuccessful and we were unable 
to  prepare  either  the  acetyl  protected  product  2.109  or  the  nitrile  protected  product 
2.110. As a cyanomethyl protected phenol would not have been susceptible to the basic 71 
conditions of the Suzuki reaction, we considered that the problems observed in the Suzuki 
coupling reaction were not caused by the protecting group. 
Despite successfully preparing six analogues of ulocladol A using the conditions reported 
by Buchwald et al., we had observed several problems. Firstly, the Suzuki coupling reaction 
was very messy and required extensive purification in order to obtain the desired product. 
As  well  as  purifying  by  column  chromatography  multiple  times,  it  was  necessary  to 
undertake acid and base washes and extractions in order to isolate a small quantity of 
product. Secondly, the reactions were very low yielding, with five out of the six analogues 
being  prepared  in  equal  to  or  less  than  10%.  Finally,  the  conditions  were  still  not 
applicable to all substrates and we have not been able to prepare ulocladol A using these 
conditions.  Therefore  we  decided  to  investigate  a  catalyst  system  which  could  be 
applicable to a much broader range of bromobenzyl alcohols and enable us to prepare 
ulocladol A. We chose to use the boronic ester intermediate 2.55 and the mono substituted 




We decided to use this substrate system because the methyl group is not strongly electron 
withdrawing or donating, bulky or sterically hindering in the coupling reaction. In addition 
to this, it is inexpensive and easily prepared. We tested a variety of catalyst systems which 




Entry  Catalyst  Base  Solvent 
Conditions 
Result 
Temp  Time  Method 
1  Pd(PPh3)4 (5 mol %)  NaHCO3 (2M)  Dioxane/H2O  130 °C  10 min  Microwave  2.58 (70%) 
2  PdCl2(dppf) (5 mol %)  K2CO3 (2M)  Acetonitrile/H2O  130 °C  10 min  Microwave  2.57 (25%) 
3  Pd(PPh3)4 (5 Mol %)  NaHCO3 (2M)  Dioxane/H2O  100 °C  16 h  Sealed tube  2.58 (36%) 
4  PdCl2(dppf) (5 mol %)  K2CO3 (2M)  Acetonitrile/H2O  100 °C  16 h  Sealed tube  2.58 (5%) 
5  PEPPSI-iPr (5 mol %)  Cs2CO3 (2M)  Dioxane/H2O  100 °C  16 h  Sealed tube  2.58 (32%) 
6  PEPPSI-iPr (2 mol %)  K3PO4 (2M)  Dioxane/H2O  rt  16 h + 1 h 60 °C  Thermal 
Recovered starting 
material 
7  PEPPSI-iPr (2 mol %)  Cs2CO3  DMF  100 °C  16 h  Thermal  No product 
8  PEPPSI-iPr (6 mol %)  CsF (2M)  Dioxane/H2O  100 °C  16 h  Thermal  No product 
9  PdCl2(dppf) (5 mol %)  Cs2CO3  DMF  100 °C  16 h  Thermal  No product 
10  PdCl2(dppf) (5 mol %)  K2CO3 (2M)  Acetonitrile/H2O  75 °C  16 h  Thermal  No product 
Table 5 – Testing of catalyst conditions for Suzuki reaction73 
The catalyst testing showed some interesting results and demonstrated that not only was 
the catalyst system important, but also the mode of reaction. If we compare entries 2, 4 
and 10 we can see that all three use PdCl2(dppf) as the catalyst, an aqueous 2M K2CO3 
solution as the base, and acetonitrile as the solvent. However, the mode of reaction, time 
and temperature are different. Entry 2 was undertaken in the microwave at 130 °C for 10 
min and, of the three, reported the highest yield albeit of the uncyclised product 2.57. 
Although at a lower temperature and extended reaction time, entry 4 was undertaken in a 
sealed tube so could exceed the boiling point of acetonitrile. The cyclised product 2.58 was 
isolated in 5% yield and confirmed to be the desired product by both mass spectrometry 
and 1H NMR. 
The third entry for comparison, 10, was performed under thermal conditions at 75 °C for 
16 h, but yielded no product, cyclised or uncyclised. Whilst the lower temperature is likely 
to adversely affect the yield, it is unlikely to be so detrimental as to yield no product at all. 
Instead these results implied that the mode of reaction is very important and the outcome 
is not solely dependent on the catalyst system and base as originally suspected. 
The most successful set of conditions were obtained when using Pd(PPh3)4 as the catalyst, 
with an aqueous 2M NaHCO3 solution of base, dioxane as the solvent and heating in the 
microwave. Using this set of conditions, cyclised product 2.58 was obtained in 70% yield, 
the best result for any Suzuki reaction we had undertaken. We repeated the reaction using 
the same reagents but heating in a sealed tube at 100 °C for 16 h. Mass spectrometry 
suggested the presence of cyclised product  2.58, with 36% product isolated following 
purification. 
In addition to using the microwave, we were interested in testing catalysts which could be 
used at room temperature. PEPPSI-iPr is a relatively novel catalyst which has had success 
in Suzuki coupling reactions for a variety of substrates at room temperature.71, 72 We tested 
this catalyst  with a variety of bases, solvents and conditions but with limited success, 
entries 6-8. The only successful conditions with this catalyst were those reported in entry 
5  where  a  sealed  tube was  used.  Mass  spectrometry  showed  the  presence  of  cyclised 
product 2.58 however 1H NMR spectroscopy suggested that this was in minimal yield and 
the crude was not purified. 74 
Due  to  the  success  shown  in  the  microwave,  we  decided  to  move  on  and  apply  the 
microwave conditions used in entry 1 to other substrates. 
The  first  novel  substrate  we  applied  the  conditions  to  was  2-bromo-4-
(trifluoromethyl)benzyl  alcohol  (2.111)  which,  when  coupled  with  the  pinacol  ester, 
would yield a regioisomer of analogue 2.87 (Scheme 70). 
 
Scheme 70 
The product 2.112 was isolated in 32% yield following column chromatography and acid 
and  base  washes.  Although  the  acid  and  base  washes  were  still  required  to  remove 
bromobenzyl  alcohol  starting  material,  the  separation  of  other  impurities  by  column 
chromatography was improved with fewer co-running spots. The product was confirmed 
by 1H NMR spectroscopy with the expected broad singlets at 5.21 ppm and 5.05 ppm for 
the CH2 protons, the phenolic OH signal at 10.64 ppm and 5 aromatic protons between 
6.65-7.81 ppm. In addition to this, the 13C NMR showed splitting on the carbons ipso and 
ortho to the CF3 group on the right hand ring due to the half spin of fluorine. A 19F NMR 
also confirmed the presence of fluorine in the molecule with a peak at -62.78 ppm. 
Another  analogue  we  were  interested  in  with  respect  to  exploring  SAR  was  the 
regioisomer of the nitro substituted analogue 2.47, where the nitro group is substituted 
meta to the carbon-carbon bond rather than para. We were able to purchase 2-bromo-5-
nitrobenzoic acid (2.113) which could be reduced to the benzyl alcohol and then coupled 
with the boronic ester to result in an analogue substituted para to the aryl-aryl bond. The 
first step was to reduce the carboxylic acid to the benzyl alcohol (Scheme 71).73 75 
 
Scheme 71 
2-Bromo-5-nitrobenzyl alcohol (2.114) was successfully prepared in quantitative yield as 
a yellow solid. The product was confirmed by 1H NMR with the presence of three aromatic 
protons  and  a  singlet  at  4.83  ppm  for  the  CH2.  The  next  step  was  to  couple  the 




The product 2.115 was successfully prepared in 31% yield as a colourless crystalline solid. 
The structure of the product was confirmed by NMR spectroscopy with five peaks for the 
aromatic protons between 6.50 ppm and 9.00 ppm, two broad, overlapping singlets at 5.35 
ppm for the CH2 and a singlet at 4.10 ppm for the methoxy group on the left hand ring. The 
corresponding peaks and aromatic protons were identified by COSY NMR data. Unlike 
analogue 2.47 where the nitro group is substituted meta to the aryl-aryl bond, the 1H NMR 
spectrum suggests that 2.115 is a single compound due to the presence of only one set of 
signals for the aromatic protons. The molecular weight of the product was confirmed by 
mass spectrometry with a peak at m/z 356 for the [M+Na+MeOH]+ ion. An X-ray crystal 
structure also confirmed the correct product structure (Figure 21). 76 
 
Figure 21 – X-ray crystal structure of 2.115 
The nitro group can clearly be seen on the right hand ring, para to the carbon-carbon bond. 
In  addition,  on  the  left  hand  ring,  there  is an  intramolecular  hydrogen  bond  between 
O(2) H(2)...O(3). The distance between O(3) and H(2), the hydrogen acceptor bond, is 1.88 
Å which is typical for a hydrogen bond of this type. The presence of this hydrogen bond 
also explains why a sharp singlet is observed in the 1H NMR for the phenolic group. 
If we view the structure side-on, the two aryl rings are twisted out of plane with respect to 
one another (Figure 22). 77 
 
Figure 22 – Rotated views of X-ray crystal structure74 
The three views of the X-ray crystal structure demonstrate the twist in the molecule about 
the aryl-aryl bond, with the two aromatic rings being out of plane to one another. This is 
best seen in the top right structure where we are looking from the left hand side of the 
molecule back towards the nitro group on the right hand ring. The torsion angle of the 
internal ring was measured between C(5)-C(6)-C(11)-C(10) and found to be 38.6 °. This 
rotation would appear to be influenced by the formation of the intra-molecular hydrogen 
bond, which dictates the arrangement of the kinked seven membered lactone ring and in 
turn the twist of the two aryl rings. 
The 1H NMR spectrum of 2.115 suggests that only one compound is present, unlike the 1H 
NMR spectrum of the regioisomer 2.47. One possible explanation for this doubling up of 
peaks in the  1H NMR spectrum of 2.47 was the presence of a second regioisomer. We 
suggested that one way of determining if this was the case was to overlay the  1H NMR 
spectrum of 2.47 with that of a regioisomer (Figure 23). 78 
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Figure 23 - Overlay of 1H NMR spectra of 2.47 and 2.115 
From the overlaid spectra we can see that the peaks for the phenol overlap exactly. The 
peak for the methoxy group on the right hand ring of 2.115 also overlaps with one of the 
peaks associated with a methoxy group in the spectrum of 2.47. If we look at the aromatic 
regions of the two spectra, we can see that the peaks for the para substituted analogue 
2.115 are very similar to the additional set of peaks seen in the spectrum of 2.47, however 
the peaks do not exactly overlap. The slight differences seen in the positions of the peaks 
may be the consequence of two factors: the difference in field strength between the two 
spectra and secondly, the difference in concentration of the two samples. Unfortunately, 
due to lack of material, it has not been possible to reanalyse the two compounds under 
identical conditions. 
As nitro functional groups are rarely found in medicinal compounds, due to issues with 
toxicity, we decided it would be advantageous to prepare a compound which would have 
similar biological effects without the toxicity generally attributed to a nitro group. One of 
the possibilities for this is a pyridine ring. 79 
We  were  able  to  purchase  3-bromoisonicotinaldehyde  (2.116)  which  we  successfully 
reduced to the benzyl alcohol in 90% yield (Scheme 73). 
 
Scheme 73 
We then went on to couple (3-bromopyridin-4-yl)methanol (2.117) with the pinacol ester 
2.55 using microwave conditions (Scheme 74). 
 
Scheme 74 
The pyridine substituted analogue 2.118 was prepared in 10% yield. The product was 
confirmed by mass spectrometry, with a signal at 280 m/z for the [M+Na]+ molecular ion, 
and NMR with  the presence of 5 distinct signals for the 5 aromatic protons and a broad 
CH2 signal at 5.08 ppm. 
We  were  also  able  to  purchase  2-bromo-4-fluorobenzyl  alcohol  (2.119),  which  we 
successfully  coupled  with  the  pinacol  ester  2.55  to  furnish  2.120,  a  regioisomer  of 
analogue 2.86 (Scheme 75). 80 
 
Scheme 75 
Having  successfully  prepared  seventeen  analogues  of  ulocladol  A,  using  a  variety  of 
different routes, it was necessary to prepare ulocladol A in order to not only confirm the 
structure of the natural product, but to also have a sample of the natural product with 
which to compare the biological activity of the analogues. Therefore this again became the 
focus of the project. 
Unfortunately, prior to commencing with further testing of catechol protecting groups and 
conditions for the Suzuki coupling reaction, a paper was published by Podlech et al. which 




Benzyl  protected  ulocladol  A  2.122  was  prepared  by  reacting  the  pinacol  ester 
intermediate  2.55 with  the  benzyl  protected  bromobenzyl  alcohol  2.121 using  Suzuki 81 
coupling methodology. Podlech et al. used Pd(OAc)2 as the palladium source, SPhos as the 
ligand, Cs2CO3 as the base and a mixture of dioxane/H2O as the solvent. The reaction was 
heated at 80 °C for 2 h before being purified by column chromatography to furnish the 
desired product 2.122 in 65% yield. These conditions are not too dissimilar from those 
that we used prior to switching to the microwave with one of the major differences being 
the protecting group of the bromobenzyl alcohol. In this case, Podlech et al. used standard 
hydrogenolysis conditions, reacting benzyl protected 2.122 with hydrogen over Pd/C for 2 
h which yielded the desired product in 60%. 
This led us to believe that the problems that we faced had been due to the nature of the 
catechol protecting group. We decided to repeat the reactions reported by Podlech et al. in 
order  to  prepare  ulocladol  A.  The  first  step  was  to  prepare  the  benzyl  protected 
bromobenzyl alcohol (Scheme 77). 
 
Scheme 77 
2-Bromo-3,4-dihydroxy-5-methoxybenzaldehyde  (2.69) was  protected by  reacting with 
benzyl bromide at -78 °C. The desired product 2.123 was furnished in 59% yield and the 
correct  structure  confirmed  by  comparison  of  the  1H  NMR  spectrum  with  the  data 
reported by Podlech et al. Having successfully protected the catechol we then reduced the 
aldehyde to the corresponding alcohol in order to prepare the desired product 2.121 in 
quantitative yield. 
With the protected bromobenzyl alcohol 2.121 in hand, the next step was to couple with 
the pinacol ester using the Suzuki conditions reported by Podlech et al. (Scheme 78). 82 
 
Scheme 78 
The reaction proceeded in good yield to furnish the desired product 2.122. The structure 
was confirmed by comparison of the data with that of the literature. 
Having successfully prepared the precursor to ulocladol A we then attempted to deprotect 
the catechol in order to prepare the natural product. Following the conditions reported by 
Podlech  et al. we attempted to remove the  benzyl protecting groups using a standard 
hydrogenation protocol. After 1 h TLC suggested that the reaction had gone to completion 
due to the absence of starting material. The reaction was stopped and the crude product 
submitted for  1H NMR and mass spectrometry. Unfortunately, both  1H NMR and mass 
spectrometry suggested that, whilst the desired deprotection had taken place, the reaction 
had proceeded too far and the lactone ring had broken (Scheme 79). 
 
Scheme 79 
The mass spectrometry showed no signals which corresponded to either starting material 
or product, instead showing a mass ion peak of m/z 343 for the [M+Na]+ molecular ion of 
the reductively cleaved lactone ring. 
A  signal  in  the  1H  NMR  spectrum  at  1.97  ppm,  which  integrated  for  three  protons, 
suggested  the  presence  of  a methyl  group.  In  addition  to  this,  there  was no  signal  at 
approximately 5 ppm for the CH2 protons in the lactone ring. This suggested that the 83 
lactone ring had split between the oxygen atom and the CH2 yielding a carboxylic acid and 
a methyl group 2.124.  
 While it might be possible to oxidise 2.124 back to a benzylic alcohol and attempt lactone 
formation, this would add more steps to the synthesis and be inelegant. The reaction was 
repeated; however it was decided to monitor the reaction every five minutes by TLC to 
ensure that the lactone ring did not break for a second time. After five minutes the reaction 
was stopped as TLC suggested that all of the starting material had reacted.  1H NMR and 
mass spectrometry of the crude product suggested that the lactone ring was still intact and 
both benzyl groups had been removed (Scheme 80). 
 
Scheme 80 
Ulocladol A was prepared in 14% yield and the structure confirmed by comparison of the 
1H and 13C NMR spectra with that of the of the natural product (Table 6). 
 
Atom 
1H NMR (ppm)  13C NMR (ppm) 
Found  J (Hz)  Reported24  J (Hz)  Found  Reported24 
1  -  -  -  -  146.3  146.3 
2  6.58 (s)  -  6.57 (s)  -  103.1  103.1 
3  -  -  -  -  127.1  127.1 
4  -  -  -  -  118.8  118.8 
5  -  -  -  -  135.9  135.9 84 
6  -  -  -  -  133.8  133.8 
7  -  -  -  -  142.0  142.1 
8  -  -  -  -  106.9  106.9 
9  -  -  -  -  163.0  163.0 
10  6.56 (d)  2.5  6.55 (d)  2.5  100.8  100.8 
11  -  -  -  -  163.2  163.2 
12  6.92 (d)  2.5  6.92 (d)  2.5  110.2  110.2 
13 
4.80 (d)  12  4.79 (d)  11.7 
70.3  70.3 
5.12 (d)  12  5.11 (d)  11.7 
14  -  -  -  -  172.5  172.5 
15  10.31 (s)  -  10.29 (s)  -  -  - 
16  3.87 (s)  -  3.87 (s)  -  55.5  55.5 
17  5.78 (br. s)  -  5.77 (br. s)  -  -  - 
18  5.69 (br. s)  -  5.68 (br. s)  -  -  - 
19  3.95 (s)  -  3.95 (s)  -  56.3  56.3 
Table 6 – Reported and collected 1H NMR and 13C NMR data for ulocladol A 
Having successfully prepared ulocladol A using protecting groups which were stable to the 
Suzuki reaction conditions, we decided to try and change the functional groups on the right 
hand ring. We were interested in determining whether the phenol and methoxy groups 
had any effect on the SAR. Previous work in the group had led to the synthesis of the 
phenol 2.125, which has no methoxy group in the position ortho to the phenol group. From 
this  starting  material  we  successfully  prepared  the  triflate  2.126  in  51%  followed  by 
formation of the boronic ester in 14% yield (Scheme 81). 
 
Scheme 81 
Boronate ester  2.127  was confirmed to be the desired product by  1H NMR with three 
aromatic protons at 6.93 ppm, 7.14 ppm and 7.47-7.52 ppm, as well as two singlets at 1.73 85 
ppm and 1.42 ppm for the acetonide methyl groups and the pinacol ester methyl groups. 
The product was found to have the correct mass with a peak at 359 for the [M+Na+MeOH]+ 
molecular ion in the mass spectrum. The next step was to couple 2.127 with the benzyl 




The  benzyl  protected  analogue  2.128  was  prepared  in  51%  yield.  The  structure  was 
confirmed by 1H NMR with characteristic signals at 9.63 ppm for the phenol, 3.85 ppm for 
the methoxy CH3 and 6 doublets for the three CH2 groups. The set of doublets for the 
lactone ring bound CH2 were at 4.73 ppm and 4.94 ppm with a coupling constant of 12.0 
Hz, with the other four doublets at 4.55 ppm, 4.77 ppm, 5.00 ppm and 5.12 ppm which all 
had coupling constants of 11 Hz. Each CH2 corresponds to two distinct doublets in the 1H 
NMR  spectrum.  This  is  because  the  two  protons  on  each  CH2  are  diastereotopic  and 
therefore not chemically equivalent (Figure 24). 
 
Figure 24 - Diastereotopic protons 
If a molecule is achiral the diastereotopic protons usually appear as a singlet in the 1H NMR 
spectrum. In the case of ulocladol A and its analogues, each compound has two possible 
conformational isomers due to the planar axis of chirality, which is caused by the two 
aromatic rings being twisted out of plane to each other and unable to freely rotate. The two 
diastereoisomers created by this planar axis of chirality are atropisomers. The planar axis 
of chirality results in the diastereotopic protons of some of the analogues appearing as two 86 
doublets in the 1H NMR spectra. This is because Ha is split into a doublet by Hb and Hb is 
split into a doublet by Ha. 
The X-ray crystal structure of the nitro analogue,  2.115, has shown the planar axis of 
chirality between the two aryl rings. It is likely that this occurs in order to accommodate 
both the hydrogen bond, between the phenol and the carbonyl oxygen, and the seven 
membered lactone ring. This twist in the lactone ring explains why the methylene group 
adjacent to the lactone is diastereotopic. Whilst methylene groups on benzyl ethers are not 
usually diastereotopic, in the case of 2.128 it is likely that the two benzyl ether groups are 
too bulky to freely rotate resulting in the methylene groups being diastereotopic. 
In addition to the signals seen for the three CH2 groups, there was a singlet at 6.70 ppm for 
the aromatic proton on the right hand ring as well as another 6 multiplets integrating to 13 
protons for the remaining aromatic protons. The 13C NMR and DEPT spectra showed 3 CH2 
signals,  1  CH3  signal,  10  CH  signals  and  11  quaternary  signals  which  all  confirm  the 
structure of the product. With the benzyl protected analogue in hand we then attempted to 
deprotect the phenolic groups using a standard hydrogenation protocol. However 1H NMR 
suggested that only partial deprotection had occurred with the loss of only one of the 
benzyl protecting groups. The 1H NMR spectrum also suggested that the deprotection had 
been selective with only one regioisomer present and not a mixture of the two. Using 
COSY,  HMQC  and  HMBC  NMR  studies  we  were  able  to  determine  that  the  correct 
regioisomer had been deprotected on the phenol meta to the carbon-carbon bond 2.129. 
The assignment was mainly based on the correlations in the HMBC spectrum (Figure 25). 
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Figure 25 – HMBC spectrum of 2.129 
From the spectrum it is possible to assign which phenolic group has been deprotected. If 
we look at the methoxy group on the right hand ring, from the 1H NMR spectrum we can 88 
determine that the protons on the CH3 correspond to the signal at 3.98 ppm. From this 
signal we can deduce that the corresponding peak in the  13C NMR is at 56.4 ppm. Long 
range coupling then suggests that C7, the carbon the OMe group is connected to, is at 147.3 
ppm. The next step is to determine which other protons C7 couples to long range. If we 
look along the horizontal blue line, we can see that there is a long range coupling to H24 at 
5.82 ppm and H8 at 6.77 ppm. H8 is the aromatic proton next to Ar-OMe, and H24 is the 
deprotected phenol on C6. From H24 and H8 we can determine that the peaks in the 13C 
NMR at 106.9 ppm and 140.4 ppm correspond to C6 and C8 respectively. We can also 
determine which CH2 is part of the lactone and therefore which CH2 is part of the benzyl 
protecting group.  
From the HMBC spectrum we can see that H8 experiences long range coupling to a signal 
in the 13C NMR at 70.3 ppm. This carbon correlates to the CH2 protons in the 1H NMR at 
5.06 ppm and 4.83 ppm and can only correspond to C2 as the distance between H8 and 
C17, the benzyl CH2, is too great to see long range coupling. The selective deprotection of 
the benzyl group in the middle is also consistent with reactions of 3,4,5-trifunctionalized 
phenols as the central group suffers from the most steric clashes. 
Having determined which regioisomer was present the next step was to fully deprotect the 
benzyl groups in order to prepare an analogue of ulocladol A without a methoxy group on 
the left hand ring (Scheme 83). 
 
Scheme 83 
Unfortunately  the  reaction  was  unsuccessful  and,  in  addition  to  deprotecting  the 
remaining phenolic group, the lactone ring was broken. Due to lack of material and time 
constraints we were unable to repeat this reaction. 
2.3.1  Variable Temperature NMR 89 
The 1H NMR spectra of the 18 analogues prepared have all had two distinguishing features 
in common: the methylene group in the seven membered lactone ring and the phenol 
group  on  the  left  hand  ring.  However,  whilst  the  shape  of  the  signal  in  the  1H  NMR 
spectrum for the phenol on each of the analogues has remained relatively consistent, the 
methylene signal has varied from a broad singlet, seen in 2.118 (Figure 26), to two sharp 
doublets, seen in 2.82 (Figure 27). 
OC3009LS1.010.esp
10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)


























































Figure 26 - 1H NMR spectrum of 2.118 90 
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Figure 27 - 1H NMR spectrum of 2.82 
The figures above show the differences between the peak shapes of the methylene group 
in the two different analogues. It is possible that the distortion of the pyridine ring in 
2.118  results  in  the  lactone ring  adopting  a more  planar  arrangement, which  in  turn 
reduces  the  energy  barrier  for  movement  of  the  methylene  group.  Consequently  the 
methylene protons are not diastereotopic and result in a singlet in the 1H NMR spectrum. 
In the case of 2.82 the aryl-aryl bond has three ortho substituents. The greater the number 
of substituents around an aryl-aryl bond, the greater the potential for steric clashes, which 
forces the aryl rings to adopt a more staggered conformation. This could explain why the 
methylene protons are diastereotopic and therefore very sharp doublets in the  1H NMR 
spectrum. 
Use of Variable Temperature NMR would further our understanding of this phenomenon. 
If the observed signals for the methylene group in the 1H NMR spectrum coalesce into one 
signal as the sample is heated, it would indicate that the aryl-aryl bond overcomes the 
energy barrier of rotation on heating. 91 
Due to constraints in quantity of material, we chose to subject the meta substituted fluoro 
analogue 2.120 to Variable Temperature NMR. This material exhibited two broad singlets 
in 1H NMR using CDCl3 as the solvent. In order to carry out the Variable Temperature NMR 
over the desired temperature range a change in solvent to  deutero-DMSO was required 
(Figure 28). 
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Figure 28 - Variable Temperature NMR of 2.120 
The first detail to note is that the change in solvent system resulted in a change in the 
position of the 1H NMR signals. In addition to this the signal for the methylene group has 
changed from two broad singlets to two doublets, which appear to be close to coalescence. 
Upon heating it is clear that full coalescence is achieved by 60 °C; additionally the phenolic 
signal is seen to broaden whilst shifting upfield. The broadening and upfield shift of the 
phenolic signal can be explained by hydrogen bonding and exchangeable protons. At lower 
temperatures  the  phenolic  hydrogen  undergoes  hydrogen  bonding  with  the  carbonyl 
oxygen;  as  the  temperature  increases  the  hydrogen  bond  dissociates  leading  to  the 
broadening of the phenolic signal in the  1H NMR. This phenolic signal undergoes further 
broadening as the loss of the hydrogen bond results in the phenolic proton becoming 
exchangeable.  These  changes  are  consistent  with  the  proposed  explanation  for  the 92 
diastereotopic methylene protons and indicate a general increase in energy within the 
molecule.  A  final  1H  NMR  was  taken  at  25  °C  to  establish  whether  the  sample  had 
decomposed on heating. The spectrum shows that the molecule did not decompose on 
heating and instead returned to its original conformation. 93 
3  Synthesis of Alternariol and Alternariol 9-Methyl Ether 
3.1  Total Synthesis of Alternariol and Alternariol 9-Methyl Ether 
Alternariol and alternariol 9-methyl ether have been reported as cell growth inhibitors 
although the mechanism is unknown.75 Due to the resemblances in structure of alternariol 
and alternariol 9-methyl ether to ulocladol A, we thought it would be interesting to test the 
two natural products against kinases (Figure 29). 
 
Figure 29 – Ulocladol A, alternariol 9-methyl ether and alternariol 
All three natural products have a biaryl system linked by a lactone ring. The left hand rings 
are substituted in the same positions, with a phenol group ortho to the ester of the lactone 
ring and either a phenol or methoxy group  para to the ester of the lactone ring. This 
suggests that the left hand rings for each of the three natural products could come from the 
same starting material. This starting material could then be coupled to the corresponding 
fragments for the right hand ring using Suzuki coupling methodology. With this in mind we 
proposed  that  we could  prepare  alternariol  (1.3)  and  alternariol  9-methyl  ether  (1.2) 
using the same boronic ester used to prepare ulocladol A (1.1) (Scheme 84). 94 
 
Scheme 84 
We proposed that 2.55, the pinacol ester used in the synthesis of ulocladol A (1.1), could 
be  coupled  with  the  corresponding  protected  brominated  phenol  3.1  to  yield  the 
uncyclised compound 3.2. Deprotection and cyclisation of 3.2 would furnish alternariol 9-
methyl ether (1.2). The final step would be removal of the methoxy group with BBr3, a 
procedure reported in the literature by Podlech et al30. We hoped that this would furnish 
alternariol 9-methyl ether (1.2) and alternariol (1.3) in eight and nine steps respectively. 
3.2  Synthesis of Alternariol and Alternariol 9-Methyl Ether 
With the left hand ring  fragment in hand, we began to synthesise the right hand ring 
fragment (Scheme 84). 
 
Scheme 85 
We  successfully  brominated  commercially  available  orcinol  (3.3)  in  45%  yield.  The 
bromine was confirmed to be ortho to the methyl group through 1H NMR spectrometry. 
Two distinct doublets could be seen for the aromatic protons which indicated that the 
aromatic protons were in different environments. If the bromine was located between the 95 
two phenolic groups the resulting symmetry in the molecule would lead to only one signal 
in the aromatic region. 
Due to the sensitive nature of the Suzuki reaction the next step was to protect the hydroxyl 
groups. We protected the phenolic groups with acetyl and cyanomethyl ether protecting 
groups (Table 7). 
Entry  Protecting Group  Conditions  Product  Yield 
1  Acetyl 
Ac2O, DMAP, Et3N, 
DCM, rt, 16 h 
 
3.5 - 84% 
2  Cyanomethyl ether 
ICH2CN, K2CO3, 
DMF, ∆, 16 h 
 
3.6 - 34% 
Table 7 – Phenol protecting groups 
We attempted to couple 3.5 and 3.6 with the pinacol ester intermediate 2.55 as well as the 
unprotected diol 3.4 using the conditions reported by Buchwald et al. (Scheme 86).58 
 
Scheme 86 
However, we were unsuccessful each time and no product was isolated from any of the 
reactions. 
We suggested that this was due to the protecting group as found in the case of ulocladol A. 
From investigation into protecting groups for the right hand fragment of ulocladol A, we 
determined  that  acetyl  and  Boc  protecting  groups  were  unstable  to  Suzuki  coupling 
methodology. Attempts to prepare ulocladol A by coupling the pinacol ester 2.55 with the 
unprotected catechol had also been unsuccessful, however we were unsure whether this 
was due to the presence of the free catechol or the aldehyde. We had found during the 96 
synthesis of ulocladol A and its analogues that a free benzyl alcohol could be tolerated in 
the Suzuki reaction. In addition to this, a more recent set of conditions for the Suzuki 
reaction, reported by Podlech et al., seemed to be more tolerant of different functional 
groups.24 Therefore we decided to try and couple the unprotected diol 3.4 with the pinacol 
ester intermediate 2.55 using the conditions reported by Podlech et al. (Scheme 87). 
 
Scheme 87 
Recrystallisation of the crude product from methanol afforded alternariol 9-methyl ether 
(1.2) in 44% as a purple crystalline solid. The structure of the product was confirmed by 
1H NMR spectroscopy with four signals at 7.21 ppm, 6.72 ppm, 6.64 ppm and 6.61 ppm for 
the  aromatic  protons  and  two  signals  at  2.73  ppm  and  3.91  ppm  for  the  methyl  and 
methoxy groups. Two singlets, one broad at 11.82 ppm and one sharp at 10.36 ppm were 
observed  for  the  two  phenolic  groups.  An  X-ray  crystal  structure  also  confirmed  the 
structure of the product (Figure 30). 97 
 
Figure 30 – X-ray crystal structure of alternariol 9-methyl ether 
The  torsion  angle  of  the  lactone  ring  between  C(5)-C(6)-C(10)-C(9)  is  -6.28°.  This  is 
significantly different from the larger torsion angle of 38.55° for the nitro analogue of 
ulocladol  A  which  was  measured  through  the  same  atoms.  A  comparison  of  the  two 
structures side by side demonstrates how alternariol 9-methyl ether has a more planar 
conformation than the nitro analogue (Figure 31).74 
 
Figure 31 – Nitro analogue 2.115 (L); Alternariol 9-methyl ether (1.2) (R)  
The figure shows the nitro analogue 2.115 on the left and alternariol 9-methyl ether (1.2) 
on the right. The twist in the nitro analogue can clearly be seen whilst alternariol 9-methyl 
ether is almost linear. This suggests that the reason the nitro analogue is twisted is due to 
the seven-membered lactone ring which is too hindered to sit in the plane. 98 
With alternariol 9-methyl ether (1.2) in hand, the final step was to remove the methoxy 
group in order to furnish alternariol. Following a literature procedure by Podlech et al. we 
successfully removed the methoxy group using boron tribromide (Scheme 88). 
 
Scheme 88 
The  reaction  was  successful  and  the  product  was  isolated  in  57%  yield  following 
purification. The structure was confirmed by comparison of  1H NMR collected data with 
those reported in the literature (Table 8). 
 
Atom  1H NMR (MeOD) 
  Found  J (Hz)  Reported30  J (Hz) 
1  -  -  -  - 
2   6.58 (d)  2.5  6.62 (d)  2.6 
3  -  -  -  - 
4  -  -  -  - 
5  -  -  -  - 
6  6.67 (d)  2.5  6.71 (d)  2.6 
7  -  -  -  - 
8  -  -  -  - 
9  6.35 (d)  2.0  6.38 (d)  1.9 
10  -  -  -  - 
11  7.22 (d)  2.0  7.27 (d)  2.0 99 
12  -  -  -  - 
13  2.73 (s)  -  2.77 (s)  - 
Table 8 – Reported and collected 1H NMR data for alternariol 
The product was also confirmed by mass spectrometry with a peak at 313 m/z for the 
[M+Na+MeOH]+ mass ion. 
We successfully prepared the natural products alternariol 9-methyl ether (1.2), in 18% 
overall, and alternariol (1.3), in 10% overall, in six and seven steps respectively. These 
syntheses are the shortest convergent syntheses of alternariol 9-methyl ether (1.2) and 
alternariol (1.3) to date. 101 
4  Biological Results 
4.1  Biological Results for Ulocladol A and Analogues 
4.1.1  Background 
The original isolation of ulocladol A reports it to be an inhibitor of the tyrosine kinase lck. 
We tested ulocladol A and analogues against five different tyrosine kinases. These were 
Lck, Lyn, Btk, Src and Fyn. All five kinases belong to the same branch of the human kinome 
(Figure 32). 
 
Figure 32 – Tyrosine kinase branch of the human kinome76 
4.1.1.1  Src Protein Tyrosine Kinase Family 
Lck, Lyn, Src and Fyn all belong to the Src family of tyrosine kinases.77 Src and Fyn are 
expressed in most tissues, whereas Lck and Lyn are expressed primarily in hematopoietic 
cells.  Lck  and  Lyn  have  also  both  been  found  in  neurons  suggesting  they  may  have 
functions in other cells78. The Src family of protein kinases have many different functions 
within the cells from cell activation to cell growth and cell migration. Deregulation of these 
kinases has been implicated in several different types of cancer including prostate, colon 102 
and breast. Btk plays a crucial role in B cell maturation. Mutation of the Btk gene was 
found to be the cause of the immunodeficiency disease, X-lined agammaglobulinemia. 
Inhibition of any of these kinases would be beneficial in the treatment of cancer and other 
diseases. 
4.1.2  Results 
The results of the biological activity tests against 15 of the analogues and the natural 
product  are  shown  in  the  tables  below.  Ulocladol  A  is  shown  at  the  top  for  ease  of 










Analogue  MW  cLogP79 
Kinase Inhibitora 
Lck  Lyn  Btk  Src  Fyn 
pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh 
 
318  1.3  5.6 
2.51 
E-6 
93      74  5.85 
1.41 
E-6 
95      36      38 
 
256  2.6      <50      <50      <50      <50      <50 
 
301  2.4  6.91 
1.23 
E-7 
97  6.84 
1.45 
E-7 
100  5.92 
1.20 
E-6 
88  6.22 
6.03 
E-7 





328  4      26      22      6      8      3 
 
270  3.1      63      78      18      27      8 
  
Analogue  MW  cLogP 
Kinase Inhibitora 
Lck  Lyn  Btk  Src  Fyn 
pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh 
 
346  1.9  6.19 
6.46 
E-7 
97  6.54 
2.88 
E-7 
98  5.84 
1.45 
E-6 
88  6.04 
9.12 
E-7 





286  2.5      81  5.54 
2.86 
E-6 
89      55  5.28 
5.25 
E-6 
66      33 
 
316  2.3      26      4      4      0      5 
 
316  2.6  5.59 
2.57 
E-6 
81      13      -2      8      0 
 
281  2.1      3      13      7      -7      4 
  
Analogue  MW  cLogP 
Kinase Inhibitora 
Lck  Lyn  Btk  Src  Fyn 
pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh 
 
274  2.8      30      36      2      19      8 
 
324  3.5      38      18      6      11      4 
 
300  2.6      20      12      9      -6      11 
 
301  2.4      46      19      39      10      13 
 
274  2.8      35      14      54      11      17 
  
Analogue  MW  cLogP 
Kinase Inhibitora 
Lck  Lyn  Btk  Src  Fyn 
pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh  pIC50  IC50  %Inh 
 
468  5.4      52      14      18      5      6 
a) % inhibition refers to the degree of inhibition observed when  compounds were tested at 10-5M; Dose-response curves were 
performed to calculate pIC50 and IC50. 
Table 9 – Inhibitory activity of analogues against Lck, Lyn, Btk, Src and Fyn 107 
The biological data is summarised in the graph below (Figure 33). 
 
Figure 33 – Inhibitory activity of analogues 
The biological activity data show some interesting results. The data suggests that both the 
position and type of functional group on the right hand ring is important in relation to 
activity. The majority of the analogues exhibit low enzyme inhibitory activity with 10 out 
of 15 analogues inhibiting all five tyrosine kinases in less than 60% at a concentration of 
10-5 M. The most promising analogues are 2.47 with a nitro group meta to the aryl-aryl 
bond, 2.60 with three methoxy groups ortho, meta and para to the carbon-carbon bond 
and 2.66 with a methoxy group para to the carbon-carbon bond. These three analogues all 
inhibit Lck enzyme activity above 80%, as well as showing moderate to good inhibition of 
the other four tyrosine kinases. One other notable analogue is 2.82 with methoxy groups 
ortho and para to the carbon-carbon bond. This analogue selectively inhibits 81% of Lck 
enzyme activity but is inactive against the other four tyrosine kinase inhibitors. 
Whilst  we  are  unable  to  definitively  elucidate  SAR  activity  from  the  biological  data 
collected, due to the incomplete set of analogues prepared, we have split the results into 
groups in the hope that some comparisons can be made. 
The first group are the analogues which are solely substituted in the meta position to the 
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Figure 34 – Inhibitory activity of meta substituted analogues 
From the graph we can see that the nitro substituted analogue  2.47 is the only  meta 
substituted  analogue  which  shows  good  inhibitory  activity  against  all  five  kinases, 
although we cannot be certain that this is due to the effect of a single component or a 
synergistic effect resulting from the mixture of compounds. 
The  ring  closed,  methyl  substituted  analogue  2.58  shows  average  inhibitory  activity 
against Lck and Lyn but poor activity against Btk, Src and Fyn. The ring opened methyl 
substituted analogue 2.57, the nitrile substituted analogue 2.84 and the fluoro substituted 
analogue 2.120 all show poor inhibitory activity against all five kinases. This suggests that 
a group which can form hydrogen bonds is necessary in the meta position of the right hand 
ring. 
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Figure 35 – Effect of para substituents on activity 
In general, the substituents in the para position on the right hand ring have poor inhibitory 
activity, with the methoxy substituted analogue  2.66 being the only one to inhibit Lck 
above 50%. Surprisingly the nitro analogue  2.115 does not inhibit any of the kinases 
above 50% unlike its regioisomer 2.47, which inhibits all the kinases above 85%. 
The graph below looks at two pairs of regioisomers which are substituted in the meta and 
para positions with either a fluoro or nitro group (Figure 36). 
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Analogue  (10-5 M concentration)







The graph shows that the meta substituted nitro analogue 2.47 is the most active of the 
four analogues shown. It exhibits greater than 95% inhibition of the Lck, Lyn, Src and Fyn 
tyrosine kinases as well as inhibiting the Btk tyrosine kinase at 88%. If we look at the meta 
substituted  fluoro  analogue  2.120  we can  see  that  the  activity is much  lower  and, in 
general, exhibits less than 50% inhibition of all the kinases. 
The para substituted groups all exhibit enzyme inhibitory activity of less than 50%. This 
includes the para substituted nitro analogue. Despite the meta substituted analogue being 
the  most  active  analogue,  the  para  substituted  analogue  does  not  exhibit  the  same 
inhibitory activity, implying that the meta position is important in the biological activity. 
The para substituted fluoro analogue is also inactive against the five tyrosine kinases with 
inhibition of less than 40%. 
The next graph shows the biological activity of the methoxy substituted analogues (Figure 
37). 
 
Figure 37 – Effect of methoxy groups on activity 
From the graph we can see that 2.60, the trisubstituted ortho, meta and para methoxy 
analogue is the most active compound. The para substituted analogue 2.66 shows good 
inhibitory activity against Lck and Lyn but is less effective against Btk, Src and Fyn. The 
meta and para disubstituted compound 2.78 is inactive against all the tyrosine kinases, 
whereas the ortho and para disubstituted compound 2.82 shows activity against Lck but is 
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The model structure of ulocladol A bound to the Lck active site showed the right hand ring 
of ulocladol A pointing towards the back of the enzyme active site. This suggested that the 
phenolic groups on the right hand ring were interacting with hydrogen bond acceptor 
sites. The trimethoxy substituted analogue 2.60 has no phenolic groups on the right hand 
ring with  which it can  form  hydrogen bonds  to  an  acceptor;  however,  the  trimethoxy 
groups can act as hydrogen bond acceptors, implying that there are hydrogen bond donor 
sites within the pocket. 
Unfortunately we are unable to determine whether changing the groups on the left hand 
ring would have a large effect on biological activity. We can tell from the unsubstituted 
analogue 2.45 that the groups on the right hand ring play a large role in activity with the 
highest inhibition of all the kinases being 14%. We were unsuccessful in our attempts to 
deprotect the benzyl protected analogue 2.128 to yield an analogue which would tell us 
what effect, if any, the methoxy group on the left hand ring had on the activity. 
4.2  Biological Results for Alternariol 9-Methyl Ether and Alternariol 
4.2.1  Background 
Alternariol 9-methyl ether and alternariol were both tested for activity against the same 
five tyrosine kinases used for ulocladol A and analogues. 
4.2.2  Results 
The  results  for  the  biological  activity  of  alternariol  9-methyl  ether  and  alternariol  are 
shown below (Table 10). 
Compound  MW  cLogP 
Tyrosine Kinase (% Inhibition at 10-5 M) 
Lck  Lyn  Btk  Src  Fyn 
 
272  2.5  24  15  17  8  12 
 
258  1.9  85  58  32  34  44 
Table 10 – Inhibitory activity of alternariol 9-methyl ether and alternariol 
The data show that alternariol 9-methyl ether (1.2) exhibits minimal inhibitory activity 
against all of the tyrosine kinases, with the greatest inhibition being against Lck with an 112 
inhibition of 24%. Alternariol (1.3) shows better activity, with an inhibition of Lck of 85% 
at 10-5 M concentrations. 
The X-ray crystal structure of alternariol 9-methyl ether (1.2) suggested that the molecule 
adopts a more planar conformation than the ulocladol analogues (Figure 38). 
 
Figure 38 - Side on view of alternariol 9-methyl ether (1.2) looking from the left hand ring back 
towards the right hand ring 
Due to the change in conformation it is difficult to predict whether alternariol (1.3) and 
alternariol 9-methyl ether (1.2) bind to a tyrosine kinase active site in the same way as 
ulocladol A and its analogues. From the biological data collected for these two natural 
products,  we can  only  deduce  that  when  the methoxy  group  on  the  left  hand  ring  of 
alternariol 9-methyl ether (1.2) is removed to furnish alternariol (1.3) there is an increase 
in the inhibitory activity against the five tyrosine kinases. 
In order to elucidate full SAR activity for ulocladol A (1.1), alternariol 9-methyl ether (1.2) 
and alternariol (1.3) a much larger range of analogues for all three would be required. 
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5  Conclusion 
5.1  Ulocladol A and Analogues 
We  have  successfully  prepared  ulocladol  A  in  0.4%  over  ten  steps  in  a  convergent 
synthesis. The route is applicable to the synthesis of analogues of ulocladol A and has been 
used to prepare eighteen different analogues with a variety of functional groups on the 
right hand ring. Fifteen of these analogues have been tested for biological activity against 
five tyrosine kinases. 
Two analogues, the meta substituted nitro analogue 2.47 and the trimethoxy substituted 
analogue 2.60, have been found to exhibit greater inhibition of Lck than ulocladol A, and 
show very good inhibitory activity against the other four kinases. 
Due to time constraints and lack of material, we were unable to investigate the effect the 
substituents on the left hand ring have on biological activity beyond the lack of activity 
observed when there are no substituents on the right hand ring. 
5.2  Alternariol 9-Methyl Ether and Alternariol 
We have successfully prepared alternariol 9-methyl ether and alternariol in a convergent 
route which did not require protection of the phenolic groups on the right hand ring. 
Alternariol 9-methyl ether was prepared in five steps in 18% overall and alternariol was 
prepared  in  six  steps  in  10%  overall.  This  is  the  shortest  convergent  synthesis  of 
alternariol  9-methyl  ether  and  alternariol  to  date.  Alternariol  9-methyl  ether  and 
alternariol were both tested for biological activity against the five tyrosine kinases, with 
alternariol found to selectively inhibit Lck at 85%. 
5.3  Chemistry 
Over the course of the project we have used several different catalyst systems on different 
substrates. This has mainly been due to the difficulties found in coupling substrates which 
have  differing  steric  and  electronic  effects  on  the  Suzuki  reaction. We  also  found  that 
switching the position of the boronate from the right hand ring to the left hand ring was 
more practical due to the increased number and variety of substrates available to couple 
(Figure 39). 114 
 
Figure 39 - Switching the boronate group from the left hand ring (A) to the right (B) was more practical 
The initial catalyst system, a thermal reaction using PdCl2(dppf), proved to be low yielding 
and often resulted in a mixture of cyclised and uncyclised product which required either 
further  reaction  or  extensive  purification.  A  change  to  the  conditions  reported  by 
Buchwald et al. allowed us to prepare a further six analogues of ulocladol A, however the 
problems with low yields and extensive purification were not solved.46 
We  then  began  testing  different  catalyst  systems  under  both  thermal  and  microwave 
conditions. This resulted in the use of Pd(PPh3)4 and 2M NaHCO3 in dioxane to prepare a 
further four analogues and, although the yields did not improve by a great amount, the 
final compounds required less extensive purification. 
The final catalyst system, reported by Atemöller et al. in their synthesis of ulocladol A, was 
successfully used to prepare two analogues of ulocladol A, one of which was the precursor 
to ulocladol A, and ulocladol A itself.24 In addition to this we also applied this method to the 
successful  synthesis  of  alternariol  9-methyl  ether,  which  then  enabled  us  to  prepare 
alternariol.  We  found  that  the method  reported  by  Atemöller  et al.  resulted  in higher 
yielding reactions with the resulting compounds being easier to purify. 
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6  Future Work 
Due to time limits and availability of starting materials we have been unable to establish a 
complete picture of SAR relating to ulocladol A. If it were possible to undertake further 
work in this area it would be interesting to build a complete picture of SAR and determine 
which of the functional groups on ulocladol A were involved in the inhibition of the Lck 
enzymes active site. If possible it would also be beneficial to obtain protein X-ray crystal 
structures of the analogues bound to the Lck enzyme active site to determine the true 
bonding motif. 
In addition to this it would be interesting to resynthesise the nitro analogue 2.47 ensuring 
that only one compound was present. The compound could then be retested against the 
tyrosine kinases to determine whether the results of the first biological assay were due to 
the  nitro  analogue  2.47,  or  whether  a  synergistic  effect,  caused  by  the  mix  of  two 
compounds, occurred. 
Furthermore, given the apparent role of the lactone ester in binding to the enzyme active 
site, it would be of interest to examine the effect on inhibitory action if the lactone ester 
was replaced with either a thioester or an amide. 
Whilst only limited work was carried out in the area of alternariol 9-methyl ether and 
alternariol,  it  would  be  interesting  to  determine  how  the  two  molecules  bind  to  the 
enzyme active site and if the more planar conformation of the molecules, when compared 
to ulocladol A, has any effect on inhibitory activity. It would also be of interest to exploit 
the synthetic methodology discovered to produce additional analogues of alternariol with 
the aim of formulating a SAR for this molecular core. 
 117 
7  Experimental 
7.1  General Experimental 
All reagents were used directly as obtained from commercial suppliers unless otherwise 
stated.  When  dry  solvents  were  required,  THF  was  freshly  distilled  from  sodium 
benzophenone ketyl under argon; CH2Cl2 was freshly distilled from calcium hydride under 
argon and toluene was freshly distilled from sodium metal under argon. 
Reactions  were  monitored  by  thin  layer  chromatography  using  pre-coated  aluminium 
backed sheets of silica and visualised with UV light and a cerium molybdate stain. Column 
chromatography was carried out using MN Kieselgel 60, 0.04-0.063 mm 230-400 mesh 
ASTM silica gel. 
Melting points were determined using an Electrothermal melting point apparatus and are 
uncorrected. 
Infrared spectra were recorded using a Thermo Nicolet 380 FT-IR spectrometer with a 
Smart  Orbit  Golden  Gate  attachment  and  processed  using  the  Omnic  software  suite. 
Absorptions are reported in wavenumbers (cm-1). 
NMR spectra were recorded on either a Bruker AV300 spectrometer or a Bruker DPX400 
spectrometer operating at 300 or 400 MHz respectively for 1H experiments, and 75 MHz or 
100 MHz respectively for  13C and Dept-135 experiments. Proton and carbon NMR were 
taken in CDCl3, unless stated otherwise, using tetramethylsilane as an internal standard. 
Spectral data was processed using ACD Labs software. Chemical shift,  δ, is reported in 
parts per million with multiplicities described using the abbreviations s, singlet; d, doublet; 
t, triplet; q, quartet; m, multiplet; and br, broad. 
Electrospray mass spectra were recorded using a Thermoquest Trace MS and Micromass 
Platform II single quadrapole mass spectrometer.  
High  resolution  mass  spectra  were  collected  by  the  School  of  Chemistry  Mass 
Spectrometry Service using a Bruker Apex III FT-ICR mass spectrometer fitted with an 
Apollo electrospray ionisation source. 
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7.2  Kinase Inhibition Assays 
Inhibition  of  kinase  activity  was  measured  using  the  Immobilized  Metal  Assay  for 
Phosphochemicals (IMAP) assay. IMAP is a homogeneous fluorescence polarization (FP) 
assay  based  on  affinity  capture  of  phosphorylated  peptide  substrates.  IMAP  uses 
fluorescein-labeled  peptide  substrates  that,  upon  phosphorylation by  a  protein  kinase, 
bind  to  so-called  IMAP  nanoparticles,  which  are  derivatized  with  trivalent  metal 
complexes. Binding causes a change in the rate of the molecular motion of the peptide, and 
results in an increase in the FP value observed for the fluorescein label attached to the 
substrate peptide. 
Ten point serial dilutions using a √10 dilution factor were used for dose response testing 
of compounds. Starting concentration was 10-6 M for Lck and 10-5 M for Src, FynT, Btk and 
Lyn IMAP assays. Dose-response curves were run as two experiments (N=1) on duplicate 
plates (n=2). All data was normalized to percentage effect based on maximum (Max) and 
minimum (Min) control values. On every 384 assay plate 16 wells were used as minimum 
wells  (wells  with  ATP,  0%  effect)  and  16  wells  were  used  as  maximum  wells  (wells 
without  ATP,  100%  effect).  16  wells  were  used  for  measuring  the  background  signal, 
obtained from a kinase reaction containing all constituents except the labelled peptide 
substrate. Percentage effect was plotted against log dilution concentration of compound to 
obtain sigmoid dose response curves. pIC50 values were calculated using ActivityBase. 
All biochemical assays were run at KM,ATP of the enzyme using non-saturated conditions, 
meaning that during the incubation time it was assured that the signal increase was linear 
with time. For all biochemical assays a reference standard was used on each plate. Newly 
purchased enzyme batches were tested in serial dilutions with the reference standard to 
assure that comparable compound pIC50s were obtained in all assays run over time using 
different enzyme batches. 
 
7.2.1  Lck IMAP Assay 
Enzyme  used  was  N-terminal  His6-tagged  recombinant  full-length  human  Lck  from 
Millipore.  Phosphorylation  substrate  was  a  fluorescein-labeled  peptide  (5FAM-
KVEKIGEGTYGVV-NH2) derived from p34cdc2 from Molecular Devices. Enzymes, substrate 
and ATP were diluted in Kinase Reaction buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% 119 
Tween-20, 0.05% NaN3 pH 7.2, 1 mM DTT). The final volume at the kinase reaction step of 
the assay in the 384-well plate was 20 μL. Final amount of enzyme in the reaction was 0.1 
U/mL. Enzyme was pre-incubated with compounds diluted in 1% DMSO for 60 minutes at 
room temperature in the dark. Subsequently, peptide substrate to a final concentration of 
100 nM, and ATP to a final concentration of 6 μM were added and the mix was incubated 
for 120 minutes at room temperature in the dark. IMAP progressive binding buffer (75% 
1x buffer A, 25% 1x buffer B with 1:600 Progressive Binding Reagent; Molecular Devices) 
was added, followed by an incubation step of 60 minutes at room temperature in the dark. 
Finally, the FP signal was read on an Envision Multilabel reader (Perkin Elmer). 
 
7.2.2  Src IMAP Assay 
Enzyme  used  was  N-terminal  His6-tagged  recombinant  full-length  human  Src  from 
Millipore. Peptide substrate was fluorescein labelled p34cdc2 peptide substrate (5FAM-
KVEKIGEGTYGVV-NH2) from Molecular Devices. Enzymes, substrate and ATP were diluted 
in Kinase Reaction buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% Tween-20, 0.05% NaN3 
pH 7.2, 1 mM DTT). The final volume at the kinase reaction step of the assay in the 384-
well plate was 20 μL. Final amount of enzyme in the reaction was 0.2 U/mL. Enzyme was 
pre-incubated with compounds diluted in 1% DMSO for 60 minutes at room temperature 
in the dark. Subsequently, peptide substrate to a final concentration of 100 nM, and ATP to 
a final concentration of 4 μM were added and the mix was incubated for 120 minutes at 
room temperature in the dark. IMAP progressive binding buffer (75% 1x buffer A, 25% 1x 
buffer B with 1:600 Progressive Binding Reagent; Molecular Devices) was added, followed 
by an incubation step of 60 minutes at room temperature in the dark. Finally, the FP signal 
was read on an Envision Multilabel reader (Perkin Elmer). 
 
7.2.3  FynT IMAP Assay 
Recombinant  full-length  human  FynT  was  expressed  and  purified  at  Schering-Plough. 
Thrombin cleavage was used to remove a His6-tag that was used for purification. The final 
preparation of the enzyme was over 90% pure. Peptide substrate was fluorescein labelled 
p34cdc2  peptide  substrate  (5FAM-KVEKIGEGTYGVV-NH2)  from  Molecular  Devices. 
Enzymes, substrate and ATP were diluted in Kinase Reaction buffer (10 mM Tris-HCl, 10 120 
mM MgCl2, 0.01% Tween-20, 0.05% NaN3 pH 7.2, 1 mM DTT). The final volume at the 
kinase reaction step of the assay in the 384-well plate was 20 μL. Final concentration of the 
enzyme  in  the  reaction  was  125  ng/mL.  Enzyme  was  pre-incubated  with  compounds 
diluted  in  1%  DMSO  for  60  minutes  at  room  temperature  in  the  dark.  Subsequently, 
peptide substrate to a final concentration of 100 nM, and ATP to a final concentration of 
0.2 μM were added and the mix was incubated for 120 minutes at room temperature in the 
dark. IMAP progressive binding buffer (75% 1x buffer A, 25% 1x buffer B with 1:600 
Progressive Binding Reagent; Molecular Devices) was added, followed by an incubation 
step of 60 minutes at room temperature in the dark. Finally, the FP signal was read on an 
Envision Multilabel reader (Perkin Elmer). 
 
7.2.4  Btk IMAP Assay 
Enzyme  used  was  N-terminal  His6-tagged  recombinant  full-length  human  Btk  from 
Millipore.  Peptide  substrate  was  fluorescein  labelled  Blk/Lyntide  peptide  substrate 
(5FAM-EFPIYDFLPAKKK-NH2) from Molecular Devices. Enzymes, substrate and ATP were 
diluted in Kinase Reaction buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% Tween-20, 0.05% 
NaN3 pH 7.2, 1 mM DTT). The final volume at the kinase reaction step of the assay in the 
384-well plate was 20 μL. Final amount of enzyme in the reaction was 0.1 U/mL. Enzyme 
was  pre-incubated  with  compounds  diluted  in  1%  DMSO  for  60  minutes  at  room 
temperature in the dark. Subsequently, peptide substrate to a final concentration of 50 nM, 
and ATP to a final concentration of 5 μM were added and the mix was incubated for 120 
minutes at room temperature in the dark. IMAP progressive binding buffer (75% 1x buffer 
A,  25%  1x  buffer  B with  1:600 Progressive  Binding  Reagent;  Molecular Devices)  was 
added, followed by an incubation step of 60 minutes at room temperature in the dark. 
Finally, the FP signal was read on an Envision Multilabel reader (Perkin Elmer). 
 
7.2.5  Lyn IMAP Assay 
Enzyme  used  was  N-terminal  His6-tagged  recombinant  full-length  human  Lyn  from 
Millipore.  Peptide  substrate  was  fluorescein  labelled  Blk/Lyntide  peptide  substrate 
(5FAM-EFPIYDFLPAKKK-NH2) from Molecular Devices. Enzymes, substrate and ATP were 
diluted in Kinase Reaction buffer (10 mM Tris-HCl, 10 mM MgCl2, 0.01% Tween-20, 0.05% 121 
NaN3 pH 7.2, 1 mM DTT). The final volume at the kinase reaction step of the assay in the 
384-well  plate  was  20  μL.  Final  amount  of  enzyme  in  the  reaction  was  62.5  mU/mL. 
Enzyme was pre-incubated with compounds diluted in 1% DMSO for 60 minutes at room 
temperature in the dark. Subsequently, peptide substrate to a final concentration of 100 
nM, and ATP to a final concentration of 2 μM were added and the mix was incubated for 
120 minutes at room temperature in the dark. IMAP progressive binding buffer (75% 1x 
buffer A, 25% 1x buffer B with 1:600 Progressive Binding Reagent; Molecular Devices) was 
added, followed by an incubation step of 60 minutes at room temperature in the dark. 
Finally, the FP signal was read on an Envision Multilabel reader (Perkin Elmer). 
 
7.3  Experimental 
3,4,5-Trimethoxybenzyl benzoate (2.10). 
 
To a solution of 3,4,5-trimethoxybenzyl alcohol (0.5 mL, 0.003 mol) and benzoyl chloride 
(0.843 g, 0.006 mol) in acetonitrile (15 mL) under argon was added triethylamine (0.4 mL, 
0.003 mol) dropwise. The reaction mixture was stirred at RT for 3 h and then poured into 
ice cold water (15 mL). The product was extracted with DCM (3 x 15 mL), dried over 
MgSO4 and concentrated in vacuo. Purification by column chromatography (SiO2, 0-25% 
EtOAc in hexane) afforded 2.10 as a white solid (0.933 g, 98%). 
M.P: 45 – 47 °C 
IR  max/cm-1: 2945, 1720, 1595 
1H NMR (300 MHz, CDCl3):   8.09 (2 H, dd, J=8.4 Hz, H8, H12), 7.54 – 7.62 (1 H, m, H10), 
7.41 – 7.49 (2 H, m, H9, H11), 6.69 (2 H, s, H2, H6), 5.30 (2 H, s, H14), 3.89 (6 H, s, H15, 
H17), 3.86 (3 H, s, H16) ppm 122 
13C NMR (75 MHz, CDCl3):   166.4 (C13), 153.3 (C3, C5), 138.0 (C7), 133.1 (C10), 131.6 
(C4), 130.1 (C1), 129.7 (C9, C11), 128.4 (C8, C12), 105.5 (C2, C6), 67.0 (C14), 60.8 (C16), 
56.1 (C15, C17) ppm 
LRMS ES+ m/z (%): 325 ([M+Na]+, 48), 627 ([2M+Na]+, 100). 
 
2-Bromo-3,4,5-trimethoxybenzyl alcohol (2.14). 
 
To a solution of 3,4,5-trimethoxybenzyl alcohol (1.181 g, 5.958 mmol) in CHCl3 (40 mL) 
was added N-bromosuccinimide (1.110 g, 6.260 mmol). The reaction mixture was stirred 
at reflux for 3 h. The organic phase was washed with water (3 x 25 mL), dried over MgSO4 
and the solvent removed in vacuo. Column chromatography (SiO2, 35% EtOAc in hexane) 
afforded 2.14 as a white solid (1.402 g, 85%). 
M.P: 52 – 54 °C reported M.P : 54.5 – 55.5 °C80 
IR  max/cm-1: 3432, 2954, 1572, 1481, 1448, 1426, 1396 
1H NMR (300 MHz, CDCl3):   6.90 (1H, s, H6), 4.72 (2H, s, H10), 3.91 (3H, s, H8), 3.89 (6H, s, 
H7, H9), 1.95 (1H, br s, H11) ppm 
13C NMR (75 MHz, CDCl3):   153.0 (C), 150.9 (C), 135.3 (C), 118.4 (C), 108.4 (C), 107.7 (C6), 
65.1 (C10), 61.1 (C7), 61.0 (C8), 56.2 (C9) ppm 
LRMS ES+ m/z (%): 331, 333 ([M+Na+MeOH]+, 100). 
The 1H NMR spectra corresponded to the reported data.80 
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2-Bromo-3,4,5-trimethoxybenzyl benzoate (2.15). 
 
To a solution of 2-bromo-3,4,5-trimethoxybenzyl alcohol 2.14 (0.831 g, 0.003 mol) and 
benzoyl chloride (0.843 g, 0.006 mol) in acetonitrile (15 mL) under argon was added 
triethylamine (0.4 mL, 0.003 mol) dropwise. The reaction mixture was stirred at rt for 3 h 
and then poured into ice cold water (15 mL). The product was extracted with DCM (3 x 15 
mL), dried over MgSO4 and concentrated in vacuo. Purification by column chromatography 
(SiO2, 0-25% EtOAc in hexane) afforded 2.15 as a colourless oil (1.070 g, 94%). 
IR  max/cm-1: 2933, 1724, 1576 
1H NMR (300 MHz, CDCl3):   8.02 (2 H, d, J = 8.1 Hz, H8, H12), 7.42 – 7.57 (1 H, m, H10), 
7.28 – 7.42 (2 H, m, H9, H11), 6.85 (1 H, s, H6), 5.34 (2 H, s, H14), 3.84 (3H, s, H17), 3.83 (3 
H, s, H16), 3.78 (3 H, s, H15) ppm  
13C NMR (75 MHz, CDCl3):   170.2 (C13), 165.6 (C), 152.4 (C), 150.7 (C), 142.8 (C), 132.7 
(C10), 130.4 (C), 129.2 (C19, C23), 128.0 (C8, C20), 109.8 (C), 109.0 (C6), 66.0 (C14), 60.6 
(C15), 60.5 (C16), 55.7 (C17) ppm 
LRMS ES+ m/z (%): 403, 405 ([M+Na]+, 100) 
HRMS (ES): C17H17O5Br [M+Na]+ calculated 403.0152, found 403.0154. 
 
3,4,5-Trimethoxybenzyl 2-bromobenzoate (2.21). 
 
To a solution of 3,4,5-trimethoxybenzyl alcohol (0.83 mL, 0.005 mol) and 2-bromobenzoyl 
chloride (2.195 g, 0.010 mol) in acetonitrile (20 mL) under argon was added triethylamine 124 
(0.7 mL, 0.005 mol) dropwise. The reaction mixture was stirred at rt for 3 h and then 
poured into ice cold water (20 mL). The product was extracted with DCM (3 x 20 mL), 
dried  over  MgSO4  and  concentrated  in vacuo.  Purification  by  column  chromatography 
(SiO2, 0-25% EtOAc in hexane) afforded 2.21 as a colourless oil (2.203 g, 58%). 
IR  max/cm-1: 2941, 1720, 1595, 1504 
1H NMR (300 MHz, (CD3)2CO):   7.77 – 7.87 (1 H, m, H8), 7.67 – 7.76 (1 H, m, H11), 7.41 – 
7.53 (2 H, m, H9, H10), 6.83 (2 H, s, H2, H6), 5.30 (2 H, s, H14), 3.83 (6 H, s, H15, H17), 3.72 
(3 H, s, H16) ppm 
13C NMR (75 MHz, CDCl3):     165.3 (C13), 152.8 (C), 137.5 (C), 133.7 (CH), 132.2 (C), 
131.6 (C), 130.8 (C), 130.6 (CH), 126.7 (CH), 121.0 (C12), 105.1 (C2, C6), 67.0 (C14), 60.2 
(C16), 55.6 (C15, C17) ppm 




A mixture of copper iodide (0.014 g, 0.075 mmol) and sodium iodide (0.450 g, 3.00 mmol) 
was  purged with  argon  for  20  min.  To  this mixture  was  added  dioxane  (2  mL),  N,N’-
dimethylethylene diamine (0.02 mL, 0.15 mmol) and a solution of 3,4,5-trimethoxybenzyl-
2-bromobenzoate 2.21 (0.572 g, 1.50 mmol) in dioxane (1 mL). The solution was stirred at 
110 °C for 23 h after which it was cooled to rt and diluted with 30% aqueous ammonia 
solution (7 mL). The product was extracted with DCM (3 x 25 mL), dried over MgSO4 and 
the  solvent  removed  in  vacuo.  The  resulting  crude  material  was  purified  by  column 
chromatography (10% EtOAc in hexane) to yield a pale yellow oil (0.613 g).  
1H  NMR spectroscopy and mass spectroscopy suggested the product was a mixture of 
starting material and iodinated product in a 2:1 ratio. The two compounds could not be 
separated by column chromatography or crystallisation. 125 
1H NMR (400 MHz, CDCl3):   7.99 (1 H, d, J=8.0 Hz, H8a), 7.80 (3 H, dd, J=7.5, 2.0 Hz, H11a, 
H8), 7.63 – 7.70 (2 H, m, H11), 7.31 – 7.42 (5 H, m, H9, H10, H9a), 7.15 (1 H, td, J=7.7, 1.8 
Hz, H10a), 6.69-6.72 (6 H, m, H2, H6, H2a, H6a), 5.31 (6 H, s, H14, H14a), 3.88 (18 H, s, H17, 
H15, H17a, H15a), 3.86 (9 H, s, H16, H16a) ppm 




To  a  solution  of  2-bromobenzyl  chloride  (1.750  g,  0.008  mol)  and  2-bromo-3,4,5-
trimethoxybenzyl alcohol 2.14 (1.108 g, 0.004 mol) in acetonitrile (16 mL) under argon, 
was added triethylamine (0.56 mL, 0.004 mol) dropwise. The reaction mixture was stirred 
at rt for 3 h and then poured into ice cold water (15 mL). The product was extracted with 
DCM  (3  x  15  mL),  dried  over  MgSO4  and  the  solvent  removed  in  vacuo.  Column 
chromatography (15% EtOAc in hexane) afforded 2.27 as a yellow solid (1.836 g, quant.). 
M.P: 42 – 44 °C 
IR  max/cm-1: 2937, 1727, 1591, 1565 
1H NMR (400 MHz, CDCl3):   7.83 (1H, dd, J=7.0, 2.0 Hz, H8), 7.63 (1 H, dd, J=7.0, 1.0 Hz, 
H11), 7.28 – 7.37 (2 H, m, H9, H10), 6.93 (1 H, s, H6), 5.40 (2 H, s, H14), 3.89 (3 H, s, H17), 
3.88 (3 H, s, H15), 3.85 (3 H, s, H16) ppm 
13C NMR (101 MHz, CDCl3):   165.3 (C13), 152.6 (C), 150.9 (C), 143.1 (C) 134.2 (C10), 
132.6 (C8), 131.7 (C), 131.4 (C11) 130.1 (C), 127.1 (C9), 121.5 (C12), 110.0 (C2), 109.3 
(C6), 67.0 (C14), 60.9 (C15), 60.85 (C16), 56.1 (C17) ppm 
LRMS ES+ m/z (%): 513, 515, 517 ([M+Na+MeOH]+, 100) 
HRMS (ES): C17H16O5Br2Na [M+Na]+ calculated 480.9257, found 480.9263. 126 
2-Bromo-1-(((2-bromobenzyl)oxy)methyl)-3,4,5-trimethoxybenzene (2.33). 
 
To a stirred solution of 2-bromo-3,4,5-trimethoxybenzylalcohol 2.14 (0.420 g, 1.5 mmol), 
2-bromobenzaldehyde (0.12 mL, 1 mmol) and triethylsilane (0.24 mL, 1.5 mmol) in DCM 
(5 mL) at 0°C was added TFA (0.22 mL, 3 mmol) dropwise. The colourless solution was 
gradually warmed to rt. After 16 h the reaction mixture was poured into water (5 mL) and 
the organic layer separated, dried over MgSO4 and the solvent removed in vacuo. The crude 
was  purified  by  column  chromatography  (10% EtOAc  in hexane)  to  yield  the  desired 
product 2.33 as a colourless oil (0.105 g, 24%). 
IR  max/cm-1: 2936, 1568, 1482, 1393  
1H NMR (400 MHz, CDCl3):   7.51 – 7.58 (2 H, m, H8, H11), 7.33 (1 H, td, J=7.5, 7.5, 1.0 Hz, 
H9), 7.17 (1 H, td, J=7.8, 7.8, 2.0 Hz, H10), 6.97 (1 H, s, H6), 4.72 (2 H, s, H14), 4.67 (2 H, s, 
H13), 3.91 (3 H, s, H17), 3.89 (3 H, s, H15), 3.87 (3 H, s, H16) ppm 
13C NMR (75 MHz, CDCl3):   152.8 (C), 150.7 (C), 142.3 (C), 137.3 (C), 132.6 (CH), 129.3 
(CH), 129.1 (CH), 127.4 (CH), 122.8 (C), 109.5 (C), 108.7 (C), 107.8 (C6), 72.1 (C14), 72.0 
(C13), 61.0 (C15), 60.9 (C16), 56.1 (C17) ppm 
LRMS ES+ m/z (%): 467, 469, 471 ([M+Na]+, 100) 




To a stirred suspension of 2,4,6-trihydroxybenzoic acid monohydrate (5.000 g, 27mmol) in 
TFA (40 mL, 537 mmol) at 0 °C was added TFAA (25 mL, 180 mmol) and acetone (5 mL, 68 
mmol). The reaction mixture was slowly warmed to rt and left for 12 h. NaHCO3 was added 
until no further effervescence occurred. The product was extracted with EtOAc (3 x 50 
mL), dried over MgSO4 and concentrated in vacuo. Purification by column chromatography 
(SiO2, 35% EtOAc in hexane) afforded 2.38 as a white solid (3.418 g, 61 %). 
M.P: 194 – 196 °C reported M.P: 203 – 206 °C48 
IR  max/cm-1: 3236, 1637, 1591, 1482 
1H NMR (300 MHz, (CD3)2CO):   10.45 (1 H, s, H12), 9.66 (1 H, br. s, H11), 6.08 (1H, d, J = 
1.8 Hz, H5), 6.00 (1H, d, J = 2.2 Hz, H3), 1.72 (6 H, s, H9, H10) ppm 
13C NMR (75 MHz, (CD3)2CO):   167.3 (C3), 165.9 (C), 164.2 (C), 158.3 (C), 107.8 (C), 98.1 
(C5), 96.3 (C3), 93.2 (C8), 25.7 (C9, C10) ppm 
LRMS ES+ m/z (%):209 ([M-H]-, 100). 




To a solution of 5,7-dihydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 2.38 (4.767 g, 
22.7 mmol) and methanol (0.96 mL, 23.8 mmol) in THF (60 mL) at 0 °C under argon, was 
added  triphenylphosphine  (6.247  g,  23.8  mmol)  and  DIAD  (4.7  mL,  23.8  mmol).  The 
reaction mixture was warmed to rt and stirred for 2 h. The product was extracted with 
EtOAc (3 x 30 mL), washed with water (3 x 20 mL) and brine (3 x 20 mL), dried over 
MgSO4 and the solvent removed in vacuo. Column chromatography (SiO2, 10% EtOAc in 
hexane) afforded 2.39 as a white solid (4.403 g, 87%). 128 
M.P: 104 – 107 °C reported M.P: 108 – 109 °C47 
IR  max/cm-1: 3183, 1690, 1629 
1H NMR (300 MHz, CDCl3):   10.43 (1 H, s, H12), 6.14 (1H, d, J = 2.3 Hz, H5), 6.00 (1H, d, J = 
2.3 Hz, H3), 3.81 (3 H, s, H11) 1.72 (6 H, s, H9, H10) ppm 
13C NMR (75 MHz, CDCl3):   167.7 (C7), 165.2 (C), 163.1 (C), 156.9 (C), 106.9 (C), 95.7 (C5), 
94.6 (C3), 93.1 (C8), 55.7 (C11), 25.6 (C9, C10) ppm 
LRMS ES+ m/z (%): 247 ([M+Na]+, 100). 





To  a  biphasic  solution  of  5-hydroxy-7-methoxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-
one 2.39 (3.834 g, 17.1 mmol) in toluene (80 mL) and aqueous LiOH (1.229 g, 51.3 mmol 
in 25 mL H2O) at 0 °C, was added trifluoromethanesulfonic anhydride (6 mL, 35.4 mmol) 
dropwise. The reaction mixture was stirred at 0 °C for 3 h after which EtOAc (50 mL) was 
added. The organic phase was washed with sat. NaHCO3 solution (3 x 30 mL) and water (3 
x 25 mL), dried over MgSO4 and the solvent removed in vacuo. Column chromatography 
(SiO2, 10% EtOAc in hexane) afforded 2.40 as a white solid (5.293 g, 87%). 
M.P: 63 – 66 °C reported M.P: 58 – 59 °C47 
IR  max/cm-1: 1743, 1629, 1576 
1H NMR (300 MHz, CDCl3):   6.53 (1 H, d, J = 2.3 Hz, H5), 6.48 (1 H, d, J = 2.3 Hz, H3), 3.87 
(3 H, s, H11), 1.73 (6 H, s, H9, H10) ppm 129 
13C NMR (75 MHz, CDCl3):   165.5 (C7), 158.8 (C4), 157.0 (C), 149.9 (C), 118.7 (C12, d, 
J=321.8 Hz), 106.6 (C), 105.3 (C5), 101.1 (C3), 101.0 (C), 56.3 (C11), 25.5 (C9, C10) ppm 
LRMS ES+ m/z (%): 357 ([M+H]+, 100). 




To  a  mixture  of  7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl 
trifluoromethanesulfonate  2.40  (0.100  g,  0.281  mmol),  K3PO4  (0.089  g,  0.421  mmol), 
PdCl2(dppf) (0.010g, 0.014 mmol) and 2-(hydroxymethyl)benzene boronic acid hemi-ester 
(0.041 g, 0.309 mmol) was added THF (5 mL) under argon. The reaction mixture was 
stirred  at  reflux  for  5  h  after  which  a  further  0.75  eq.  of  2-(hydroxymethyl)benzene 
boronic  acid  hemi-ester  (0.028  g,  0.211  mmol) was  added.  The  reaction  mixture  was 
stirred at reflux for a further 16 h and then cooled to rt. 3 M NaOAc solution (0.5 mL) and 
30% H2O2 (0.5 mL) were added and the reaction mixture stirred at rt for 1 h. The product 
was extracted with EtOAc (10 mL), filtered through celite and washed with water (10 mL) 
and brine (10 mL). The organic phase was dried over MgSO4 and the solvent removed in 
vacuo. Column chromatography (SiO2, 35% EtOAc in hexane) afforded  2.45 as  a white 
solid (0.024 g, 34%). 
M.P: 98 – 100 °C 
IR  max/cm-1: 3044, 1654, 1612, 1568 
1H NMR (300 MHz, CDCl3):   10.65 (1 H, s, H15), 7.46 – 7.57 (2 H, m, H5, H6), 7.40 – 7.45 (2 
H, m, H1, H2), 6.65 (1 H, d, J=2.6 Hz, H12), 6.62 (1 H, d, J=2.6 Hz, H10), 5.17 (1 H, br s, H13), 
5.00 (1 H, br s, H13), 3.90 (3 H, s, H16) ppm 130 
13C NMR (75 MHz, CDCl3):   172.6 (C14), 164.0 (C), 163.8 (C), 141.1 (C), 139.4 (C), 134.2 
(C), 130.2 (CH), 129.3 (CH), 128.9 (CH), 128.0 (CH), 109.2 (CH), 106.3 (C), 101.2 (CH), 69.8 
(C13), 55.6 (C16) ppm 
LRMS ES+ m/z (%): 255 ([M-H]-, 94) 




To  a  mixture  of  7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl 
trifluoromethanesulfonate  2.40  (0.178  g,  0.500  mmol),  K3PO4  (0.151  g,  0.750  mmol), 
PdCl2(dppf)  (0.092g,  0.013  mmol)  and  2-(hydroxymethyl)-4-nitrobenzene boronic  acid 
hemi-ester (0.098 g, 0.550 mmol) was added THF (10 mL) under argon. The reaction 
mixture was stirred at reflux for 24 h and then cooled to rt. 3 M NaOAc solution (0.5 mL) 
and 30% H2O2 (0.5 mL) were added and the reaction mixture stirred at rt for 1 h. The 
product was extracted with EtOAc (10 mL), filtered through celite and washed with water 
(10 mL) and brine (10 mL). The organic phase was dried over MgSO4  and the solvent 
removed  in vacuo.  Column chromatography  (SiO2,  10% EtOAc in hexane) afforded  the 
desired product 2.47 as a yellow solid (0.056 g, 32%). 
M.P: 186 – 188 °C  
IR  max/cm-1: 3023, 1729, 1663, 1613, 1528, 1423, 1347 
1H NMR (300 MHz, CDCl3):   10.61 (1 H, s, H15), 8.55 (1 H, d, J=2.2 Hz, H5), 8.44 (1 H, d, 
J=2.2 Hz, H5), 8.35 (1 H, dd, J=8.2, 2.4 Hz, H1), 8.30 (1 H, dd, J=8.4 Hz, H1), 7.71 (1 H, d, 
J=8.4 Hz, H2), 7.64 (1 H, d, J=8.4 Hz, H2), 7.15 (1 H, d, J=2.6 Hz, H12), 7.05 (1 H, d, J=2.2 Hz, 
H12), 6.69 (2 H, q, J=2.6 Hz, H14), 5.04 – 5.25 (4 H, m, H13), 4.01 (3 H, s, H16), 3.93 (3 H, s, 
H16) ppm 131 
13C NMR (75 MHz, CDCl3):   164.4 (C), 164.3 (C), 162.6 (C), 149.4 (C), 149.1 (C), 141.1 (C), 
141.0 (C), 140.2 (C), 138.9 (C), 138.5 (C), 138.2 (C), 130.3 (CH), 129.3 (CH), 124.4 (CH), 
124.3 (CH), 123.6 (CH), 123.6 (CH), 113.9 (CH), 110.1 (CH), 110.0 (CH), 102.2 (CH), 68.5 
(C13), 67.5 (C13), 56.4 (C16), 55.8 (C16)  ppm 




To a solution of ZrCl4 (0.682 g, 2.93 mmol) in THF (17 mL) was added NaBH4 (0.443 g, 
11.70 mmol) at 0 °C under argon. The reaction mixture was stirred for 10 min after which 
a  solution  of  2-bromo-4-methylbenzoic  acid  (0.500  g,  2.34 mmol)  in  THF  (4  mL)  was 
added dropwise. After stirring at rt for 16 h the product was extracted with EtOAc (20 mL), 
washed with water (2 x 20 mL) and brine (2 x 20 mL), dried over MgSO4 and the solvent 
removed in vacuo. Column chromatography (SiO2, 35% EtOAc in hexane) afforded 2.51 as 
a white solid (0.420 g, 90%). 
M.P: 42 – 44 °C reported M.P: 57 °C81 
IR  max/cm-1: 3330, 1606, 1490, 1446 
1H NMR (300 MHz, CDCl3):   7.39 (1 H, d, J=1.5 Hz, H2), 7.34 (1 H, d, J=7.7 Hz, H5), 7.13 (1 
H, dd, J=7.7, 1.5 Hz, H4), 4.72 (2 H, s, H8), 2.34 (3 H, s, H7), 1.95 (1 H, br s, H9) ppm 
13C NMR (75 MHz, CDCl3):   139.4 (C6), 136.7 (C7), 133.1 (C2), 128.9 (C5), 128.4 (C4), 
122.6 (C1), 65.0 (C8), 20.7 (C7) ppm 
HRMS (ES): C8H9OBrNa [M+Na]+ calculated 222.9729, found 222.9728. 
The 1H NMR spectra corresponded to the reported data.81 




A  solution  of  7-methoxy-2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl 
trifluoromethanesulfonate 2.40 (1.425 g, 4.2 mmol), Pd(PPh3)4 (0.277 g, 0.2 mmol) and 
freshly distilled triethylamine (1.7 mL, 12.6 mmol) in THF (20 mL) was degassed under 
argon in a ultrasonication bath for 10 min. A 1M solution of 4,4,5,5-Tetramethyl-1,3,2-
dioxaborolane in THF  (21 mL, 21 mmol) was added dropwise over 5 min and the reaction 
mixture heated to reflux for 4 h. The solvent was removed  in vacuo to yield the crude 
product. Column chromatography (SiO2, 10% EtOAc in hexane) afforded 2.55 as a white 
solid (1.230 g, 92%). 
M.P: 88 – 90 °C reported M.P: 108 – 110 °C53 
IR  max/cm-1: 1720, 1603, 1580, 1444 
1H NMR (300 MHz, CDCl3):   6.65 (1 H, d, J=2.4 Hz, H5), 6.38 (1 H, d, J=2.4 Hz, H3), 3.82 (3 
H, s, H10), 1.70 (6 H, s, H8, H9), 1.40 (12 H, s, H13 – H16) ppm 
LRMS ES+ m/z 357 ([M+Na]+, 100) 
HRMS (ES): C17H23BO6Na [M+Na]+ calculated 357.1480, found 357.1486. 
The 1H NMR spectra corresponded to the reported data.53 




To a stirred solution of the pinacol ester 2.55 (0.050 g, 0.150 mmol) in THF (5 mL), under 
argon,  was  added  (2-bromo-4-methylphenyl)methanol  2.51  (0.045  g,  0.224  mmol), 
PdCl2(dppf)  (0.006  g,  0.0078  mmol)  and  K3PO4  (0.048  g,  0.244  mmol).  The  reaction 
mixture was stirred at reflux for 24 h and then cooled to rt. 3 M NaOAc solution (0.5 mL) 
and 30% H2O2 (0.5 mL) were added and the reaction mixture stirred at rt for 1 h. EtOAc 
(10 mL) was added and the solution filtered through celite. The resulting filtrate was 
washed with water (3 x 10 mL) and brine (3 x 10 mL), dried over MgSO4 and the solvent 
removed in vacuo. Column chromatography (SiO2, 10% EtOAc in hexane) afforded 2.57 as 
a thick yellow paste (0.026 g, 56%). 
M.P: 39 – 41 °C 
IR  max/cm-1: 3463, 2941, 1735, 1610, 1580, 1289 
1H NMR (400 MHz, CDCl3):   7.41 (1 H, d, J=7.7 Hz, H1), 7.22 (1 H, d, J=7.5 Hz, H2), 6.92 (1 
H, s, H5), 6.47 – 6.50 (1 H, m, H12), 6.44 – 6.47 (1 H, m, H10), 4.41 (1 H, d, J=12.0 Hz, H13), 
4.37 (1 H, d, J=12.3 Hz, H13), 3.86 (3 H, s, H19), 2.37 (3 H, s, H20), 1.78 (3 H, s, H18), 1.74 
(3 H, s, H17) ppm 
13C NMR (101 MHz, CDCl3):   164.6 (C15), 160.5 (C), 158.6 (C), 146.1 (C), 139.8 (C1), 137.3 
(C), 134.8 (C2), 129.0 (C), 128.9 (C5), 113.3 (C12), 105.7 (C), 105.5 (C), 100.9 (C10), 63.4 
(C13), 55.8 (C19), 26.0 (C18), 25.3 (C17), 21.2 (C20) ppm 
LRMS ES m/z (%): 351 ([M+Na]+, 100) 
HRMS (ES): C19H20O5Na [M+Na]+ calculated 351.1203, found 351.1209. 
   134 
4-Hydroxy-2-methoxy-10-methyldibenzo[c,e]oxepin-5(7H)-one (2.58). 
 
To a stirred solution of 2.57 (0.026 g, 0.083 mmol) in THF (2 mL), under argon, was added 
NaH (0.004 g, 0.166 mmol) at rt. After 5 hours the reaction was diluted with EtOAc (10 
mL) and the organic solution washed with brine (3 x 5 mL) and NH4Cl (3 x 5 mL). The 
solution was dried over magnesium sulphate and the solvent removed in vacuo to yield the 
desired product 2.58 without further purification as a white solid (0.019 g, 50%). 
M.P: 99 – 101 °C 
1H NMR (400 MHz, CDCl3):   10.66 (1 H, s, H15), 7.37 (1 H, s, H5), 7.31 (1 H, d, J=8.0 Hz, 
H2), 7.24 (1 H, d, J=8.0 Hz, H1), 6.65 (1 H, d, J=2.5 Hz, H12), 6.61 (1 H, d, J=2.5 Hz, H10), 
5.16 (1 H, br s, H13), 4.94 ( 1 H, br s, H13), 3.90 (3 H, s, H17), 2.44 (3 H, s, H17) ppm 
13C NMR (101 MHz, CDCl3):   180.8 (C14), 172.7 (C11), 164.0 (C9), 163.7 (C), 140.2 (C), 
139.3 (C), 131.4 (C), 129.9 (C2), 129.6 (C1), 127.9 (C5), 109.0 (C12), 106.4 (C), 101.1 
(C10), 69.6 (C13), 55.6 (C16), 21.4 (C17) ppm 
LRMS ES m/z (%): 293 ([M+Na]+, 100) 




To a stirred solution of the pinacol ester 2.55 (0.235 g, 0.703 mmol) in THF (15 mL), under 
argon,  was  added  2-bromo-3,4,5-trimethoxybenzylalcohol  2.14  (0.312  g,  1.13  mmol), 
PdCl2(dppf) (0.031 g, 0.042 mmol) and K3PO4 (0.299 g, 1.41 mmol). The reaction mixture 135 
was stirred at reflux for 24 h and then cooled to rt. 3 M NaOAc solution (3 mL) and 30% 
H2O2 (3 mL) were added and the reaction mixture stirred at rt for 1 h. EtOAc (30 mL) was 
added and the solution was filtered through celite. The organic filtrate was washed with 
water (3 x 15 mL) and brine (3 x 15 mL), dried over MgSO4 and the solvent removed in 
vacuo. Column chromatography (SiO2, 10% EtOAc in hexane) afforded a mixture of cyclised 
and uncyclised product (0.248 g, 0.61 mmol). 
The crude was taken up in THF (5 mL) and cooled to 0 °C. NaH (0.022 g, 0.92 mmol) was 
added and the reaction mixture at 0 °C for 6 h. EtOAc (10 mL) was added and the organic 
solution washed with water (3 x 10 mL) and brine (3 x 10 mL), dried over MgSO4 and the 
solvent removed in vacuo. Purification by column chromatography (SiO2, 10% EtOAc in 
hexane) afforded the desired product as a white solid. However, the product contained an 
unknown  impurity  which  could  not  be  removed  with  acid  and  base  washes, 
recrystallisation or further column chromatography. The impure product was isolated as 
an off-white solid (0.053 g, 22%). 
1H NMR (300 MHz, CDCl3):   10.19 (1 H, s, H15), 6.86 (1 H, d, J=2.6 Hz, H12), 6.75 (1 H, s, 
H2), 6.58 (1 H, d, J2.6 Hz, H10), 5.10 (1 H, d, J=12.1 Hz, H13), 4.82 (1 H, d, J=12.1 Hz, H13), 
3.93 (3 H, s, CH3), 3.90 (3 H, s, CH3), 3.88 (3 H, s, CH3), 3.62 (3 H, s, H16) ppm 
LRMS ES m/z (%): 369 ([M+Na]+, 100) 
Attempts to obtain 13C and DEPT NMR spectra were hampered by the degradation of the 




To a solution of ZrCl4 (0.629 g, 2.7 mmol) in THF (16 mL) was added NaBH4 (0.409 g, 10.8 
mmol) under argon. After stirring for 10 min, a solution of 2-bromo-5-methoxylbenzoic 
acid (0.500 g, 2.16 mmol) in THF (4 mL) was added, and the reaction mixture stirred for a 
further 16 h. The product was extracted with EtOAc (20 mL), washed with water (2 x 20 136 
mL) and brine (2 x 20 mL), dried over MgSO4 and the solvent removed in vacuo. Column 
chromatography (35% EtOAc in hexane) afforded 2.64 as a white solid (0.416 g, 87%). 
M.P: 33 – 35 °C reported M.P: 46.5 – 48.5 °C82 
IR  max/cm-1: 3319, 2911, 2823, 1467, 1013 
1H NMR (300 MHz, CDCl3):   7.42 (1H, d, J=8.7 Hz, H6), 7.07 (1H, d, J=3.1 Hz, H3), 6.72 (1H, 
dd, J=8.7, 3.1 Hz, H1), 4.71 (2H, s, H7), 3.81 (3H, s, H9), 2.02 (1H, br. s, H8) ppm 
13C NMR (75 MHz, CDCl3):   159.3 (C2), 140.7 (C4), 133.1 (C6), 114.8 (C1), 114.3 (C3), 
112.5 (C5), 65.0 (C7), 55.5 (C9) ppm 
HRMS (ES): C8H9O2BrNa [M+Na]+ calculated 238.9678, found 238.9677. 




To a stirred solution of 2.65 (0.020 g, 0.058 mmol) in THF (2 mL) under argon was added 
NaH (0.001 g, 0.070 mmol) at 0 °C. The colourless solution was warmed to rt over 3 hour 
after which EtOAc (10 mL) was added. The organic solution was washed with brine (3 x 10 
mL) and NH4Cl (3 x 10 mL), dried over MgSO4 and the solvent removed in vacuo to yield 
the desired product 2.66 as an off-white solid (0.010 g, 62%). 
M.P: 166 – 168 °C 
IR  max/cm-1: 3089, 3023, 1729, 1663, 1613 
1H NMR (300 MHz, CDCl3):   10.59 (1 H, s, H15), 7.41 (1 H, d, J=8.4 Hz, H5), 6.95 (1 H, dd, 
J=8.6, 2.7 Hz, H6), 6.86 (1 H, d, J=2.9 Hz, H2), 6.50 (2 H, q, J=2.6 Hz, H10, H12), 5.13 (1 H, br. 
s, H13), 4.78 (1 H, br. s, H13), 3.81 (3 H, s, H16), 3.80 (3 H, s, H17) ppm 137 
13C NMR (101 MHz, CDCl3):   172.8 (C14), 164.1 (C11), 164.0 (C9), 160.1 (C1), 141.1 (C7), 
135.5 (C3), 131.8 (C4), 130.7 (C5), 115.6 (C6), 113.4 (C2), 108.8 (C10), 106.0 (C8), 100.7 
(C12), 69.9 (C13), 55.6 (C16), 55.6 (C17) ppm 
LRMS ES+ m/z (%): 287 ([M+H]+, 100) 




A stirred slurry of 5-bromovanillin (10.000 g, 0.044 mol), sodium hydroxide (12.120 g, 
0.302 mol) and copper powder (0.056 g, 0.001 mmol) in water (150 mL) was heated to 
reflux. After 24 h Na2HPO4 (0.246 g, 0.002 mol) was added and the reaction mixture heated 
for a further 30 min. The mixture was cooled to rt and filtered to remove a whitish green 
precipitate. The filtrate was acidified to pH 4 using 1 N HCl and the product then extracted 
with EtOAc (3 x 300 mL). The filtrate was stirred in activated carbon, filtered and the 
organic solution washed with saturated EDTA solution (3 x 100 mL) and brine (3 x 100 
mL). The combined organic extracts were dried over MgSO4 and the solvent removed in 
vacuo. Recrystallisation of the resulting crude from toluene furnished the desired product 
2.68 as an off white solid (3.936 g, 54%). 
 M.P: 108 – 110 °C reported M.P: 132 – 133 °C55 
IR  max/cm-1: 3296, 1675, 1588, 1508, 1459 
1H NMR (300 MHz, (CD3)2SO):   10.76 (1 H, br. s, H7), 9.77 (1 H, s, H8, H9), 7.73 (1 H, s, 
H1), 7.41 (1 H, s, H5), 3.91 (3 H, s, H10) ppm 
13C NMR (75 MHz, (CD3)2SO):   190.7 (C7), 150.1 (C), 148.9 (C), 129.2 (C), 129.1 (C), 109.8 
(C), 109.5 (C), 56.6 (C10) ppm 138 




To a stirred solution of 3,4-dihydroxy-5-methoxybenzaldehyde 2.68 (0.505 g, 3.0 mmol) in 
acetic acid (1 mL) was added bromine (0.16 mL, 3.15 mmol) in acetic acid (1 mL) at rt. A 
yellow precipitate formed on addition of the bromine which was filtered off and washed 
with saturated sodium thiosulphate solution (10 mL) and water (10 mL). Recrystallisation 
of  the  resulting  crude  from  ethanol  furnished  the  desired  product  2.69  as  a  yellow 
crystalline solid (0.300 g, 41%). 
M.P: 150 – 152 °C reported M.P: 171 – 172 °C57 
IR  max/cm-1: 3100, 1656, 1572, 1486, 1459 
1H NMR (400 MHz, (CD3)2CO):   10.22 (1 H, s, H7), 8.73 (2 H, br. s, H8, H9), 7.12 (1 H, s, 
H5), 3.91 (1 H, s, H10) ppm 
LRMS ES- m/z (%): 245, 247 ([M-H]-, 100). 
The 1H NMR spectra corresponded to the reported data.57 
 
3-Bromo-4-formyl-6-methoxy-1,2-phenylene diacetate (2.70). 
 139 
To a solution of 2-bromo-3,4-dihydroxy-5-methoxybenzylalcohol 2.69 (1.20 g, 5.1 mmol), 
triethylamine (1.8 mL, 12.7 mmol) and DMAP (0.025 g, 0.2 mmol) in DCM (20 mL), was 
added acetic anhydride (1.2 mL, 12.7 mmol) under argon. The reaction mixture was stirred 
at  rt  for  90  min  after which  the  organic  solution  was  washed  with  saturated  Na2CO3 
solution (3 x 10 mL) and water (3 x 10 mL), dried over MgSO4 and the solvent removed in 
vacuo. Column chromatography (SiO2, 40% EtOAc in hexane) afforded the desired product 
2.70 as a white crystalline solid (1.251 g, 78%). 
M.P: 112 – 114 °C reported M.P: 125 °C56 
IR  max/cm-1: 1782, 1694, 1384, 1371 
1H NMR (300 MHz, CDCl3):   10.19 (1 H, s, H7), 7.38 (1 H, s, H5), 3.80 (3 H, s, H12), 2.29 (3 
H, s, H11), 2.22 (3 H, s, H9) ppm 
LRMS ES+ m/z (%): 385, 387 ([M+Na+MeOH]+, 100). 
The 1H NMR spectra corresponded to the reported data.56 
 
3,4-Diacetoxy-2-bromo-5-methoxybenzyl alcohol (2.71). 
 
To a solution of 3-bromo-4-formyl-6-methoxy-1,2-phenylene diacetate 2.70 (0.320 g, 0.97 
mmol) in MeOH (10 mL) at 0 °C, was added NaBH4 (0.018 g, 0.48 mmol). The reaction 
mixture was stirred at 0 °C for 30 min after which water (10 mL) was added and the 
solution acidified with 1 M H2SO4. The product was extracted with DCM (3 x 10 mL), the 
combined organic extractions dried over MgSO4 and the solvent removed in vacuo. The 
desired product 2.71 was isolated as a purple solid with no further purification required 
(0.308 g, 96%). 
M.P: 114 – 116 °C reported M.P: 138 °C56 140 
IR  max/cm-1: 3501, 1777, 1493 
1H NMR (300 MHz, (CD3)2CO):   7.31 (1 H, s, H5), 4.67 (2 H, s, H7), 3.87 (3 H, s, H12), 2.33 
(3 H, s, H11), 2.26 (3 H, s, H9) ppm 
13C NMR (75 MHz, (CD3)2CO):   168.1 (C8), 167.9 (C10), 152.7 (C), 142.4 (C), 140.7 (C6), 
132.9 (C4), 109.6 (C5), 106.6 (C1), 64.2 (C7), 56.8 (C12), 20.3 (C9), 20.1 (C11) ppm. 




An  oven  dried  two-necked  flask was  cooled  under vacuum  and  backfilled  with argon. 
Pinacol ester 2.55 (0.200 g, 0.600 mmol), 2-bromo-4,5-dimethoxybenzylalcohol (0.148 g, 
0.600 mmol) and potassium phosphate (0.256 g, 1.2 mmol) were added and the flask 
evacuated and backfilled with argon three times. A second oven dried two-necked flask 
was cooled under vacuum and backfilled with argon. Tris(dibenzylideneacetone)palladium 
(0.005 g, 0.006 mmol) and SPhos (0.010 g, 0.024 mmol) were added and the flask was 
evacuated and backfilled with argon three times. THF (2 x 1 mL) was added to each flask, 
the palladium complex transferred to the reaction flask with additional THF (3 mL) and 
the reaction mixture stirred at reflux for 21 h. The reaction mixture was cooled, diluted 
with EtOAc (10 mL) and filtered through a pad of silica gel. Column chromatography (SiO2, 
10% EtOAc in hexane) yielded an off white solid. The product was washed with ether (5 
mL) and the supernatant liquid decanted off. The remaining solid was dissolved in 5 M 
NaOH solution (5 mL), extracted with EtOAc (2 x 5 mL) and the organic layer dried over 
MgSO4, filtered and the solvent removed in vacuo. The basic layer was acidified to pH 5 
using 2 M HCl, re-extracted with EtOAc (2 x 5 mL) and the organic layer dried over MgSO4, 
filtered and the solvent removed in vacuo. The product 2.78 was isolated from the acidic 
extraction as a white solid (0.064 g, 34%). 141 
M.P: 192 – 194 °C 
IR  max/cm-1: 2938, 1652, 1607, 1567, 1520 
1H NMR (300 MHz, CDCl3):   10.69 (1 H, s, H15), 7.03 (1 H, s, H2), 6.92 (1 H, s, H5), 6.61 (1 
H, d, J=2.6 Hz, H12), 6.59 (1 H, d, J=2.6 Hz, H10), 5.15 (1 H, br. s, H13), 4.90 (1 H, br. s, H13), 
3.96 (3 H, s), 3.95 (3 H, s), 3.91 (3 H, s) ppm 
13C NMR (75 MHz, CDCl3):   172.7 (C14), 163.9 (C11), 150.2 (C), 150.0 (C), 149.4 (C), 132.0 
(C), 126.8 (C), 112.1 (C2), 110.8 (C5), 108.9 (C12), 104.6 (C), 104.2 (C), 100.4 (C10), 69.5 
(C13), 56.2 (C16, 18), 55.6 (C17) ppm 
LRMS ES+ m/z (%): 339 ([M+Na]+, 100) 




To a stirred solution of methyl-3,5-dimethoxybenzoate (1.000 g, 5.1 mmol) in acetonitrile 
(8  mL)  at  0°C  was  added  N-bromosuccinimide  (0.910  g,  5.1 mmol).  The solution  was 
stirred for 7 h after which the product was extracted with EtOAc (2 x 25 mL), washed with 
brine (1 x 25 mL), dried over MgSO4 and the solvent removed in vacuo.  Purification by 
column  chromatography  (SiO2,  20%  EtOAc  in  hexane)  afforded  2.80  as  a  white  solid 
(1.133 g, 80%). 
M.P: 54 – 57 °C reported M.P: 55 – 57 °C59 
IR  max/cm-1: 1720, 1572, 1433 
1H NMR (300 MHz, CDCl3):   6.78 (1 H, d, J=2.6 Hz, H5), 6.56 (1 H, d, J=2.6 Hz, H3), 3.91 (3 
H, s, H10), 3.86 (3 H, s, H7), 3.80 (3 H, s, H8) ppm 142 
LRMS ES+ m/z (%): 329, 331 ([M+Na+MeOH]+, 100). 




To a stirred solution of methyl 2-bromo-3,5-dimethoxybenzoate 2.80 (1.000 g, 3.6 mmol) 
in THF (10 mL) at 0°C was added a 1N solution of DIBAL in hexane (9.1 mL, 9.1 mmol) 
dropwise. After 30 min a 1M solution of potassium phosphate (15 mL) was added and the 
product extracted with ether (3 x 10 mL). The organic solution was washed with brine (15 
mL),  dried  over  MgSO4  and  the  solvent  removed  in  vacuo.    Purification  by  column 
chromatography (SiO2, 30% EtOAc in hexane) afforded the desired product 2.81 as a white 
solid (0.764 g, 85%) 
M.P: 90 – 93 °C reported M.P: 94 – 95.2 °C59 
IR  max/cm-1: 3277, 1588, 1455, 1417 
1H NMR (400 MHz, CDCl3):   6.71 (1 H, d, J=2.8 Hz, H5), 6.45 (1 H, d, J=2.8 Hz, H3), 4.74 (2 
H, s, H9), 3.88 (3 H, s, H7), 3.83 (3 H, s, H8) ppm 
LRMS ES m/z (%): 269, 271 [M + Na]+, 100). 




This product was synthesised by Joanna Loh, an undergraduate student on a 6 month 
placement from Singapore. 
An  oven  dried  two-necked  flask was  cooled  under vacuum  and  backfilled  with argon. 
Pinacol ester 2.55 (0.250 g, 0.75 mmol), 2-bromo-3,5-dimethoxybenzylalcohol 2.81 (0.124 
g, 0.50 mmol) and potassium phosphate (0.212 g, 1.00 mmol) were added and the flask 
evacuated and backfilled with argon three times. A second oven dried two-necked flask 
was cooled under vacuum and backfilled with argon. Tris(dibenzylideneacetone)palladium 
(0.005 g, 0.01 mmol) and SPhos (0.008 g, 0.02 mmol) were added to the flask which was 
then evacuated and backfilled with argon three times. THF (2 x 0.75 mL) was added to 
each flask after which the Palladium complex was transferred to the reaction flask with 
additional THF (2 mL) for washing. The reaction mixture was stirred at reflux for 21 h. The 
reaction mixture was cooled, diluted with EtOAc (10 mL) and filtered through a pad of 
silica gel. Column chromatography (SiO2, 10% EtOAc in hexane) yielded an off white solid. 
The solid was washed with ether (5 mL) and the supernatant liquid decanted off. The 
remaining solid was dissolved in 5M NaOH solution (5 mL), extracted with EtOAc (2 x 5 
mL) and the organic layer dried over MgSO4, filtered and the solvent removed in vacuo. 
The basic layer was acidified to pH 5 using 2 M HCl, re-extracted with EtOAc (2 x 5 mL) and 
the organic solution dried over MgSO4, filtered and the solvent removed  in vacuo.  The 
desired product 2.82 was isolated from the acidic extraction as a white solid (0.012 g, 8%). 
M.P: 190 – 193 °C 
IR  max/cm-1: 3338, 1656, 1610 
1H NMR (400 MHz, CDCl3):   10.18 (1 H, s, H15), 6.82 (1 H, d, J=2.5 Hz, H2), 6.62 (1 H, d, 
J=2.5 Hz, H6), 6.58 (1 H, d, J=2.5 Hz, H12), 6.54 (1 H, d, J=2.5 Hz, H10), 5.11 (1 H, d, J=12.0 
Hz, H13), 4.82 (1 H, d, J=12.0 Hz, H13), 3.88 (3 H, s), 3.87 (3 H, s), 3.80 (3 H, s) ppm 
13C NMR (101 MHz, CDCl3):   172.5 (C14), 162.9 (C16), 162.5 (C), 160.7 (C), 158.3 (C), 
137.2 (C), 136.0 (C), 130.9 (C), 111.2 (C12), 106.9 (C), 104.7 (C2), 100.4 (C10), 100.3 (C6), 
96.4 (C), 70.3 (C13), 56.0 (C17), 55.6 (C16), 55.5 (C18) ppm 
LRMS ES+ m/z (%): 339 ([M+Na]+, 100) 
HRMS (ES): C17H16O6Na [M+Na]+ calculated 339.0839, found 339.0848. 144 
8-Hydroxy-10-methoxy-7-oxo-5,7-dihydrobenzo[c,e]ozepine-2-carbonitrile (2.84). 
 
Two flasks were oven dried, cooled under vacuum and backfilled with argon. To one flask, 
pinacol ester  2.55 (0.150 g, 0.45 mmol), 2-bromo-4-cyanobenzylalcohol (0.095 g, 0.45 
mmol) and potassium phosphate (0.191 g, 0.9 mmol) were added and the flask evacuated 
and  backfilled  with  argon  three  times.  Tris(dibenzylideneacetone)palladium  (0.004  g, 
0.0045 mmol) and SPhos (0.007 g, 0.018 mmol) were added to the second flask which was 
then evacuated and backfilled with argon three times. THF (2 x 1 mL) was added to each 
flask  after  which  the  Palladium  complex  was  transferred  to  the  reaction  flask  with 
additional THF (2 mL) for washing. The reaction mixture was stirred at reflux for 16 h. The 
reaction mixture was cooled, diluted with EtOAc (10 mL) and filtered through a pad of 
silica gel. Column chromatography (SiO2, 10% EtOAc in hexane) yielded an off white solid. 
Ether (5 mL) was added and the supernatant liquid decanted off. The remaining solid was 
dissolved in 5 M NaOH solution (5 mL) and extracted with EtOAc (2 x 5 mL). The organic 
layer was dried over MgSO4, filtered and the solvent removed in vacuo. The basic layer was 
acidified to pH 5 using 2 M HCl, re-extracted with EtOAc (2 x 5 mL). The organic layer was 
dried over MgSO4, filtered and the solvent removed in vacuo. The desired product 2.84 was 
isolated from the EtOAc extraction of the acidic solution as a white solid (0.008 g, 6%). 
M.P: 221 – 223 °C 
IR  max/cm-1: 1659, 1618, 1569, 1380, 1225, 1164 
1H NMR (300 MHz, CDCl3):   10.55 (1 H, br. s, H15), 7.83 (1 H, d, J=1.1 Hz, H5), 7.72 (1 H, 
dd, J=7.7, 1.5 Hz, H1), 7.55 (1 H, d, J=7.7 Hz, H2), 6.64 (1 H, d, J=2.2 Hz, H12), 6.59 (1 H, d, 
J=2.2 Hz, H10), 5.16 (1 H, br. s, H13), 5.02 (1 H, br. s, H13), 3.90 (3 H, s, H16) ppm 
13C NMR (75 MHz, CDCl3):   164.3 (C14), 163.8 (C16), 145.7 (C), 140.5 (C), 138.6 (C), 138.5 
(C), 132.8 (C5), 132.2 (C1), 128.9 (C2), 117.8 (C), 114.2 (C), 109.6 (C), 105.6 (C12), 102.0 
(C10), 68.8 (C13), 55.8 (C16) ppm 145 
LRMS ES+ m/z (%): 585 ([2M+Na]+, 100) 




Two flasks were oven dried, cooled under vacuum and backfilled with argon. To one flask, 
pinacol ester  2.55 (0.150 g, 0.45 mmol), 2-bromo-5-fluorobenzylalcohol (0.092 g, 0.45 
mmol) and potassium phosphate (0.191 g, 0.9 mmol) were added and the flask evacuated 
and  backfilled  with  argon  three  times.  Tris(dibenzylideneacetone)palladium  (0.004  g, 
0.0045 mmol) and SPhos (0.007 g, 0.018 mmol) were added to the second flask which was 
then evacuated and backfilled with argon three times. THF (2 x 1 mL) was added to each 
flask  after  which  the  Palladium  complex  was  transferred  to  the  reaction  flask  with 
additional THF (2 mL) for washing. The reaction mixture was stirred at reflux for 16 h 
after which it was diluted with EtOAc (10 mL) and filtered through a pad of silica gel. 
Column chromatography (SiO2, 10% EtOAc in hexane) yielded an off white solid. Ether (5 
mL) was added and the supernatant liquid decanted off. The remaining solid was dissolved 
in 5 M NaOH solution (5 mL), extracted with EtOAc (2 x 5 mL) and the combined organic 
extracts dried over MgSO4, filtered and the solvent removed in vacuo. The basic layer was 
acidified to pH 5 using 2 M HCl, re-extracted with EtOAc (2 x 5 mL) and the combined 
organic extracts dried over MgSO4, filtered and the solvent removed in vacuo. The product 
2.86 was isolated from the EtOAc extraction of the acidic solution as a white solid (0.012 g, 
10%). 
M.P: 167 – 169 °C 
IR  max/cm-1: 1663, 1607, 1569, 1504, 1274 146 
1H NMR (400 MHz, CDCl3):   10.61 (1 H, s, H15), 7.54 (1 H, dd, J=8.8, 5.3 Hz, H5), 7.21 (1 H, 
td, J=8.5, 3.0 Hz, H6), 7.15 (1 H, dd, J=8.0, 2.5 Hz, H2), 6.61 (1 H, d, J=2.5 Hz, H12), 6.59 (1 H, 
d, J=2.5 Hz, H10), 5.15 (1 H, br. s, H13), 4.93 (1 H, br. s, H13), 3.90 (3 H, s, H16) ppm 
13C NMR (101 MHz, CDCl3):   172.4 (C14), 164.1 (C11), 164.0 (C), 163.9 (C1, d, J=250.8), 
140.0 (C), 136.0 (C3, d, J=7.8 Hz), 135.4 (C4, d, J=2.9 Hz), 131.3 (C5, d, J=8.7 Hz), 117.2 (C6, 
d, J=21.4 Hz), 115.0 (C2, d, J=22.4 Hz), 109.3 (C12), 105.9 (C), 101.1 (C10), 69.1 (C13), 55.7 
(C16) ppm 
19F NMR (282 MHz, CDCl3):   -112.17 (1 F, s, F17) ppm 
LRMS ES+ m/z (%): 329 ([M+Na+MeOH]+, 96) 




Two flasks were oven dried, cooled under vacuum and backfilled with argon. To one flask, 
pinacol ester 2.55 (0.150 g, 0.45 mmol), 2-bromo-5-(trifluoromethyl)benzylalcohol (0.115 
g, 0.45 mmol) and potassium phosphate (0.191 g, 0.9 mmol) were added and the flask 
evacuated  and  backfilled  with  argon  three  times.  Tris(dibenzylideneacetone)palladium 
(0.004 g, 0.0045 mmol) and SPhos (0.007 g, 0.018 mmol) were added to the second flask 
which was then evacuated and backfilled with argon three times. THF (2 x 1 mL) was 
added to each flask after which the Palladium complex was transferred to the reaction 
flask with additional THF (2 mL) for washing. The reaction mixture was stirred at reflux 
for 16 h after which it was diluted with EtOAc (10 mL) and filtered through a pad of silica 
gel. Column chromatography (SiO2, 10% EtOAc in hexane) yielded an off white solid. Ether 
(5  mL)  was  added  and  the  supernatant  liquid  decanted  off.  The  remaining  solid  was 
dissolved in 5 M NaOH solution (5 mL), extracted with EtOAc (2 x 5 mL) and the combined 
organic extracts dried over MgSO4, filtered and the solvent removed in vacuo. The basic 147 
layer was acidified to pH 5 using 2 M HCl, re-extracted with EtOAc (2 x 5 mL) and the 
combined organic extracts dried over MgSO4, filtered and the solvent removed in vacuo. 
The product 2.87 was isolated from the EtOAc extraction of the acidic solution as a white 
solid (0.010 g, 7%). 
M.P: 134 – 136 °C 
IR  max/cm-1: 1653, 1614, 1569, 1335 
1H NMR (400 MHz, CDCl3):   10.63 (1 H, s, H15), 7.78 (1 H, dd, J=8.0, 1.0 Hz, H6), 7.66 – 
7.72 (2 H, m, H2, H5), 6.67 (1 H, d, J=2.5 Hz, H12), 6.65 (1 H, d, J=2.5 Hz, H10), 5.22 (1 H, br. 
s, H13), 5.05 (1 H, br. s, H13), 3.92 (3 H, s, H16) ppm 
13C NMR (101 MHz, CDCl3):   172.1 (C14), 164.2 (C), 164.1 (C), 142.8 (C), 139.4 (C), 134.8 
(C), 131.0 (C, q, J=33.0 Hz), 129.9 (C), 126.9 (C, q, J=3.7 Hz), 125.0 (C, q, J=3.6 Hz), 109.8 
(C), 106.0 (C), 101.9 (C), 69.1 (C13), 55.7 (C16) ppm 
LRMS ES+ m/z (%): 379 ([M+Na+MeOH]+, 100) 





Two flasks were oven dried, cooled under vacuum and backfilled with argon. To one flask, 
pinacol ester 2.55 (0.150 g, 0.45 mmol), (6-bromo-1,3-benzoldioxol-5-yl)methanol (0.104 
g, 0.45 mmol)and potassium phosphate (0.191 g, 0.90 mmol) were added and the flask 
evacuated  and  backfilled  with  argon  three  times.  Tris(dibenzylideneacetone)palladium 
(0.004 g, 0.0045 mmol) and SPhos (0.007 g, 0.018 mmol) were added to the second flask 
which was then evacuated and backfilled with argon three times. THF (2 x 1 mL) was 
added to each flask after which the Palladium complex was transferred to the reaction 148 
flask with additional THF (2 mL) for washing. The reaction mixture was stirred at reflux 
for 16 h after which it was diluted with EtOAc (10 mL) and filtered through a pad of silica 
gel. Column chromatography (SiO2, 10% EtOAc in hexane) yielded an off white solid. Ether 
(5  mL)  was  added  and  the  supernatant  liquid  decanted  off.  The  remaining  solid  was 
dissolved in 5 M NaOH solution (5 mL), extracted with EtOAc (2 x 5 mL) and the combined 
organic extracts dried over MgSO4, filtered and the solvent removed in vacuo. The basic 
layer was acidified to pH 5 using 2 M HCl, re-extracted with EtOAc (2 x 5 mL) and the 
combined organic extracts dried over MgSO4, filtered and the solvent removed in vacuo. 
The product 2.89 was isolated from the EtOAc extraction of the acidic solution as a white 
solid (0.007 g, 5%). 
M.P: 212 – 214 °C 
IR  max/cm-1: 2926, 1663, 1610, 1497, 1482, 1255 
1H NMR (400 MHz, CDCl3):   10.59 (1 H, s, H15), 7.01 (1 H, s, H5), 6.89 (1 H, s, H2), 6.58 (1 
H, d, J=2.5 Hz, H12), 6.56 (1 H, d, J=2.5 Hz, H10), 6.06 (2 H, s, H17), 5.10 (1 H, d, J=12.0 Hz, 
H13), 4.83 (1 H, d, J=12.0 Hz, H13), 3.89 (3 H, s, H16) ppm 
13C NMR (101 MHz, CDCl3):   172.6 (C14), 163.9 (C), 163.6 (C), 149.2 (C), 148.1 (C), 141.0 
(C), 133.7 (C), 128.2 (C), 109.5 (C6), 108.8 (C5), 108.2 (C12), 106.2 (C), 101.8 (C17), 100.9 
(C10), 69.4 (C13), 55.6 (C16) ppm 
LRMS ES+ m/z (%): 623 ([2M+Na]+, 100) 




To a stirred solution of di-tert-butyldicarbonate (0.524 g, 2.4 mmol) in DCM (10 mL), 
under argon, was added 2-bromo-3,4-dihydroxy-5-methoxybenzaldehyde 2.69 (0.296 g, 
1.2 mmol) and 4-dimethylaminopyridine (0.015 g, 0.12 mmol). After 2 h the solvent was 
removed  in vacuo  to  yield  the  desired  product  2.98  as  a  white  solid  without  further 
purification (1.017 g, 95%). 
M.P: 106 – 108 °C 
IR  max/cm-1: 1773, 1686, 1595, 1482, 1376, 1327 
1H NMR (300 MHz, CDCl3):   10.29 (1 H, s, H7), 7.44 (1 H, s, H5), 3.90 (3 H, s, H14), 1.54 (9 
H, s, H13), 1.52 (9 H, s, H10) ppm 
13C NMR (75 MHz, CDCl3):   190.0 (C7), 152.1 (1 C, Ar), 149.2 (C11), 149.0 (C8), 142.3 (C), 
138.8 (C), 130.9 (C), 113.8 (C),109.4 (C5), 84.9 (C12), 84.6 (C9) 56.5 (C14), 27.4 (C13), 
27.3 (C10) ppm 
LRMS ES+ m/z (%): 501, 503 ([M+Na+MeOH]+, 100) 
HRMS (ES): C19H27O9BrNa [M+Na+MeOH]+ calculated 501.0731, found 501.0739. 
 
2-Bromo-3,4-di-tertbutoxycarbonyloxy-5-methoxybenzyl alcohol (2.99). 
 
To a stirred solution of  2-bromo-3,4-di-tert-butoxycarbonyloxy-5-methoxybenzaldehyde 
2.98 (0.537 g, 1.2 mmol) in ethanol (10 mL) at -50 °C was added sodium borohydride 
(0.023 g, 0.6 mmol). After 30 min water (20 mL) was added and the product extracted with 
EtOAc (3 x 10 mL). The combined organic extracts were washed with brine (15 mL), dried 
over MgSO4 and the solvent removed in vacuo to yield the desired product 2.99 as a yellow 
solid without further purification (0.537 g, 99 %). 150 
M.P: 92 – 94°C 
IR  max/cm-1: 2983, 1780, 1255 
1H NMR (400 MHz, CDCl3):   7.11 (1H, s, H5), 4.72 (2 H, s, H7), 3.88 (3 H, 2, H14), 1.56 (9 H, 
s, H13), 1.54 (9 H, s, H10) ppm 
13C NMR (101 MHz, CDCl3):   151.8 (C4), 150.0 (C11), 149.7 (C8), 141.6 (C), 138.3 (C), 
132.9 (C), 109.2 (C7), 106.8 (C), 84.5 (C9), 84.0 (C12), 64.6 (C7), 56.4 (C14), 27.6 (C10, 
C13) ppm 
LRMS ES+ m/z (%): 919, 921, 923 ([2M+Na]+, 100) 




To a stirred solution of 2-bromo-3,4-dihydroxy-5-methoxybenzaldehyde 2.69 (0.988 g, 4 
mmol) and K2CO3 (1.658 g, 12 mmol) in DMF (20 mL) was added iodoacetonitrile (0.98 
mL, 12 mmol). The reaction mixture was heated to 60 °C for 16 h after which it was cooled 
to rt. Water (50 mL) was added and the product extracted with 1:1 toluene:EtOAc (3x25 
mL). The combined organic extracts were washed with water (25 mL) and brine (25 mL), 
dried  over  MgSO4  and  the  solvent  removed  in  vacuo.  Purification  by  column 
chromatography (SiO2, 40% EtOAc in hexane) afforded the desired product  2.101 as a 
white solid (0.410 g, 32%). 
M.P: 129 – 131 °C 
IR  max/cm-1: 2986, 2937, 1682, 1588, 1478, 1436, 1387, 1372, 1334, 1285, 1168, 1123  151 
1H NMR (300 MHz, CDCl3):   10.31 (1 H, s, H7), 7.45 (1 H, s, H5), 4.98 (2 H, s, H10), 4.89 (2 
H, s, H8), 3.99 (3 H, s, H12) ppm 
13C NMR (101 MHz, CDCl3):   190.0 (C7), 152.4 (C4), 147.8 (C), 144.5 (C), 130.6 (C), 114.6 
(C), 109.5 (C5), 58.2 (C8), 57.8 (C10), 56.6 (C12) ppm 
LRMS ES+ m/z (%): 379, 381 ([M+Na+MeOH]+, 100) 
HRMS (ES): C12H9O4BrN2Na [M+Na]+ calculated 346.9638, found 346.9644. 
 
2-Bromo-3,4-diacetonitrile-5-methoxybenzyl alcohol (2.102). 
 
To  an  ice-cold,  stirred  solution  of  2-bromo-3,4-diacetonitrile-5-methoxybenzaldehyde 
2.101 (0.446 g, 1.37 mmol) in ethanol (10 mL) was added sodium borohydride (0.052 g, 
1.37 mmol). After 30 min water (20 mL) was added to the flask and the product was 
extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed with brine 
(20 mL), dried over MgSO4 and the solvent removed in vacuo. The desired product 2.102 
was isolated without further purification as a white solid (0.412 g, 92%). 
M.P: 111 – 113 °C 
IR  max/cm-1: 3436, 3376, 1470, 1448, 1417, 1323 
1H NMR (300 MHz, CDCl3):   7.04 (1 H, s, H5), 4.76 (2 H, s, H10), 4.75 (2 H, s, H8), 4.55 (2 H, 
s, H7), 3.82 (3 H, s, H12) ppm 
13C NMR (75 MHz, CDCl3):   152.2 (C4), 147.2 (C), 138.7 (C), 138.0 (C), 115.0 (C11), 114.9 
(C9), 108.3 (C5), 106.5 (C), 63.3 (C7), 57.8 (C10), 57.6 (C8), 56.0 (C12) ppm 
LRMS ES+ m/z (%): 349, 351 ([M+Na]+, 100) 152 
HRMS (ES): C12H11O4BrN2Na [M+Na]+ calculated 348.9794, found 348.9799. 
 
5-Bromo-4-formyl-2-methoxyphenyl acetate (2.104). 
 
To a stirred suspension of 4-acetoxy-3-methoxybenzaldehyde (0.583 g, 3.0 mmol) and 
potassium bromide (1.214 g, 10.2 mmol) in water (22 mL) was added bromine (0.17 mL, 
3.3  mmol)  dropwise.  The  suspension  was  stirred  at rt  for  10  h.  The resulting  orange 
precipitate was collected by filtration and washed with water (3 x 10 mL). The precipitate 
was recrystallised from chloroform and the desired product 2.104 isolated as an orange 
crystalline solid (0.772 g, 94%). 
M.P: 96 – 98 °C reported M.P: 109 – 110 °C83 
IR  max/cm-1: 3407, 1763, 1492, 1463 
1H NMR (300 MHz, CDCl3):   10.27 (1 H, s, H7), 7.51 (1 H, s, H2), 7.36 (1 H, s, H5), 3.88 (3 H, 
s, H10), 2.34 (3 H, s, H9) ppm 
13C NMR (75 MHz, CDCl3):   190.8 (C7), 167.8 (C8), 151.2 (C), 144.9 (C), 131.6 (C), 127.9 
(C2), 117.8 (C), 112.1 (C5), 56.3 (C10), 20.5 (C9) ppm. 
 
5-Bromo-4-(hydroxymethyl)-2-methoxyphenyl acetate (2.105). 
 153 
To  an  ice-cold,  stirred  solution  of  5-bromo-4-formyl-2-methoxyphenyl  acetate  2.104 
(0.308 g, 1.13 mmol) in ethanol (10 mL) was added sodium borohydride (0.021 g, 0.56 
mmol). After 0.5 h, the reaction mixture was warmed to rt and the water (20 mL) added. 
The product was extracted with EtOAc (3 x 15 mL) and the combined organic extracts 
dried  over  MgSO4  and  concentrated  in  vacuo.  The  crude  was  purified  by  column 
chromatography (SiO2, 25% EtOAc in hexane) to yield the desired product  2.105 as a 
white solid (0.093 g, 30%). 
M.P: 80 – 82 °C 
IR  max/cm-1: 3440, 1758, 1595, 1486, 1463 
1H NMR (300 MHz, CDCl3):   7.22 (1 H, s, H2), 7.15 (1 H, s, H5), 4.68 (2 H, d, J=5.9 Hz, H7), 
3.83 (3 H, s, H11), 2.31 (3 H, s, H10) ppm 
13C NMR (101 MHz, CDCl3):   168.8 (C9), 150.7 (C), 139.2 (C), 138.3 (C), 126.6 (C5), 112.3 
(C2), 111.2 (C), 64.6 (C7), 56.1 (C11), 20.5 (C10) ppm. 




To a stirred solution of 4-acetoxy-3-methoxybenzaldehyde (1.165 g, 6.0 mmol) and KBr 
(2.428 g, 20.4 mmol) in water (44 mL) was added bromine (0.34 mL, 6.6 mmol) dropwise. 
The  orange  solution  was  stirred  at  rt  overnight.  The  resulting  orange  precipitate  was 
collected by filtration and washed with water. The crude material was suspended in 6M 
HCl (30 mL) and heated to 90 °C with stirring for 9 h. The resulting off-white precipitate 
was  collected  by  filtration  and  dissolved  in EtOAc  (30 mL).  The  organic solution  was 
washed with saturated sodium hydrogen carbonate solution (3 x 20 mL), dried over MgSO4 
and the solvent removed in vacuo. The desired product 2.106 was isolated without further 
purification as an off-white solid (0.815 g, 59% over two steps). 154 
M.P: 142 – 144 °C reported M.P: 174 – 174 °C85 
IR  max/cm-1: 3107, 1663, 1595, 1557, 1508, 1417 
1H NMR (400 MHz, CDCl3):   10.04 (1 H, s, H7), 9.29 (1 H, br s, H8), 7.30 (1 H, s, H2), 7.05 (1 
H, s, H5), 3.82 (3 H, s, H9) ppm 
13C NMR (101 MHz, CDCl3):   190.5 (C7), 153.1 (C), 147.4 (C), 125.3 (C), 120.3 (C), 119.4 
(C2), 110.6 (C5), 55.9 (C9) ppm 
LRMS ES- m/z (%): 229, 231 ([M-H]-, 100). 




To a stirred solution of 2.106 (0.578 g, 2.5 mmol) and K2CO3 (0.691 g, 5.0 mmol) in DMF 
(10 mL) was added iodoacetonitrile (0.41 mL, 5.0 mmol). The reaction mixture was heated 
to 60 °C for 16 h after which it was cooled to rt. Water (10 mL) was added and the product 
extracted with 1:1 toluene:EtOAc (3 x 20 mL). The combined organic extracts were washed 
with water (20 mL) and brine (20 mL), dried over MgSO4 and the solvent removed  in 
vacuo. Purification by column chromatography (SiO2, 30% EtOAc in hexane) afforded the 
desired product 2.107 as a white solid (0.386 g, 57 %) 
M.P: 84 – 86 °C 
IR  max/cm-1: 1663, 1426, 1380, 1281 
1H NMR (400 MHz, CDCl3):   10.24 (1 H, s, H7), 7.50 (1 H, s, H2), 7.23 (1 H, s, H5), 4.92 (2 H, 
s, H8), 3.94 (3 H, s, H10) ppm 155 
13C NMR (101 MHz, CDCl3):   190.5 (C7), 150.6 (C), 149.9 (C), 129.3 (C), 120.0 (C2), 119.1 
(C9), 114.1 (C), 111.9 (C5), 56.3 (C10), 54.9 (C8) ppm 
LRMS ES+ m/z (%): 324, 326 ([M+Na+MeOH]+, 100) 




To an ice-cold, stirred solution of 2.107 (0.270 g, 1.0 mmol) in ethanol (10 mL) was added 
sodium borohydride (0.038 g, 1.0 mmol). After 0.5 h, the reaction mixture was warmed to 
rt and the water (10 mL) added. The product was extracted with EtOAc (3 x 15 mL) and 
the combined organic extracts dried over MgSO4 and concentrated in vacuo. The crude was 
purified by column chromatography (SiO2, 30% EtOAc in hexane) to yield the desired 
product 2.108 as a white solid (0.160 g, 59%). 
M.P: 107 – 109 °C 
IR  max/cm-1: 3402, 2937, 1750, 1497, 1467, 1383 
1H NMR (400 MHz, CDCl3):   7.10 (1 H, s, H2), 7.08 (1 H, s, H5), 4.73 (2 H, s, H9), 4.53 (2 H, 
s, H7), 3.79 (3 H, s, H11) ppm 
13C NMR (101 MHz, CDCl3):   154.5 (C), 149.2 (C), 141.2 (C), 125.9 (C), 119.5 (C), 116.5 (C), 
115.3 (C), 67.8 (C), 60.3 (C), 60.2 (C) ppm 
LRMS ES+ m/z (%): 294, 296 ([M+K]+, 99). 
   156 
4-Hydroxy-2-methoxy-10-(trifluoromethyl)dibenzo[c,e]oxepin-5(7H)-one (2.112). 
 
A solution of pinacol ester 2.55 (0.067 g, 0.2 mmol), 2-bromo-4-(trifluoromethyl)benzyl 
alcohol (0.051 g, 0.2 mmol), Pd(PPh3)4 (0.012 g, 0.01 mmol) and 2 M NaHCO3 (0.3 mL, 0.6 
mmol) in 1,4-dioxane (2 mL) was degassed for 10 min. The solution was then heated in a 
microwave  to  130 °C  for  10 min.  The  product  was  then  diluted  with  EtOAc  (10 mL), 
washed with brine (2 x 10 mL) and water (2 x 10 mL), dried over MgSO4 and the solvent 
removed in vacuo. Column chromatography (SiO2, 10% EtOAc in hexane) yielded an off 
white solid which was confirmed as impure product. The product was washed with ether 
(5 mL) and the supernatant liquid decanted off. The remaining solid was dissolved in 5 M 
NaOH solution (5 mL). The basic solution was extracted with EtOAc (2 x 5 mL) and the 
organic layer dried over MgSO4, filtered and the solvent removed in vacuo. The basic layer 
was acidified to pH 5 using 2 M HCl and re-extracted with EtOAc (2 x 5 mL). The organic 
layer  was  dried  over  MgSO4,  filtered  and  the  solvent  removed  in vacuo.  The  desired 
product  2.112 was isolated from EtOAc extraction of the acidic layer as a white solid 
(0.020 g, 32%). 
M.P: 163 – 165 °C 
IR  max/cm-1: 1664, 1612, 1570, 1376 
1H NMR (400 MHz, CDCl3):   10.64 (1 H, s, H15), 7.81 (1 H, s, H5), 7.71 (1 H, dd, J=7.8, 1.3 
Hz, H1), 7.57 (1 H, d, J=8.0 Hz, H2), 6.65-6.67 (2 H, m, H10, H12), 5.21 (1 H, br. s, H13), 5.05 
(1 H, br. s, H13), 3.92 (3 H, s, H16) ppm 
13C NMR (101 MHz, CDCl3):   173.3 (C14), 172.1 (C), 164.2 (C6, d, J=12.6 Hz), 140.2 (C), 
139.4 (C), 137.5 (C), 132.7 (C17, t, J=33.0 Hz), 128.6 (C2), 126.2 (C5, q, J=3.9 Hz), 
125.6 (C1, q, J=3.9 Hz), 122.3 (C), 109.7 (C12), 105.9 (C), 101.7 (C10), 69.0 (C13), 
55.8 (C16) ppm 
19F {H} NMR (282 MHz, CDCl3):   -62.78 (3 F, s, F17) ppm 157 
LRMS ES- m/z (%): 323 ([M-H]+, 20) 




A  stirred  solution  of  2-bromo-5-nitrobenzoic  acid  (0.246  g,  1  mmol)  and  sodium 
borohydride (0.113  g,  3  mmol) in  tetrahydrofuran  (5  mL) was  cooled  to  0  °C.  Boron 
trifluoride diethyletherate (0.38 mL, 3 mmol) was added dropwise, the solution warmed to 
rt and stirred for 16 h. The reaction mixture was quenched with 1 M sodium hydroxide 
solution (10 mL) and stirred for 3 h. The solution was diluted with water (10 mL) and the 
product extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over 
MgSO4 and the solvent removed in vacuo to yield the desired product 2.114 as a yellow 
solid without further purification (0.235 g, quant.). 
M.P: Decomp. 75 °C 
IR  max/cm-1: 3232, 1535, 1342, 1021 
1H NMR (300 MHz, CDCl3):   8.43 (1 H, d, J=2.7 Hz, H5), 8.02 (1 H, dd, J=8.7, 2.7 Hz, H3), 
7.72 (1 H, d, J=8.7 Hz, H2), 4.83 (2 H, s, H7) ppm 
13C NMR (75 MHz, CDCl3):   147.5 (C), 142.0 (C), 133.3 (C), 128.7 (C), 123.3 (C), 122.9 (C), 
64.0 (C7) ppm 
No mass ion peak was detected in either negative or positive LRMS. 
   158 
4-Hydroxy-2-methoxy-9-nitrodibenzo[c,e]oxepin-5(7H)-one (2.115). 
 
A solution of the pinacol ester 2.55 (0.067 g, 0.2 mmol), 2-bromo-5-nitrobenzyl alcohol 
2.114 (0.139 g, 0.6 mmol), Pd(PPh3)4 (0.012 g, 0.01 mmol), 2M NaHCO3 (0.3 mL, 0.6 mmol) 
and 1,4-dioxane (2 mL) was degassed for 10 min. The solution was heated in a microwave 
to 130 °C for 10 min after which it was diluted with EtOAc (10 mL). The organic solution 
was washed with brine (2 x 10 mL), water (2 x 10 mL), dried over MgSO4 and the solvent 
removed  in vacuo.  Column  chromatography  (SiO2,  10%  EtOAc  in  hexane)  yielded  the 
desired product 2.115 as a white solid (0.019 g, 31%). 
M.P: 203 – 205 °C 
IR  max/cm-1: 3081, 1662, 1605, 1570, 1523 
1H NMR (400 MHz, CDCl3):   10.61 (1 H, s, H15), 8.37 (1 H, dd, J=8.5, 2.5 Hz, H6), 8.32 (1 H, 
d, J=2.5 Hz, H2), 7.74 (1 H, d, J=8.5 Hz, H5), 6.70 (1 H, d, J=2.5 Hz, H12), 6.67 (1 H, d, J=2.5 
Hz, H10), 5.22 (1 H, br. s, H13), 5.11 (1 H, br. s, H13), 3.93 (3 H, s, H16) ppm 
13C NMR (101 MHz, CDCl3):   171.8 (C14), 164.3 (C11), 164.3 (C9), 147.6 (C), 145.6 (C), 
138.5 (C), 135.5 (C), 130.5 (C5), 125.0 (C6), 123.1 (C2), 110.3 (C12), 105.8 (C), 102.4 
(C10), 68.7 (C13), 55.8 (C16) ppm 
LRMS ES+ m/z (%): 356 ([M+Na+MeOH]+, 100) 




To a stirred solution of 3-bromo-4-pyridinecarboxaldehyde (0.186 g, 1 mmol) in ethanol 
(10 mL) was added sodium borohydride (0.038 g, 1 mmol). After 1 h water (10 mL) and 
EtOAc (30 mL) was added. The organic layer was separated, dried over MgSO4 and the 
solvent removed in vacuo. The desired product 2.117 was isolated as a white solid without 
further purification (0.169 g, 90%). 
1H NMR (400 MHz, CDCl3):   8.54 (1 H, s, H2), 8.44 (1 H, d, J=5.0 Hz, H3), 7.47 (1 H, d, J=5.0 
Hz, H4), 4.69 (2 H, s, H6), 2.86 (1 H, br s, H7) ppm 
13C NMR (101 MHz, CDCl3):   151.4 (C2), 149.7 (C5), 148.8 (C3), 122.8 (C4), 120.2 (C1), 
63.8 (C6) ppm 




A solution of the pinacol ester 2.55 (0.067 g, 0.2 mmol), (3-bromopyridin-4-yl)methanol 
2.117 (0.038 g, 0.2 mmol), Pd(PPh3)4 (0.012 g, 0.01 mmol) and 2 M NaHCO3 (0.15 mL, 0.6 
mmol) in 1,4-dioxane (2 mL) was degassed for 10 min. The reaction mixture was heated to 
130°C for 10 min in a microwave after which it was poured into water (10 mL) and the 
product extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over 
MgSO4 and the solvent removed in vacuo. The desired product 2.118 was isolated after 
column chromatography (SiO2, 10% EtOAc in hexane) as a white solid (0.005 g, 10%). 
M.P: 146 – 148 °C 
IR  max/cm-1: 3014, 1655, 1614, 1567 
1H NMR (400 MHz, CDCl3):   10.69 (1 H, s, H15), 8.83 (1 H, s, H5), 8.71 (1 H, d, J=5.0 Hz, 
H1), 7.37 (1 H, d, J=4.5 Hz, H2), 6.68 (1 H, d, J=2.5 Hz, H12), 6.67 (1 H, d, J=2.5 Hz, H10), 
5.08 (2 H, br s, H13), 3.92 (3 H, s, H16) ppm 160 
13C NMR (101 MHz, CDCl3):   172.0 (C14), 164.6 (C), 164.3 (C), 150.1 (C5), 149.6 (C1), 
141.8 (C), 134.7 (C), 130.8 (C), 121.7 (C2), 109.3 (C12), 106.0 (C), 101.9 (C10), 68.2 (C13), 
55.8 (C16) ppm 
LRMS ES+ m/z 302 (%): ([M+Na+MeOH]+, 13) 




A solution of the pinacol ester 2.55 (0.067 g, 0.2 mmol), 2-bromo-4-fluorobenzyl alcohol 
(0.041 g, 0.2 mmol), Pd(PPh3)4 (0.012 g, 0.01 mmol) and 2 M NaHCO3 (0.15 mL, 0.6 mmol) 
in 1,4-dioxane (2 mL) was degassed for 10 min. The reaction mixture was heated to 130°C 
for 10 min in a microwave after which it was poured into water (10 mL) and the product 
extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over MgSO4 
and the solvent removed in vacuo. The desired product 2.120 was isolated after column 
chromatography (SiO2, 10% EtOAc in hexane) as a white solid (0.005 g, 10%). 
1H NMR (400 MHz, CDCl3):   10.63 (1 H, s, H15), 7.42 (1 H, dd, J=8.0, 5.5 Hz, H2), 7.27 (1 H, 
dd, J=9.5, 2.5 Hz, H5), 7.13 (1 H, td, J=8.3, 2.5 Hz, H1), 6.64 (1 H, d, J=2.5 Hz, H12), 6.62 (1 H, 
d, J=2.5 Hz, H10), 5.14 (1 H, br. s, H13), 4.97 (1 H, br. s, H13), 3.91 (3 H, s, H16) ppm 
13C NMR (101 MHz, CDCl3):   172.4 (C14), 164.1 (C), 163.9 (C), 163.5 (C6, d,  J=248.8), 
141.6 (C4, d, J=7.8 Hz), 139.8 (C), 130.2 (C3, d, J=2.9 Hz), 129.9 (C2, d, J=8.7 Hz), 116.3 (C5, 
d, J=23.3 Hz), 115.7 (C1, d, J=22.4), 109.3 (C12), 106.1 (C), 101.6 (C10), 68.9 (C13), 55.7 
(C16) ppm 
LRMS ES+ m/z (%): 297 ([M+Na]+, 100) 




To a stirred suspension of sodium hydride (0.400 g, 10 mmol) in DMF (5 mL) at -78 °C was 
added 2-bromo-3,4-dihydroxy-5-methoxybenzaldehyde 2.69 (0.988 g, 4 mmol) in DMF (5 
mL) and benzyl bromide (1.4 mL, 12 mmol). After 2 h the solution was poured into water 
(10 mL) and the product extracted with EtOAc (3 x 10 mL). The combined organic extracts 
were dried over MgSO4 and the solvent removed in vacuo. The crude product was purified 
by  column chromatography  (SiO2,  10%  EtOAc in  hexane)  to yield  the  desired  product 
2.123 as a white solid (1.003 g, 59%). 
M.P: 76 – 79 °C reported M.P: 82 – 86 °C24 
IR  max/cm-1: 3064, 3032, 2943, 2866, 1688, 1576, 1451 
1H NMR (300 MHz, CDCl3):   10.32 (1 H, s, H7), 7.31-7.52 (11 H, m), 5.16 (2 H, s, H8), 5.07 
(2 H, s, H15), 3.92 (3 H, s, H22) ppm 
HRMS (ES): C22H19BrO4Na [M+Na]+ calculated 449.0359, found 449.0356. 




To a stirred solution of 3,4-bis(benzyloxy)-2-bromo-5-methoxybenzaldehyde 2.123 (0.855 
g, 2 mmol) in THF (12 mL) at -78 °C under argon was added DIBAL-H (3.4 mL, 4 mmol) 
dropwise. After 2 h, 2M HCl (2 mL) was added dropwise and the resulting solution poured 
into water (20 mL). The product was extracted with EtOAc (3 x 30 mL), the combined 
organic extracts dried over MgSO4 and the solvent removed in vacuo. The desired product 
2.121  was  isolated  in  quantitative yield  as  a  white  solid  with  no  further  purification 
required. 
M.P: 72 – 74 °C reported M.P: 74 – 76 °C24 
IR  max/cm-1: 3397, 2936, 1569, 1454, 1415 
1H NMR (300 MHz, CDCl3):   7.43-7.53 (4 H, m, H10,14,17,21), 7.31-7.40 (6 H, m, H11-
13,18-20), 6.94 (1 H, s, H5), 5.06 (2 H, s, H8), 5.04 (2 H, s, H15), 4.75 (2 H, d, J=6.0 Hz, H7), 
3.89 (3 H, s, H22) ppm 
LRMS ES+ m/z (%): 451, 453 ([M+Na]+, 100). 





A mixture of dioxane (6 mL) and water (1 mL) was degassed for 10 min before being 
added to a flask containing pinacol ester 2.55 (0.434 g, 1.3 mmol), (3,4-Bis(benzyloxy)-2-
bromo-5-methoxyphenyl)methanol 2.121 (0.429 g, 1 mmol), palladium acetate (0.007 g, 
0.03 mmol), SPhos (0.025 g, 0.06 mmol) and caesium carbonate (0.977 g, 3 mmol). The 
solution was heated to 80 °C for 2 h. The reaction mixture was cooled to rt, NH4Cl (2 mL) 
added and the product extracted with EtOAc (3 x 10 mL). The combined organic extracts 163 
were  dried  over  MgSO4  and  the  solvent  removed  in  vacuo.  Purification  by  column 
chromatography  (SiO2,  10%  EtOAc  in  hexane) yielded  the  desired  product  2.122  as  a 
white solid (0.251 g, 54%). 
M.P: 112 – 114 °C reported M.P: 180 – 182 °C24 
IR  max/cm-1: 2941, 1734, 1657, 1611, 1565 
1H NMR (300 MHz, CDCl3):   10.26 (1 H, s, H15), 7.50 (2 H, dd, J=7.7, 2.1 Hz, Ph), 7.32-7.41 
(3 H, m, Ph), 7.12-7.25 (3 H, m, Ph), 6.96 (2 H, d, J=7.5 Hz, Ph), 6.84 (1 H, d, J=2.6 Hz, H12), 
6.77 (1 H, s, H2), 6.54 (1 H, d, J=2.6 Hz, H10), 5.20 (1 H, d, J=10.5 Hz, CH2), 5.02-5.11 (2 H, 
m, CH2), 4.85 (1 H, d, J=10.9 Hz, CH2), 4.80 (1 H, d, J=12.1 Hz, CH2), 4.59 (1 H, d, J=10.9 Hz, 
CH2), 3.94 (3 H, s, H16), 3.79 (3 H, s, H31) ppm 
LRMS ES+ m/z (%): 521 ([M+Na]+, 100) 
HRMS (ES): C30H26O7Na [M+Na]+ calculated 521.1571, found 521.1570. 
The 1H NMR spectra corresponded to the reported data.24 
 
Ulocladol A (1.1) 
 
An oven-dried flask was charged with protected ulocladol A 2.122 (0.199 g, 0.4 mmol), 
Pd/C (10–15 mol%) (0.006 g, 0.06 mmol) and methanol (8 mL). The flask was evacuated 
and  back-filled  with  hydrogen.  The  reaction  mixture  was  stirred  under  a  hydrogen 
atmosphere for 2 min after which it was filtered through a pad of celite and the solvent 
removed in vacuo. Purification by column chromatography (SiO2, 1% MeOH in DCM) failed 
to  remove  all  impurities.  A  second  attempt  at  purification  through  column 
chromatography  (SiO2,  10%  EtOAc  in  hexane)  also  failed  to  remove  all  impurities. 
Recrystallisation of the product from CDCl3 furnished the desired product as a white solid 
(0.018 g, 14%). 164 
M.P: Decomposed at 170 °C reported M.P: 180 – 182 °C24 
IR  max/cm-1: 3412, 1650, 1614, 1567, 1514 
1H NMR (400 MHz, CDCl3):   10.31 (1 H, s, H15), 6.92 (1 H, d, J=2.5 Hz, H12), 6.58 (1 H, s, 
H2), 6.56 (1 H, d, J=2.5 Hz, H10), 5.78 (1 H, br s, H17), 5.69 (1 H, br s, H18), 5.12 (1 H, d, 
J=12.0 Hz, H13), 4.80 (1 H, d, J=12.0 Hz, H13), 3.95 (3 H, s, H16), 3.87 (3 H, s, H19) ppm 
13C NMR (101 MHz, CDCl3):   172.5 (C14), 163.2 (C11), 163.0 (C9), 146.3 (C2), 142.0 (C7), 
135.9 (C5), 133.8 (C6), 127.1 (C3), 118.8 (C4), 110.2 (C12), 106.9 (C8), 103.1 (C1), 100.8 
(C10), 70.3 (C13), 56.3 (C19), 55.5 (C16) ppm 
LRMS ES+ m/z (%): 341 ([M+Na]+,100) 
HRMS (ES): C17H18O8Na [M+Na+MeOH]+ calculated 373.0530, found 373.0523. 
The 1H NMR spectra corresponded to the reported data.24 
 
2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl trifluoromethanesulfonate (2.126). 
 
To a biphasic solution of 5-Hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (1.503 g, 
7.7 mmol) in toluene (36 mL) and aqueous LiOH (0.556 g, 23.2 mmol in 11 mL H2O) at 0 °C, 
was added trifluoromethanesulfonic anhydride (6 mL, 35.4 mmol) dropwise. The reaction 
mixture was stirred at 0 °C for 3 h after which water (30 mL) was added. The product was 
extracted with EtOAc (3 x 20 mL), dried over MgSO4 and the solvent removed in vacuo. 
Column  chromatography  (SiO2,  20%  EtOAc  in  hexane)  afforded  2.126  as  a  white, 
crystalline solid (1.286 g, 51%). 
M.P: 102 – 104 °C reported M.P: 114 – 115 °C86 
1H NMR (300 MHz, CDCl3):   7.61 (1 H, t, J=8.3 Hz, H4), 7.06 (1 H, dd, J=8.7, 1.1 Hz, H5), 
7.01 (1 H, d, J=7.9 Hz, H3), 1.77 (6 H, s, H9, 10) ppm 165 
Rep. Data: 1H NMR87, 88 (400 MHz, CDCl3): δ 7.60 (1 H, dd, J=8.4, 8.4 Hz), 7.05 (1 H, d, J=8.4 
Hz), 7.00 (1 H, d, J=8.4 Hz), 1.76 (6 H, s) ppm. 





A  solution  of  2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl  trifluoromethanesulfonate 
2.126  (1.280  g,  3.9  mmol),  Pd(PPh3)4  (0.225  g,  0.2  mmol)  and  freshly  distilled 
triethylamine  (1.6  mL,  11.7  mmol)  in  THF  (10  mL)  was  degassed  under  argon  in  a 
ultrasonication bath for 10 min. A 1M solution of 4,4,5,5-Tetramethyl-1,3,2-dioxaborolane 
in THF  (11.7 mL, 11.7 mmol) was added dropwise over 5 min and the reaction mixture 
then heated to reflux for 4 h. The solvent was removed in vacuo to yield the crude product. 
Column chromatography (SiO2, 15% EtOAc in hexane) afforded  2.127 as a white solid 
(0.167 g, 14%). 
M.P: 103 – 105 °C 
1H NMR (400 MHz, CDCl3):   7.50 ( 1H, dd, J=7.0, 7.0 Hz, H4), 7.14 (1 H, dd, J=7.5, 1.0 Hz, 
H5), 6.93 (1 H, dd, J=8.5, 1.0 Hz, H3), 1.73 (6 H, s, H9, 10), 1.42 (12 H, s, H13-16) ppm 
13C NMR (101 MHz, CDCl3):   162.0 (C7), 155.6 (C2), 135.5 (C4), 126.3 (C5), 117.6 (C3), 
116.1 (C1), 106.2 (C8), 84.4 (C11, 12), 25.8 (C9, 10), 24.7 (C13-15) ppm. 
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10,11-Bis(benzyloxy)-4-hydroxy-9-methoxydibenzo[c,e]oxepin-5(7H)-one (2.128). 
 
A mixture of dioxane (3 mL) and water (0.5 mL) was degassed for 10 min before being 
added to a flask containing pinacol ester 2.127 (0.115 g, 0.34 mmol), (3,4-Bis(benzyloxy)-
2-bromo-5-methoxyphenyl)methanol  2.121  (0.124  g,  0.29  mmol),  palladium  acetate 
(0.002 g, 0.01 mmol), SPhos (0.007 g, 0.02 mmol) and caesium carbonate (0.283 g, 0.87 
mmol). The solution was heated to 80 °C for 2 h. The reaction mixture was cooled to rt, 
NH4Cl (1 mL) added and the product extracted with EtOAc (3 x 5 mL). The combined 
organic extracts were dried over MgSO4 and the solvent removed in vacuo. Purification by 
column chromatography (SiO2, 10% EtOAc in hexane) yielded the desired product 2.128 
as a white solid (0.070 g, 51%). 
1H NMR (400 MHz, CDCl3):   9.63 (1 H, s, H15), 7.43 (2 H, dd, J=8.0, 1.5 Hz, Ph), 7.22-7.37 (4 
H, m, Ph), 7.11-7.21 (2 H, m, Ph), 7.06 (2 H, t, J=7.3 Hz, H11), 6.95 (1 H, dd, J=8.0 Hz, H10), 
6.78-6.87 (2 H, m, H12, Ph), 6.70 (1 H, s, H2), 5.12 (1 H, d, J=11.0 Hz, H16), 5.00 (1 H, d, 
J=11.0 Hz, H16), 4.94 (1 H, d, J=12.0 Hz, H13), 4.78 (1 H, d, J=11.0 Hz, H23), 4.73 (1 H, d, 
J=12.0 Hz, H13), 4.55 (1 H, d, J=11.0 Hz, H23), 3.85 (3 H, s, H30) ppm 
13C NMR (101 MHz, CDCl3):   171.7 (C14), 159.7 (C9), 153.7 (C1), 150.8 (C), 143.1 (C6), 
137.2 (C), 135.9 (C), 134.7 (C), 132.8 (C11), 130.7 (C), 128.6 (CH), 128.4 (CH), 128.3 (CH), 
128.04 (CH), 128.02 (CH), 128.00 (CH), 126.1 (C3), 123.7 (C12), 116.4 (C10), 113.6 (C), 
107.7 (C2), 75.8 (C23), 75.4 (C16), 70.1 (C13), 56.1 (C30) ppm 
LRMS ES+ m/z (%): 491 ([M+Na]+, 100) 
HRMS (ES): C29H24O6Na [M+Na]+ calculated 491.1465, found 491.1473. 
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11-(benzyloxy)-4,10-dihydroxy-9-methoxydibenzo[c,e]oxepin-5(7H)-one (2.129). 
 
An  oven-dried  flask  was  charged  with  11-(benzyloxy)-4,10-dihydroxy-9-
methoxydibenzo[c,e]oxepin-5(7H)-one 2.128 (0.030 g, 0.06 mmol), Pd/C (10–15 mol%) 
(0.001 g, 0.01 mmol) and ethanol (3 mL). The flask was evacuated and back-filled with 
hydrogen. The reaction mixture was stirred under a hydrogen atmosphere for 2 min after 
which it was filtered through a pad of celite and the solvent removed in vacuo. Purification 
by column chromatography (SiO2, 10% EtOAc in hexane) furnished the desired product as 
a white solid (0.011 g, 48%). 
M.P: 104 – 106 °C 
IR  max/cm-1: 3413, 2936, 1666, 1607, 1567, 1500 
1H NMR (400 MHz, CDCl3):   9.70 (1 H, s, H15), 7.46 (1 H, t, J=7.8 Hz, H11), 7.34 (1 H, dd, 
J=8.1, 1.5 Hz, H12), 7.26-7.30 (1 H, m, H20), 7.18-7.26 (2 H, m, H19, 21), 7.01-7.07 (3 H, m, 
H10, 18, 22), 6.77 (1 H, s, H2), 5.82 (1 H, s, H23), 5.06 (1 H, d, J=12.1 Hz, H13), 4.82 (1 H, d, 
J=12.1 Hz, H13), 4.66 (1 H, d, J=11.1 Hz, H16), 4.60 (1 H, d, J=11.1 Hz, H16), 3.98 (3 H, s, 
H24) ppm 
13C NMR (101 MHz, CDCl3):   171.9 (C14), 159.8 (C9), 147.3 (C1), 143.8 (C5), 140.4 (C6), 
135.8 (C17), 134.7 (C4), 133.2 (C11), 128.6 (C19, 21), 128.4 (C20), 128.35 (C18, 22), 126.5 
(C7), 125.3 (C3), 123.2 (C12), 116.8 (C10), 113.8 (C8), 106.9 (C2), 75.4 (C16), 70.3 (C13), 
56.4 (C24) ppm 
HRMS (ES): C22H18O6Na [M+Na]+ calculated 401.0996, found 401.1004. 
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4-Bromo-5-methylbenzene-1,3-diol (3.4). 
 
To a stirred solution of orcinol (0.993 g, 8.0 mmol) in DCM (30 mL) and MeOH (20 mL) 
was added a solution of tetrabutyl ammoniu tribromide (3.857 g, 8.0 mmol) in DCM (30 
mL) and MeOH (20 mL) dropwise. The solution was stirred at rt for 16 h. The reaction 
mixture was concentrated and poured into water (20 mL). The product was extracted with 
DCM  (2  x  20  mL),  the  combined  organic  extracts  dried  over  MgSO4  and  the  solvent 
removed in vacuo. Purification by column chromatography (SiO2, 20% EtOAc in hexane) 
yielded the desired product 3.4 as a white solid (0.724 g, 45%). 
M.P: 134 – 136 °C reported M.P: 132 – 135 °C89 
IR  max/cm-1: 3353, 1586, 1459, 1323 
1H NMR (300 MHz, (CD3)2CO):   8.32 (2 H, br. s, H7, 9), 6.39 (1 H, d, J=2.9 Hz, H6), 6.36 (1 
H, d, J=2.9 Hz, H4), 2.27 (3 H, s, H8) ppm 
13C NMR (75 MHz, (CD3)2CO):   158.1 (C5), 155.6 (C1), 140.2 (C3), 110.3 (C4), 102.8 (C2), 
102.0 (C6), 23.4 (C8) ppm 
LRMS ES- m/z (%): 201, 203 ([M-H]-, 100). 
 
4-Bromo-5-methyl-1,3-phenylene diacetate (3.5). 
 
To a stirred solution of 4-bromo-5-methylbenzene-1,3-diol 3.4 (0.203 g, 1.0 mmol), acetic 
anhydride (0.24 mL, 2.5 mmol) and 4-dimethylaminopyridine (0.005 g, 0.04 mmol) in DCM 
(5 mL) was added triethylamine (0.35 mL, 2.5 mmol). The reaction mixture was stirred at 169 
rt for 16 h, after which it was diluted with DCM (10 mL). The organic solution was washed 
with  saturated  sodium  carbonate  solution  (10  mL),  dried  over  MgSO4  and  the  solvent 
removed in vacuo. Purification by column chromatography (SiO2, 10% EtOAc in hexane) 
furnished the desired product 3.5 as a white solid (0.242 g, 84%). 
M.P: 52 – 54 °C 
IR  max/cm-1: 1774, 1369, 1189, 1136 
1H NMR (300 MHz, CDCl3):   6.93 (1 H, d, J=3.0 Hz, H4), 6.82 (1 H, d, J=3.0 Hz, H6), 2.42 (3 
H, s, H9), 2.33 (3 H, s, H11), 2.25 (3 H, s, H8) ppm 
13C NMR (75 MHz, (CDCl3):   168.8 (C10), 168.3 (C7), 149.5 (C), 148.6 (C), 140.5 (C), 121.3 
(C), 115.6 (C6), 114.7 (C4), 23.3 (C9), 21.2 (C11), 20.8 (C8) ppm 
LRMS ES+ m/z (%): 309, 311 ([M+Na]+, 79) 




To a stirred solution of 4-bromo-5-methyl-1,3-phenylene diacetate 3.5 (0.506 g, 2.5 mmol) 
and K2CO3 (1.037 g, 7.5 mmol) in DMF (10 mL) was added iodoacetonitrile (0.61 mL, 7.5 
mmol). The reaction mixture was heated to 60 °C for 16 h after which it was cooled to rt. 
Water (10 mL) was added and the product extracted with 1:1 toluene:EtOAc (3 x 20 mL). 
The combined organic extracts were washed with water (20 mL) and brine (20 mL), dried 
over MgSO4 and the solvent removed in vacuo. Purification by column chromatography 
(40% EtOAc in hexane) afforded the desired product 3.6 as a white solid (0.240 g, 34 %) 
M.P: 104 – 106 °C 170 
IR  max/cm-1: 2929, 1582, 1470, 1446 
1H NMR (300 MHz, CDCl3):   6.60 (1 H, d, J=3.0 Hz, H6), 6.51 (1 H, d, J=3.0 Hz, H4), 4.79 (2 
H, s, H10), 4.74 (2 H, s, H7), 2.35 (3 H, s, H9) ppm 
13C NMR (75 MHz, CDCl3):   155.9 (C), 153.9 (C), 141.5 (C), 114.6 (C8), 114.5 (C11), 111.0 
(C4), 109.0 (C), 101.3 (C6), 54.9 (C7), 53.8 (C11), 23.6 (C9) ppm 
LRMS ES+ m/z (%): 303, 305 ([M+Na]+, 100) 
HRMS (ES): C11H9N2O2BrNa [M+Na]+ calculated 302.9740, found 302.9736. 
 
Alternariol-9-methyl ether (1.2). 
 
A degassed solution of 1,4-dioxane (2.4 mL) and water (0.4 mL) was added to a mixture of 
the pinacol ester 2.55 (0.174 g, 0.52 mmol), phenol 3.4 (0.081 g, 0.4 mmol), Pd (OAc)2 
(0.003 g, 0.012 mmol), SPhos (0.010 g, 0.024 mmol) and Cs2CO3 (0.391 g, 1.2 mmol) under 
argon. The stirred solution was heated in a microwave at 130 °C for 5 min. The reaction 
mixture was diluted with NH4Cl (10 mL) and the product extracted with EtOAc (3 x 10 
mL). The combined organic extracts were dried over MgSO4 and the solvent removed in 
vacuo. Recrystallisation of the crude material from methanol yielded the desired product 
1.2 as a purple crystalline solid (0.048 g, 44%). 
M.P: >246 °C reported M.P: 277 – 279 °C75 
IR  max/cm-1: 3375, 1651, 1616, 1592, 1568 
1H NMR (400 MHz, (CD3)2SO):   11.82 (1 H, br. s, H17), 10.36 (1 H, s, H14), 7.21 (1 H, d, 
J=2.4 Hz, H12), 6.72 (1 H, d, J=2.0 Hz, H2), 6.64 (1 H, d, J=2.4 Hz, H10), 6.61 (1 H, d, J=2.0 
Hz, H4), 3.91 (3 H, s, H15), 2.73 (3 H, s, H16) ppm 171 
13C NMR (101 MHz, (CD3)2SO):   166.2 (C), 164.7 (C), 164.1 (C), 158.6 (C), 152.6 (C), 138.4 
(C), 137.8 (C), 117.6 (CH), 108.8 (C), 103.4 (CH), 101.6 (CH) 99.2 (CH), 98.5 (C), 55.8 (C15), 
25.0 (C16) ppm 
LRMS ES+ m/z (%): 327 ([M+Na+MeOH]+, 100) 
HRMS (ES): C15H12O5Na [M+Na]+ calculated 295.0577, found 295.0582. 




To a stirred solution of alternariol 9-methylether 1.2 (0.030 g, 0.1 mmol) in DCM (3 mL), 
under argon, was added a 1 M solution of BBr3 in DCM (0.44 mL, 4.4 mmol). The solution 
was stirred at rt for 16 h after which MeOH (15 mL) was added dropwise. The solvent was 
removed in vacuo and the resulting crude material purified by column chromatography 
(2% MeOH in DCM) to yield the desired product 1.3 as a white solid (0.016 g, 0.063 mmol). 
IR  max/cm-1: 3438, 3162, 1659, 1608, 1416 
1H NMR (400 MHz, CD3OD):   7.22 ( 1H, d, J=2.0 Hz, H12), 6.67 (1 H, d, J=2.5 Hz, H2), 6.58 
(1 H, d, J=2.5 Hz, H4), 6.35 (1 H, d, J=2.0 Hz, H10), 2.73 (3 H, s, H16) ppm 
13C NMR (101 MHz, CD3OD):   167.1 (C), 167.0 (C), 166 (C), 160.0 (C), 154.6 (C), 140.2 (C), 
140.0 (C), 118.7 (C2), 111.1 (C), 105.7 (C12), 102.9 (C4), 102.1 (C10), 99.2 (C), 26.0 (C16) 
ppm 
LRMS ES+ m/z (%): 313 ([M+Na+MeOH]+, 60%) 
HRMS (ES): C14H11O5 [M+H]+ calculated 259.0601, found 259.0597. 
The 1H NMR spectra corresponded to the reported data.30 172 
8  Appendix 
8.1  X-Ray Crystal Structure Data for 2.115 
 
Table 1. Crystal data and structure refinement details. 
   
Identification code   2009sot1058  (LS5529/90)   
Empirical formula   C15H11NO6 
Formula weight   301.25 
Temperature   120(2) K 
Wavelength   0.71073 Å 
Crystal system   Monoclinic 
Space group   P21/c  
Unit cell dimensions  a = 4.0312(3) Å   
  b = 41.493(4) Å   = 103.619(4)° 
  c = 7.9266(8) Å   
Volume  1288.6(2) Å3 
Z  4 
Density (calculated)  1.553 Mg / m3 
Absorption coefficient  0.122 mm 1 
F(000)  624 
Crystal  Lath; Colourless 
Crystal size  0.10   0.06   0.01 mm3 
 range for data collection  2.95   25.03° 
Index ranges  4   h   4,  49   k   49,  9   l   9 
Reflections collected  7987 
Independent reflections  2254 [Rint = 0.0816] 
Completeness to   = 25.03°  98.9 %  
Absorption correction  Semi empirical from equivalents 
Max. and min. transmission  0.9988 and 0.9879 
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  2254 / 0 / 201 
Goodness-of-fit on F2  1.088 
Final R indices [F2 > 2 (F2)]  R1 = 0.0974, wR2 = 0.1687 
R indices (all data)  R1 = 0.1588, wR2 = 0.2011 
Largest diff. peak and hole  0.361 and  0.353 e Å 3 173 
8.2  X-Ray Crystal Structure Data for 1.2 
 
Table 1. Crystal data and structure refinement details. 
   
Identification code   2009sot1168 (LS5671/8) 
Empirical formula   C15H12O5 
Formula weight   272.25 
Temperature   120(2) K 
Wavelength   0.71073 Å 
Crystal system   Orthorhombic 
Space group   Fdd2  
Unit cell dimensions  a = 31.7929(10) Å   
  b = 39.3485(10) Å   
  c = 3.76590(10) Å   
Volume  4711.2(2) Å3 
Z  16 
Density (calculated)  1.535 Mg / m3 
Absorption coefficient  0.116 mm 1 
F(000)  2272 
Crystal  Rod; Colourless 
Crystal size  0.15   0.03   0.02 mm3 
 range for data collection  3.30   27.48° 
Index ranges  39   h   40,  50   k   50,  4   l   4 
Reflections collected  15064 
Independent reflections  1542 [Rint = 0.0745] 
Completeness to   = 27.48°  99.7 %  
Absorption correction  Semi empirical from equivalents 
Max. and min. transmission  0.9977 and 0.9828 
Refinement method  Full-matrix least-squares on F2 
Data / restraints / parameters  1542 / 1 / 185 
Goodness-of-fit on F2  1.090 
Final R indices [F2 > 2 (F2)]  R1 = 0.0488, wR2 = 0.0992 
R indices (all data)  R1 = 0.0615, wR2 = 0.1055 
Absolute structure parameter  Not reliably determined 
Largest diff. peak and hole  0.243 and  0.259 e Å 3 
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8.3  1H NMR Spectra 
3,4,5-Trimethoxybenzyl benzoate (2.10) 
 
Comment LS4998/74 Date 02 Jun 2008 13:05:20
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
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Formula C17H18O5 FW 302.3218 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2008\JU0208LS1\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.86 (3 H, s) 3.89 (6 H, s) 5.30 (2 H, s) 6.69 (2 H, s) 7.41 - 7.49 (2 H, 
m) 7.54 - 7.62 (1 H, m) 8.09 (2 H, dd, J=8.4, 1.0 Hz)
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2-Bromo-3,4,5-trimethoxybenzyl alcohol (2.14) 
 
Comment LS/4781/37 columned
Date 14 Feb 2007 14:04:48
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
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1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.89 (6 H, s) 3.91 (3 H, s) 4.72 (2 H, s) 6.90 (1 H, s)
Formula C10H13BrO4 FW 277.1118 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2007\FE1407LS1\10\PDATA\1\1r
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2-Bromo-3,4,5-trimethoxybenzyl benzoate (2.15) 
 
Comment LS4998/80 Date 12 Jun 2008 16:13:04
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)

























































1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.78 (3 H, s) 3.83 (3 H, s) 3.84 (3 H, s) 5.34 (2 H, s) 6.85 
(1 H, s) 7.29 - 7.42 (2 H, m) 7.42 - 7.54 (1 H, m) 8.02 (2 H, d, J=8.1 Hz)
Formula C17H17BrO5 FW 381.2179 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2008\JU1208LS1\10\PDATA\1\1r
 
   177 
3,4,5-Trimethoxybenzyl 2-bromobenzoate (2.21) 
 
Comment LS5291/23 F94-119
Date 24 Sep 2008 14:11:28
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent Acetone
Original Points Count 16384 Points Count 16384

































7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)







































































1H NMR (300 MHz, Acetone)   ppm 3.72 (3 H, s) 3.83 (6 H, s) 5.30 (2 H, s) 6.83 (2 H, s) 7.41 - 7.53 (2 H, 
m) 7.67 - 7.76 (1 H, m) 7.77 - 7.87 (1 H, m)
Formula C17H17BrO5 FW 381.2179 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2008\SE2408LS3\10\PDATA\1\1r
 
   178 
3,4,5-Trimethoxybenzyl-2-iodobenzoate (2.24) 
 
Comment LS5291/28 Date 23 Oct 2008 10:10:08
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)



































































































1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.86 (9 H, s) 3.88 (18 H, s) 5.31 (6 H, s) 6.69 - 6.72 (6 H, 
m) 7.15 (1 H, td, J=7.7, 1.8 Hz) 7.31 - 7.42 (5 H, m) 7.63 - 7.70 (2 H, m) 7.80 (3 H, dd, J=7.5, 2.0 Hz) 7.99 
(1 H, d, J=8.0 Hz)
Formula C17H17IO5 FW 428.2183 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\OC2308LS1\10\FID
 
   179 
2-Bromo-3,4,5-trimethoxybenzyl-2-bromobenzoate (2.27) 
 
Comment LS5291/39 Date 24 Nov 2008 10:35:44
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384


































8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)







































































































File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\NV2408LS1\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.85 (3 H, s) 3.88 (3 H, s) 3.89 (3 H, s) 5.40 (2 H, s) 6.93 
(1 H, s) 7.28 - 7.37 (2 H, m) 7.63 (1 H, dd, J=7.0, 1.0 Hz) 7.83 (1 H, dd, J=7.0, 2.0 Hz)
 





Date 20 Jul 2009 13:30:40
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384































7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)



















































































File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\JY2009LS3\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.87 (3 H, s) 3.89 (3 H, s) 3.91 (3 H, s) 4.67 (2 H, s) 4.72 
(2 H, s) 6.97 (1 H, s) 7.17 (1 H, td, J=7.8 x (2), 2.0 Hz) 7.33 (1 H, td, J=7.5 x (2), 1.0 Hz) 7.51 - 7.58 (2 H, 
m)
 




Date 21 Dec 2006 10:48:32
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent Acetone
Original Points Count 16384 Points Count 16384
Spectrum Offset (Hz) 1496.9465






















10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)


































Formula C10H10O5 FW 210.1834 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2006\DC2106LS1\10\PDATA\1\1r
1H NMR (300 MHz, Acetone)   ppm 1.72 (6 H, s) 6.00 (1 H, d, J=2.2 Hz) 6.08 (1 H, d, J=1.8 Hz) 9.66 (1 
H, br. s.) 10.45 (1 H, s)
 





Date 26 Oct 2006 13:58:40
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
























10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)






























1H NMR (300 MHz, CHLOROFORM-d)   ppm 1.72 (6 H, s) 3.81 (3 H, s) 6.00 (1 H, d, J=2.2 Hz) 6.14 (1 
H, d, J=2.2 Hz) 10.43 (1 H, s)
Formula C11H12O5 FW 224.2100 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2006\OC2606LS1\10\PDATA\1\1r
 




Comment LS/4781/23 columned B
Date 30 Nov 2006 18:12:16
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384




































7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)

















1H NMR (300 MHz, CHLOROFORM-d)   ppm 1.75 (6 H, s) 3.89 (3 H, s) 6.49 (1 H, d, J=2.2 Hz) 6.54 (1 
H, d, J=2.2 Hz)
Formula C12H11F3O7S
FW 356.2717
File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2006\NV3006LS2\10\PDATA\1\1r
 
   184 
4-Hydroxy-2-methoxydibenzo[c,e]oxepin-5(7H)-one (2.45) 
 
Comment LS/4781/28 Fn 7
Date 18 Dec 2006 15:57:52
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384

























11 10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)

































































1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.90 (3 H, s) 5.00 (1 H, br. s.) 5.17 (1 H, br. s.) 6.62 (1 H, 
d, J=2.6 Hz) 6.65 (1 H, d, J=2.6 Hz) 7.40 - 7.45 (2 H, m) 7.46 - 7.57 (2 H, m) 10.65 (1 H, s)
Formula C15H12O4 FW 256.2534 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2006\DC1806LS1\10\PDATA\1\1r
 





10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)




























































































































Date 21 Sep 2007 14:41:20
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.93 (3 H, s) 4.01 (3 H, s) 5.04 - 5.25 (4 H, m) 6.69 (2 H, 
q, J=2.6 Hz) 7.05 (1 H, d, J=2.2 Hz) 7.15 (1 H, d, J=2.6 Hz) 7.64 (1 H, d, J=8.4 Hz) 7.71 (1 H, d, J=8.4 
Hz) 8.30 (1 H, dd, J=8.2, 2.4 Hz) 8.35 (1 H, dd, J=8.2, 2.4 Hz) 8.44 (1 H, d, J=2.2 Hz) 8.55 (1 H, d, J=2.2 
Hz) 10.61 (1 H, s)
Formula C15H11NO6 FW 301.2509 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2007\SE2107LS1\10\PDATA\1\1r
 




Date 13 Mar 2007 09:55:12
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384















7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)



















































1H NMR (300 MHz, CHLOROFORM-d)   ppm 1.95 (1 H, br. s.) 2.34 (3 H, s) 4.72 (2 H, s) 7.13 (1 H, dd, 
J=7.7, 1.5 Hz) 7.34 (1 H, d, J=7.7 Hz) 7.39 (1 H, d, J=1.5 Hz)
Formula C8H9BrO FW 201.0605 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2007\MA1307LS1\10\PDATA\1\1r
 





Date 05 Jun 2009 11:44:16
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384





































7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)





























1H NMR (300 MHz, CHLOROFORM-d)   ppm 1.32 (12 H, s) 1.62 (6 H, s) 3.73 (3 H, s) 6.31 (1 H, d, 
J=2.6 Hz) 6.58 (1 H, d, J=2.6 Hz)
Formula C17H23BO6 FW 334.1719 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\JU0509LS1\10\PDATA\1\1r
 
   188 
5-(2-(Hydroxymethyl)-5-methylphenyl)-7-methoxy-2,3-dimethyl-
4H-benzo[d][1,3] dioxin-4-one (2.57) 
 
Comment LS5529/29 F11-20
Date 02 Jun 2009 13:20:00
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384


































7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)















































































1H NMR (400 MHz, CHLOROFORM-d)   ppm 1.74 (3 H, s) 1.78 (3 H, s) 2.37 (3 H, s) 3.86 (3 H, s) 4.28 - 
4.47 (2 H, m) 6.44 - 6.47 (1 H, m) 6.47 - 6.50 (1 H, m) 6.92 (1 H, s) 7.22 (1 H, d, J=7.5 Hz) 7.41 (1 H, d, 
J=8.0 Hz)
Formula C19H20O5 FW 328.3591 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\JU0209LS1\10\FID





Date 25 Jun 2007 15:40:48
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384



























10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)






























































1H NMR (400 MHz, CHLOROFORM-d)   ppm 2.44 (3 H, s) 3.90 (3 H, s) 4.94 (1 H, br. s.) 5.16 (1 H, br. 
s.) 6.61 (1 H, d, J=2.5 Hz) 6.65 (1 H, d, J=2.5 Hz) 7.24 (1 H, d, J=8.0 Hz) 7.31 (1 H, d, J=8.0 Hz) 7.37 (1 
H, s) 10.66 (1 H, s)
Formula C16H14O4 FW 270.2800 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\JU2507LS1\1\FID
 




Comment LS4998/32 Date 04 Jan 2008 18:44:16
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384




































10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)






























































Formula C18H18O7 FW 346.3313 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2008\JA0408LS1\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.62 (3 H, s) 3.88 (3 H, s) 3.90 (3 H, s) 3.93 (3 H, s) 4.82 
(1 H, d, J=12.1 Hz) 5.10 (1 H, d, J=12.1 Hz) 6.58 (1 H, d, J=2.6 Hz) 6.75 (1 H, s) 6.86 (1 H, d, J=2.6 Hz) 
10.19 (1 H, s)
 




Date 13 Mar 2007 10:31:28
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384

















7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)



















































1H NMR (300 MHz, CHLOROFORM-d)   ppm 2.03 (1 H, br. s.) 3.81 (3 H, s) 4.71 (2 H, s) 6.72 (1 H, dd, 
J=8.6, 3.1 Hz) 7.07 (1 H, d, J=2.9 Hz) 7.42 (1 H, d, J=8.8 Hz)
Formula C8H9BrO2 FW 217.0599 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2007\MA1307LS2\10\PDATA\1\1r
 




Date 27 Jun 2007 18:59:28
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384




























10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)






























































1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.80 (3 H, s) 3.81 (3 H, s) 4.78 (1 H, br. s) 5.13 (1 H, br. s) 
6.50 (2 H, q, J=2.6 Hz) 6.86 (1 H, d, J=2.9 Hz) 6.95 (1 H, dd, J=8.6, 2.7 Hz) 7.41 (1 H, d, J=8.4 Hz) 10.59 
(1 H, s)
Formula C16H14O5 FW 286.2794 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2007\JU2707LS1\10\PDATA\1\1r
 
   193 
3,4-Dihydroxy-5-methoxybenzaldehyde (2.68) 
 
Comment LS5529/6 Batch 3
Date 03 Apr 2009 16:15:12
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent Acetone
Original Points Count 16384 Points Count 16384
Spectrum Offset (Hz) 1849.7213



















9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)













1H NMR (300 MHz, Acetone)   ppm 3.91 (3 H, s) 7.10 (2 H, s) 8.25 (2 H, br. s) 9.77 (1 H, s)
Formula C8H8O4 FW 168.1467 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\AP0309LS3\10\PDATA\1\1r




Date 26 Feb 2008 20:09:36
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent Aceton
Original Points Count 16384 Points Count 16384
Spectrum Offset (Hz) 2464.3511





















10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)






















1H NMR (400 MHz, Aceton)   ppm 2.81 (1 H, br. s) 3.91 (3 H, s) 7.12 (1 H, s) 8.72 (1 H, br. s) 10.28 (7 H, 
s)
Formula C8H7BrO4 FW 247.0428 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\FE2608LS1\10\FID
   195 
3-Bromo-4-formyl-6-methoxy-1,2-phenylene diacetate (2.70) 
 
Comment LS4998/55B
Date 14 Apr 2008 23:13:20
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384































10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)


























1H NMR (300 MHz, CHLOROFORM-d)   ppm 2.22 (3 H, s) 2.29 (3 H, s) 3.77 - 3.83 (3 H, m) 7.37 (1 H, 
s) 10.19 (1 H, s)
Formula C12H13BrO6 FW 333.1320 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2008\AP1408LS3\10\PDATA\1\1r
 
   196 
3,4-Diacetoxy-2-bromo-5-methoxybenzyl alcohol (2.71) 
 
Comment LS4998/47
Date 29 Feb 2008 17:31:44
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent Acetone
Original Points Count 16384 Points Count 16384
Spectrum Offset (Hz) 1496.5806































7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)





















1H NMR (300 MHz, Acetone)   ppm 2.26 (3 H, s) 2.33 (3 H, s) 3.87 (3 H, s) 4.67 (2 H, s) 7.31 (1 H, s)
Formula C12H13BrO6 FW 333.1320 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2008\FE2908LS1\10\PDATA\1\1r
 
   197 
4-Hydroxy-2,9,10-trimethoxydibenzo[c,e]oxepin-5(7H)-one (2.78) 
 
Comment LS5291/36 EA acid ext
Date 13 Jan 2009 22:30:24
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 32 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0
Chemical Shift (ppm)






























































1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.91 (3 H, s) 3.95 (3 H, s) 3.96 (3 H, s) 4.90 (1 H, br. s.) 
5.15 (1 H, br. s.) 6.59 (1 H, d, J=2.6 Hz) 6.61 (1 H, d, J=2.6 Hz) 6.92 (1 H, s) 7.03 (1 H, s) 10.69 (1 H, s)
Formula C17H16O6 FW 316.3053 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2009\JA1309LS2\10\PDATA\1\1r
 
   198 
Methyl-2-bromo-3,5-dimethoxybenzoate (2.80) 
 
Comment LS4998/94 Date 31 Jul 2008 11:35:44
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384

























7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0
Chemical Shift (ppm)
































Formula C10H11BrO4 FW 275.0959 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2008\JY3108LS1\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.80 (3 H, s) 3.86 (3 H, s) 3.91 (3 H, s) 6.56 (1 H, d, J=2.6 
Hz) 6.78 (1 H, d, J=2.6 Hz)
 
   199 
2-Bromo-3,5-dimethoxybenzylalcohol (2.81) 
 
Comment LS5291/6 Date 08 Aug 2008 16:34:08
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384




















7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)





























1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.83 (3 H, s) 3.88 (3 H, s) 4.74 (2 H, s) 6.45 (1 H, d, J=2.8 
Hz) 6.71 (1 H, d, J=2.8 Hz)
Formula C9H11BrO3 FW 247.0858 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\AU0808LS2\10\FID
 
   200 
4-Hydroxy-2,9,11-trimethoxydibenzo[c,e]oxepin-5(7H)-one (2.82) 
 
Comment JL61 org 2 (EtOAc)
Date 02 Dec 2008 14:58:08
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0
Chemical Shift (ppm)










































































Formula C17H16O6 FW 316.3053 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\DC0208LS1\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.80 (3 H, s) 3.87 (3 H, s) 3.88 (3 H, s) 4.82 (1 H, d, 
J=12.0 Hz) 5.11 (1 H, d, J=12.0 Hz) 6.54 (1 H, d, J=2.5 Hz) 6.58 (1 H, d, J=2.5 Hz) 6.62 (1 H, d, J=2.5 
Hz) 6.82 (1 H, d, J=2.5 Hz) 10.18 (1 H, s)
 




Comment LS5529/22 F165-184 B
Date 19 May 2009 17:36:16
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384



























10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)



































































Formula C16H11NO4 FW 281.2628 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2009\MY1909LS1\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.90 (3 H, s) 5.02 (1 H, br. s.) 5.16 (1 H, br. s.) 6.59 (1 H, 
d, J=2.2 Hz) 6.64 (1 H, d, J=2.2 Hz) 7.55 (1 H, d, J=7.7 Hz) 7.72 (1 H, dd, J=7.7, 1.5 Hz) 7.83 (1 H, d, 
J=1.1 Hz) 10.55 (1 H, br. s.)
 




Comment LS5529/26 EA extract of base
Date 27 May 2009 19:58:56
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 32 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384


























10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)


















































































Formula C15H11FO4 FW 274.2438 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\MY2709LS1\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.90 (3 H, s) 4.93 (1 H, br. s.) 5.15 (1 H, br. s.) 6.59 (1 H, 
d, J=2.5 Hz) 6.61 (1 H, d, J=2.5 Hz) 7.15 (1 H, dd, J=8.0, 2.5 Hz) 7.21 (1 H, td, J=8.5, 3.0 Hz) 7.54 (1 H, 
dd, J=8.8, 5.3 Hz) 10.61 (1 H, s)
 




Comment LS5529/27 EA extract of base
Date 19 Jun 2009 04:18:08
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 32 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)





























































Formula C16H11F3O4 FW 324.2513 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\JU1809LS1\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.92 (3 H, s) 5.05 (1 H, br. s.) 5.22 (1 H, br. s.) 6.65 (1 H, 
d, J=2.5 Hz) 6.67 (1 H, d, J=2.5 Hz) 7.66 - 7.72 (2 H, m) 7.78 (1 H, dd, J=8.0, 1.0 Hz) 10.63 (1 H, s)
 




Comment LS5529/21.1 acid EA extract
Date 22 May 2009 19:29:04
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 64 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384






























10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)

























































Formula C16H12O6 FW 300.2629 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\MY2209LS4\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.89 (3 H, s) 4.83 (1 H, d, J=12.0 Hz) 5.10 (1 H, d, J=12.0 
Hz) 6.06 (2 H, s) 6.56 (1 H, d, J=2.5 Hz) 6.58 (1 H, d, J=2.5 Hz) 6.89 (1 H, s) 7.01 (1 H, s) 10.59 (1 H, s)
 





Date 06 Apr 2009 16:40:48
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384












































10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)



























Formula C18H23BrO8 FW 447.2744 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2009\AP0609LS2\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 1.52 (9 H, s) 1.54 (9 H, s) 3.90 (3 H, s) 7.44 (1 H, s) 10.29 
(1 H, s)
 
   206 




Date 20 Jun 2009 04:09:36
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384












































7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)


























Formula C18H25BrO8 FW 449.2903 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\JU1909LS3\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 1.54 (9 H, s) 1.56 (9 H, s) 3.88 (3 H, s) 4.72 (2 H, s) 7.11 
(1 H, s)
 




Date 26 Mar 2009 16:42:40
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384






























10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)





























File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\MA2609LS2\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.99 (3 H, s) 4.89 (2 H, s) 4.98 (2 H, s) 7.45 (1 H, s) 10.31 
(1 H, s)
 
   208 
2-Bromo-3,4-diacetonitrile-5-methoxybenzyl alcohol (2.102) 
 
Comment LS5529/3 Date 27 Mar 2009 13:49:52
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384





























7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)




























File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\MA2709LS1\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.82 (3 H, s) 4.55 (2 H, s) 4.75 (2 H, s) 4.76 (2 H, s) 7.04 
(1 H, s)
 
   209 
5-Bromo-4-formyl-2-methoxyphenyl acetate (2.104) 
 
Comment LS5291/58 Date 16 Dec 2008 19:31:12
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384


























10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)



























Formula C10H9BrO4 FW 273.0801 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2008\DC1608LS6\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 2.34 (3 H, s) 3.88 (3 H, s) 7.36 (1 H, s) 7.51 (1 H, s) 10.27 
(1 H, s)
 
   210 
5-Bromo-4-(hydroxymethyl)-2-methoxyphenyl acetate (2.105) 
 
Comment LS5291/59 F10-15
Date 19 Dec 2008 10:08:00
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
























7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)






























Formula C10H11BrO4 FW 275.0959 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2008\DC1908LS1\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 2.31 (3 H, s) 3.83 (3 H, s) 4.68 (2 H, d, J=5.9 Hz) 7.15 (1 
H, s) 7.22 (1 H, s)
 
   211 
2-Bromo-4-hydroxy-5-methoxybenzaldehyde (2.106) 
 
Comment LS5529/13 Date 06 Apr 2009 20:13:52
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384





















10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)


























Formula C8H7BrO3 FW 231.0434 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\AP0609LS1\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.82 (3 H, s) 7.05 (1 H, s) 7.30 (1 H, s) 9.29 (1 H, br. s.) 
10.04 (1 H, s)
 




Date 07 Apr 2009 10:44:16
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
























11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)





























File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\AP0709LS1\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.94 (3 H, s) 4.92 (2 H, s) 7.23 (1 H, s) 7.50 (1 H, s) 10.24 
(1 H, s)
 





Date 23 Apr 2009 09:46:56
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384























7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)

























File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\AP2309LS1\10\PDATA\1\1r
 




Comment LS5529/79 Date 03 Sep 2009 19:41:52
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 64 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)

























































1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.92 (3 H, s) 5.05 (1 H, br. s.) 5.21 (1 H, br. s.) 6.65 - 6.67 
(2 H, m) 7.57 (1 H, d, J=8.0 Hz) 7.71 (1 H, dd, J=7.8, 1.3 Hz) 7.81 (1 H, s) 10.64 (1 H, s)
Formula C16H11F3O4 FW 324.2513 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\SE0309LS6\10\FID
 
   215 
(2-Bromo-5-nitrophenyl)methanol (2.114) 
 
Comment LS5529/24 Date 08 May 2009 18:23:12
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384





















8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)









































1H NMR (300 MHz, CHLOROFORM-d)   ppm 2.73 (1 H, br. s.) 4.70 (2 H, s) 7.64 (1 H, d, J=8.7 Hz) 7.93 
(1 H, dd, J=8.7, 2.6 Hz) 8.36 (1 H, d, J=2.6 Hz)
Formula C7H6BrNO3 FW 232.0314 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\MY0809LS6\10\PDATA\1\1r
 




Comment LS5529/90 Date 23 Sep 2009 16:17:04
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)






















































































































Formula C15H11NO6 FW 301.2509 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\SE2309LS1\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.93 (3 H, s) 5.11 (1 H, br. s.) 5.22 (1 H, br. s.) 6.67 (1 H, 
d, J=2.5 Hz) 6.70 (1 H, d, J=2.5 Hz) 7.74 (1 H, d, J=8.5 Hz) 8.32 (1 H, d, J=2.5 Hz) 8.37 (1 H, dd, J=8.5, 
2.5 Hz) 10.61 (1 H, s)
 
   217 
(3-Bromopyridin-4-yl)methanol (2.117) 
 
Comment LS5529/76 Date 19 Aug 2009 10:57:04
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384














8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)


































1H NMR (400 MHz, CHLOROFORM-d)   ppm 2.86 (1 H, br. s.) 4.69 (2 H, s) 7.47 (1 H, d, J=5.0 Hz) 8.44 
(1 H, d, J=5.0 Hz) 8.54 (1 H, s)
Formula C6H6BrNO FW 188.0219 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\AU1909LS1\10\FID
 





Date 30 Oct 2009 15:25:52
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384


























10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)


















































1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.92 (3 H, s) 5.08 (2 H, br. s.) 6.67 (1 H, d, J=2.5 Hz) 6.68 
(1 H, d, J=2.5 Hz) 7.37 (1 H, d, J=4.5 Hz) 8.71 (1 H, d, J=5.0 Hz) 8.83 (1 H, s) 10.69 (1 H, s)
Formula C14H11NO4 FW 257.2414 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\OC3009LS1\10\FID
 




Comment LS5529/78 Date 03 Sep 2009 23:15:12
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 128 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384


























10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)






















































































Formula C15H11FO4 FW 274.2438 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\SE0309LS7\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.91 (3 H, s) 4.97 (1 H, br. s.) 5.14 (1 H, br. s.) 6.62 (1 H, 
d, J=2.5 Hz) 6.64 (1 H, d, J=2.5 Hz) 7.13 (1 H, ddd, J=8.3, 2.5 Hz) 7.27 (1 H, dd, J=9.5, 2.5 Hz) 7.42 (1 H, 
dd, J=8.0, 5.5 Hz) 10.63 (1 H, s)
 




Date 22 Sep 2009 17:19:12
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)































































1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.92 (3 H, s) 5.07 (2 H, s) 5.16 (2 H, s) 7.31 - 7.52 (11 H, 
m) 10.32 (1 H, s)
Formula C22H19BrO2 FW 395.2891 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\SE2209LS2\10\PDATA\1\1r
 
   221 
(3,-Bis(benzyloxy)-2-bromo-5-methoxyphenyl)methanol (2.121) 
 
Comment LS5671/15 Date 06 Oct 2009 09:32:00
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0
Chemical Shift (ppm)




































































1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.89 (3 H, s) 4.75 (2 H, d, J=6.0 Hz) 5.04 (2 H, s) 5.06 (2 
H, s) 6.94 (1 H, s) 7.31 - 7.40 (6 H, m) 7.43 - 7.53 (4 H, m)
Formula C22H21BrO4 FW 429.3037 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\OC0609LS1\10\PDATA\1\1r
 





Date 30 Sep 2009 14:07:12
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384










































10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)



























































































































1H NMR (300 MHz, CHLOROFORM-d)   ppm 3.79 (3 H, s) 3.94 (3 H, s) 4.59 (1 H, d, J=10.9 Hz) 4.80 (1 
H, d, J=12.1 Hz) 4.85 (1 H, d, J=10.9 Hz) 5.02 - 5.11 (2 H, m) 5.20 (1 H, d, J=10.5 Hz) 6.54 (1 H, d, J=2.6 
Hz) 6.77 (1 H, s) 6.84 (1 H, d, J=2.6 Hz) 6.96 (2 H, d, J=7.5 Hz) 7.12 - 7.25 (3 H, m) 7.32 - 7.41 (3 H, m) 
7.50 (2 H, dd, J=7.7, 2.1 Hz) 10.26 (1 H, s)
Formula C30H26O7 FW 498.5232 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\SE3009LS1\10\PDATA\1\1r
 
   223 
Ulocladol A (1.1) 
 
Comment LS5671/13 Date 03 Oct 2009 00:08:32
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384































10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)


























































































1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.87 (3 H, s) 3.95 (3 H, s) 4.80 (1 H, d, J=12.0 Hz) 5.12 (1 
H, d, J=12.0 Hz) 5.69 (1 H, br. s.) 5.78 (1 H, br. s.) 6.56 (1 H, d, J=3.0 Hz) 6.58 (1 H, s) 6.92 (1 H, d, 
J=2.5 Hz) 10.31 (1 H, s)
Formula C16H14O7 FW 318.2782 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\OC0209LS1\10\FID
 




Comment LS5671/16 Date 06 Oct 2009 09:36:16
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
































8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)









































Formula C11H9F3O6S FW 326.2458 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\OC0609LS2\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 1.77 (6 H, s) 7.01 (1 H, d, J=7.9 Hz) 7.06 (1 H, dd, J=8.7, 
1.1 Hz) 7.61 (1 H, t, J=8.3 Hz)
 





Date 22 Oct 2009 00:04:16
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384


































7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)





















































1H NMR (400 MHz, CHLOROFORM-d)   ppm 1.42 (12 H, s) 1.73 (6 H, s) 6.93 (1 H, dd, J=8.5, 1.0 Hz) 
7.14 (1 H, dd, J=7.5, 1.0 Hz) 7.50 (1 H, dd, J=7.0 Hz)
Formula C16H21BO5 FW 304.1459 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\OC2109LS3\10\FID
 





Date 21 Oct 2009 21:34:56
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384










































9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)































































































































Formula C29H24O6 FW 468.4973 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\OC2109LS2\10\FID
1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.85 (3 H, s) 4.55 (1 H, d, J=11.0 Hz) 4.73 (1 H, d, J=12.0 
Hz) 4.78 (1 H, d, J=11.0 Hz) 4.94 (1 H, d, J=12.0 Hz) 5.00 (1 H, d, J=11.0 Hz) 5.12 (1 H, d, J=11.0 Hz) 
6.70 (1 H, s) 6.78 - 6.87 (2 H, m) 6.95 (1 H, dd, J=8.0, 1.0 Hz) 7.06 (2 H, t, J=7.3 Hz) 7.11 - 7.21 (2 H, m) 
7.22 - 7.37 (4 H, m) 7.43 (2 H, dd, J=8.0, 1.5 Hz) 9.63 (1 H, s)
 





Date 30 Oct 2009 14:41:04
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 64 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384



































9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)

























































































1H NMR (400 MHz, CHLOROFORM-d)   ppm 3.98 (3 H, s) 4.60 (1 H, d, J=11.1 Hz) 4.66 (1 H, d, J=11.1 
Hz) 4.82 (1 H, d, J=12.1 Hz) 5.06 (1 H, d, J=12.1 Hz) 5.82 (1 H, s) 6.77 (1 H, s) 7.01 - 7.07 (3 H, m) 7.18 - 
7.26 (2 H, m) 7.26 - 7.30 (1 H, m) 7.34 (1 H, dd, J=8.1, 1.5 Hz) 7.46 (1 H, t, J=7.8 Hz) 9.70 (1 H, s)
Formula C29H24O6 FW 468.4973 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\OC3009NJWLS1\1\FID
 
   228 
4-Bromo-5-methylbenzene-1,3-diol (3.4) 
 
Comment LS5291/18 F25-48 recrys
Date 08 Sep 2008 16:53:36
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 16 Solvent Acetone
Original Points Count 16384 Points Count 16384
















8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)





























1H NMR (300 MHz, Acetone)   ppm 2.27 (3 H, s) 6.36 (1 H, d, J=2.9 Hz) 6.39 (1 H, d, J=2.9 Hz) 8.32 (2 
H, br. s.)
Formula C7H7BrO2 FW 203.0333 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300.1\300 
1\2008\SE0808LS1\10\PDATA\1\1r
 
   229 
4-Bromo-5-methyl-1,3-phenylene diacetate (3.5) 
 
Comment LS5529/86 F7-11
Date 07 Sep 2009 15:13:20
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384


























7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)

































Formula C11H11BrO4 FW 287.1066 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\SE0709LS3\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 2.25 (3 H, s) 2.33 (3 H, s) 2.42 (3 H, s) 6.82 (1 H, d, J=3.0 
Hz) 6.93 (1 H, d, J=3.0 Hz)
 




Comment LS5529/18 Date 05 May 2009 17:29:52
Frequency (MHz) 300.13 Nucleus 1H
Number of Transients 8 Solvent CHLOROFORM-d
Original Points Count 16384 Points Count 16384
























6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)


































File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\300 
2\2009\MY0509LS4\10\PDATA\1\1r
1H NMR (300 MHz, CHLOROFORM-d)   ppm 2.35 (3 H, s) 4.74 (2 H, s) 4.79 (2 H, s) 6.51 (1 H, d, J=3.0 
Hz) 6.60 (1 H, d, J=3.0 Hz)
 
   231 
Alternariol-9-methyl ether (1.2) 
 
OC0209NJWLS1.001.esp
11 10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)























































Date 02 Oct 2009 16:14:56
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 128 Solvent DMSO-d6
Original Points Count 16384 Points Count 16384
Spectrum Offset (Hz) 2442.7415


























1H NMR (400 MHz, DMSO-d6)   ppm 2.73 (3 H, s) 3.91 (3 H, s) 6.61 (1 H, d, J=2.0 Hz) 6.64 (1 H, d, 
J=2.4 Hz) 6.72 (1 H, d, J=2.0 Hz) 7.21 (1 H, d, J=2.4 Hz) 10.36 (1 H, br. s.) 11.82 (1 H, br. s.)
Formula C15H12O5 FW 272.2528 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\OC0209NJWLS1\1\FID
 




Date 21 Oct 2009 18:44:16
Frequency (MHz) 400.13 Nucleus 1H
Number of Transients 16 Solvent MeOH
Original Points Count 16384 Points Count 16384


























7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0
Chemical Shift (ppm)










































1H NMR (400 MHz, MeOH)   ppm 2.73 (3 H, s) 6.35 (1 H, d, J=2.0 Hz) 6.58 (1 H, d, J=2.5 Hz) 6.67 (1 H, 
d, J=2.5 Hz) 7.22 (1 H, d, J=2.0 Hz)
Formula C14H10O5 FW 258.2262 File Name C:\DOCUMENTS AND SETTINGS\LAUREN\DESKTOP\NMR\400 
1\OC2109LS1\10\FID
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